Molecular targeting combined with photon and proton irradiation in human pancreatic cancer cells by Görte, Josephine Elisabeth
 
Aus dem Nationalen Zentrum für Strahlenforschung in der Onkologie - OncoRay 
Direktorin Frau Prof. Dr. M. Krause 
Arbeitsgruppe: Molekulare und Zelluläre Strahlenbiologie 






Molecular targeting combined with photon and proton  








zur Erlangung des akademischen Grades 
Doktor der Biomedizin 




der Medizinischen Fakultät Carl Gustav Carus 
der Technischen Universität Dresden 
 
von 
Josephine Elisabeth Görte, M.Sc. 
 































1. Gutachter: Prof. Dr. med. habil. Nils Cordes 
 
2. Gutachter: Prof. Dr. rer. nat. Ben Wielockx 
 
 
Tag der mündlichen Prüfung:  
 
gez. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 







Abbreviations ........................................................................................................................ V 
List of Figures ....................................................................................................................... IX 
List of Tables ........................................................................................................................ XI 
1 Introduction ......................................................................................................................1 
2 Background .....................................................................................................................3 
2.1 Pancreatic Ductal Adenocarcinoma ...........................................................................3 
2.1.1 Epidemiology ...................................................................................................3 
2.1.2 Molecular mechanisms and pathophysiology ...................................................4 
2.1.3 Therapeutic management for PDAC ................................................................5 
2.2 Ionizing radiation: physical and biological effects .......................................................6 
2.3 Radiation-induced DNA damage and DNA damage repair .........................................8 
2.4 Extracellular matrix and cell adhesion ...................................................................... 10 
2.5 Cell adhesion molecules: integrins ........................................................................... 12 
2.6 β1 integrins .............................................................................................................. 15 
2.6.1 Role in physiology and cancer ....................................................................... 15 
2.6.2 Targeting β1 integrins in clinical studies ........................................................ 17 
2.7 Cell adhesion and cancer therapy resistance ........................................................... 17 
3 Hypothesis and Aims ..................................................................................................... 19 
4 Materials and Methods .................................................................................................. 20 
4.1 Materials .................................................................................................................. 20 
4.1.1 Devices.......................................................................................................... 20 




4.1.3 siRNA ............................................................................................................ 22 
4.1.4 Inhibitors ........................................................................................................ 23 
4.1.5 Chemotherapeutic agents .............................................................................. 24 
4.1.6 Protein ladders .............................................................................................. 24 
4.1.7 Method kits .................................................................................................... 24 
4.1.8 Primary antibodies ......................................................................................... 24 
4.1.9 Secondary antibodies .................................................................................... 25 
4.1.10 Solutions for cell biological applications ......................................................... 25 
4.1.11 Solutions for protein-biochemical and molecular-biological 
applications ................................................................................................... 26 
4.1.12 Solutions for immunofluorescence stainings .................................................. 28 
4.1.13 Additional solutions and chemicals ................................................................ 28 
4.1.14 PC programs ................................................................................................. 29 
4.2 Methods ................................................................................................................... 29 
4.2.1 Cell lines ........................................................................................................ 29 
4.2.2 Cell culture and passaging............................................................................. 30 
4.2.3 Cell freezing and thawing .............................................................................. 30 
4.2.4 siRNA knockdown ......................................................................................... 30 
4.2.5 Inhibitor treatment and chemotherapy ........................................................... 32 
4.2.6 Generation of radioresistant PDAC cell lines ................................................. 32 
4.2.7 Radiation exposure ........................................................................................ 32 
4.2.8 3D tumoroid formation assay ......................................................................... 33 
4.2.9 Total protein extracts, SDS-PAGE and Western Blotting ............................... 34 
4.2.10 Kinome analysis ............................................................................................ 37 
4.2.11 Phosphoproteome analysis............................................................................ 38 
4.2.12 Fluorescence microscopy .............................................................................. 38 
4.2.13 Statistics ........................................................................................................ 38 
5 Results .......................................................................................................................... 40 
5.1 The role of β1 integrins in radiochemoresistance of 3D, matrix-based PDAC 




5.1.1 β1 integrin mRNA expression and survival analysis on publicly 
available PDAC patient data .......................................................................... 40 
5.1.2 Effect of β1 integrin inhibition in combination with photon irradiation 
on 3D PDAC tumoroid growth ........................................................................ 41 
5.1.3 β1 integrin protein expression and localization in PDAC cell cultures ............ 44 
5.1.4 Effect of β1 integrin targeting in combination with radiochemotherapy 
on 3D PDAC tumoroid growth ........................................................................ 46 
5.1.5 Impact of β1 integrin targeting on kinase activity in 3D therapy-naïve 
and radioresistant PDAC cultures .................................................................. 49 
5.1.6 Identification of PTKs and STKs putatively involved in β1 integrin-
induced radiation response in 3D PDAC cultures .......................................... 57 
5.1.7 Effect of β1 integrin inhibition in combination with proton irradiation on 
3D PDAC tumoroid growth............................................................................. 60 
5.2 Comparative proton and photon irradiation of 3D, matrix-based PDAC cell 
cultures .................................................................................................................... 62 
5.2.1 Effect of proton and photon irradiation on 3D PDAC tumoroid growth ............ 62 
5.2.2 Effect of proton and photon irradiation on phosphoproteome of 3D 
PDAC cultures ............................................................................................... 64 
5.2.3 Exploitation of radiation type-specific phosphoproteomic changes to 
increase radiosensitivity of 3D PDAC cultures ............................................... 70 
5.2.4 Comparative proton and photon irradiation combined with 
pharmacological inhibitors in 3D PDAC cultures ............................................ 74 
5.2.5 Comparative proton and photon irradiation combined with DNA 
damage repair inhibition on 3D PDAC tumoroid growth ................................. 76 
6 Discussion ..................................................................................................................... 78 
6.1 β1 integrins mediate radioresistance in therapy-naïve and radioresistant 3D 
PDAC cell cultures ................................................................................................... 79 
6.2 Chemo- and radiochemosensitivity is independent of β1 integrins in 3D 
PDAC cultures ......................................................................................................... 82 
6.3 β1 integrin inhibition regulates kinome activity differentially in therapy-naïve 




6.4 Erk2, PKD1, and CK1δ potentially participate in β1 integrin signaling in 
therapy-naïve 3D PDAC cultures ............................................................................. 84 
6.5 Multitargeting approaches highly efficient in the therapy-naïve 3D PDAC cell 
cultures .................................................................................................................... 86 
6.6 Acquired radioresistance results in resistance to targeted therapies in 3D 
PDAC cell cultures ................................................................................................... 87 
6.7 Comparative proton and photon irradiation combined with pharmacological 
inhibitors in 3D PDAC cultures ................................................................................. 90 
7 Summary ....................................................................................................................... 94 
8 Zusammenfassung ........................................................................................................ 96 
9 Bibliography ................................................................................................................... 98 
Acknowledgements ................................................................................................................. i 
Appendix ................................................................................................................................ ii 
Curriculum Vitae ................................................................................................................ ii 
Veröffentlichungen ............................................................................................................ iii 
Anlage 1 ................................................................................................................................ iv 
Anlage 2 ................................................................................................................................. v 






2D  Two dimensional 
3D  Three dimensional 
53BP1  Tumor suppressor p53-binding protein 1 
5-FU  5-Fluoruracil 
Akt  Protein kinase B 
AKT  Serine/threonine protein kinase B 
Alt-NHEJ Alternative non-homologous end-joining 
APS  Ammonium persulfate 
ATM  Ataxia telangiectasia mutated 
ATR  Ataxia telangiectasia and Rad3-related protein 
AU  Arbitrary unit 
BRAF  Serine/threonine-protein kinase B-raf 
BRCA1 Breast cancer tumor suppressor protein-1 
BRCA2 Breast cancer 2 tumor suppressor 
BSA  Bovine serum albumin 
c-Abl  Tyrosine-protein kinase c-Abl 
CAM-DR Cell adhesion-mediated drug resistance 
CAM-RR Cell adhesion-mediated radioresistance 
CDKN2A Cyclin-dependent kinase inhibitor 2A 
cDMEM Complete Dulbecco’s modified medium eagle 
CK1δ  Casein kinase I isoform delta 
c-NHEJ Classical non-homologous end joining 
Co  Control 
CO2  Carbon dioxide 
CtIP  C-terminal binding protein interacting protein 
Ctrl  Control 
DAPI  4′,6-diamidino-2-phenylindole 
ddH2O  Double distilled water 




DMEM  Dulbecco’s modified medium eagle 
DMSO  Dimethyl sulfoxide 
DNA  Deoxyribonucleic acid 
DNA-PK DNA-dependent protein kinase 
DNA-PKcs DNA-PK catalytic subunit 
DSB  Double strand break 
EC10  10 % effective concentration 
ECM  Extracellular matrix 
EGF  Epidermal growth factor 
EGFR  Epidermal growth factor receptor 
ER  Enhancement ratio 
ER  Enhancement ratio 
Erk  Extracellular signal-regulated kinase 
ER-α  Estrogen Receptor α 
EZM  Extrazelluläre Matrix 
FAK  Focal adhesion kinase 
FCS  Fetal calf serum 
FDA  Food and Drug Administration (US) 
FGFR  Fibro 
GFR  Growth factor receptor 
Gy  Gray 
H2AX  H2A histone family member X 
H2O  Water 
HNSCC Head and neck squamous cell carcinoma 
HR  Homologous recombination 
i  Inhibitor 
ICAP1  Integrin cytoplasmic domain-associated protein 1 
IgG  Immunglobulin G 
ILK  Integrin linked kinase 
JNK  c-Jun N-terminal kinase 
KRAS  GTPase KRas 
KU70  X-ray repair cross complementing 6 (XRCC6) 
KU80  X-ray repair cross complementing 5 (XRCC5) 
LET  Linear energy transfer 
LIG4  Ligase IV 
lrECM  Laminin-rich extracellular matrix 




Mre11  Meiotic recombination 11 
MRN  Complex consisting of Mre11, Rad50 and Nbs1 
mRNA  Messenger RNA 
N.s.  not significant 
NaCl  Sodium chloride 
NaOH  Sodium hydroxide 
Nbs1  Nijmegen breakage syndrome protein 1 
NEAA  Non-essential amino acids 
NHEJ  Non-homologous end joining 
PARP  Poly (ADP-ribose) polymerase 
PBS  Phosphate buffered saline 
PDAC  Pancreatic ductal adenocarcinoma 
PDGFR Platelet-derived growth factor receptor 
PI3K  Phosphatidylinositol-4,5-bisphosphate 3-kinase 
PKD1  Protein kinase D1 
PNK  Polynucleotide kinase 3’ phosphatase 
Pol θ  DNA polymerase theta 
PPI  Peptide phosphorylation intensity 
PSC  Pancreatic stellate cell 
PTK  Phospho-tyrosine kinase 
RAD50 RAD50 double strand break repair protein 
RAD51 RAD51 recombinase 
RAD52 DNA repair protein RAD52 homolog 
RGD  Tripeptide Arg-Gly-Asp 
RNAi  RNA interference 
RPA  Replication protein A 70 KDa DNA-binding subunit 
RR  Radioresistant 
RTK  Receptor tyrosine kinase 
S  Serin 
SDS  Sodium dodecyl sulfate 
SDS-PAGE Sodium dodecyl sulphate polyacrylamide gel electrophoresis 
Ser  Serine 
SHARPIN SHANK-associated RH domain-interacting protein 
siC  Control siRNA 
siRNA  Small interfering RNA 
SMAD4 Mothers against decapentaplegic homologue 4 




SSB  Single strand break 
STK  Serine/threonine kinase 
TBS  Tris buffered saline 
TCGA  The Cancer Genome Atlas 
TF  Tumoroid formation 
Thr  Threonine 
TN  Therapy-naïve 
TP53  Tumor protein P53 
Tyr  Tyrosine 
VEGFR Vascular endothelial growth factor receptor 
x g  Relative centrifugal force (RCF) 
XLF  XRCC4-like factor 
XRCC4 X-ray repair cross complementing 4 
Y  Tyrosine 
γH2AX  Phosphorylated H2AX 
Δ  Delta 
 
 
Additionally, generally accepted abbreviations of the SI-unit system are used.
List of Figures 
IX 
 
List of Figures 
Figure 2.1: Percentage of cancer-related deaths in Germany. ............................................... 4 
Figure 2.2: Depth-dose-profiles of photon and proton irradiation. .......................................... 7 
Figure 2.3: Direct and indirect actions of ionizing radiation. ................................................... 8 
Figure 2.4: DNA repair mechanisms. ....................................................................................10 
Figure 2.5: Integrin structure and activation. .........................................................................12 
Figure 2.6: Integrin-mediated signaling in cancer. ................................................................14 
Figure 2.7: The family of integrin receptors. ..........................................................................15 
Figure 4.1: Scheme of semi-dry blotting. ..............................................................................37 
Figure 5.1: β1 integrin mRNA overexpression in PDAC patient samples correlates with poor 
prognosis. .....................................................................................................................40 
Figure 5.2: β1 integrin inhibition confers radiosensitization in therapy-naïve and radioresistant 
3D PDAC cell cultures. ..................................................................................................41 
Figure 5.3: β1 integrin comprises critical role in radiation response in a panel of 3D PDAC 
cell cultures. ..................................................................................................................43 
Figure 5.4: β1 integrin protein expression and localization vary in PDAC cell cultures. .........44 
Figure 5.5: Mature β1 integrin expression correlates with sensitizing enhancement upon 
AIIB2 and irradiation in 3D TN-PDAC cultures. ..............................................................45 
Figure 5.6: Chemosensitivity and radiochemosensitivity remain largely unaltered upon β1 
integrin targeting............................................................................................................47 
Figure 5.7: β1 integrin inhibition decreases peptide phosphorylation events both in therapy-
naïve and radioresistant 3D PDAC cultures. ..................................................................49 
Figure 5.8: Putative kinases deregulated upon β1 integrin inhibition in therapy-naïve and 
radioresistant 3D PDAC cultures. ..................................................................................54 
Figure 5.9: β1 integrin targeting affects kinase activity differentially in therapy-naïve PDAC 
cultures and their radioresistant counterpart. .................................................................55 
Figure 5.10: Single and double RNAi knockdown screen of PTKs and STKs with β1 integrin 
reveals kinase- and cell line-dependent radiosensitization. ...........................................58 
List of Figures 
X 
 
Figure 5.11: Radioresistant 3D MiaPaCa-2 cultures are less susceptible for single and 
double depletion of β1 integrin together with PTKs or STKs than their therapy-naïve 
counterpart. ...................................................................................................................60 
Figure 5.12: Proton irradiation induced reduction of 3D tumoroid growth is augmented cell 
line-dependently by β1 integrin targeting. ......................................................................61 
Figure 5.13: Proton irradiation tends to be more effective in reducing PDAC tumoroid growth 
than photon irradiation. ..................................................................................................63 
Figure 5.14: Phosphoproteome of 3D PDAC cell cultures is differentially affected by proton 
and photon irradiation. ...................................................................................................65 
Figure 5.15: Identification of cell line-overlapping protein alterations induced by proton and 
photon irradiation...........................................................................................................69 
Figure 5.16: Photon and proton irradiated 3D PDAC cell cultures differentially respond to 
tamoxifen, trastuzumab and prexasertib. .......................................................................71 
Figure 5.17: Photon and proton irradiated 3D PDAC cell cultures differentially respond to 
lapatinib. ........................................................................................................................72 
Figure 5.18: Photon and proton irradiation differentially affect the phosphorylation status of 
Chk1, ER-α and HER2 of 3D PDAC cell cultures. .........................................................73 
Figure 5.19: Targeting of signal transduction and DNA repair enzymes sensitizes PDAC cell 
cultures to photon and proton irradiation. ......................................................................75 
Figure 5.20: Targeting NHEJ associated enzymes seems generally potent to sensitize 3D 
PDAC cell cultures to photon and proton irradiation. .....................................................77 
List of Tables 
XI 
 
List of Tables 
Table 4.1. Devices used for biochemical, molecular-biological or cell culture applications. ...20 
Table 4.2. Materials used for biochemical, cell culture or molecular-biological applications. .21 
Table 4.3. SiRNAs used to silence the indicated genes. Corresponding sequences are 
shown. ...........................................................................................................................22 
Table 4.4. Inhibitors used in cell culture experiments. ..........................................................23 
Table 4.5. Chemotherapeutics used in cell culture experiments. ..........................................24 
Table 4.6. Method kits used for biochemical applications. ....................................................24 
Table 4.7. Primary antibodies used for Western blot or immunofluorescence stainings. .......24 
Table 4.8. Secondary antibodies used for Western blot or immunofluorescence stainings. ..25 
Table 4.9. Solutions and compositions used for cell biological applications. .........................25 
Table 4.10. Solutions and compositions used for protein-biochemical and molecular-
biological applications. ..................................................................................................26 
Table 4.11. Solutions and compositions used for immunofluorescence stainings. ................28 
Table 4.12. Additional solutions and chemicals used for biochemical or molecular-biological 
applications. ..................................................................................................................28 
Table 4.13. PC programs for data analysis and presentation................................................29 
Table 4.14: Pancreatic cancer cell lines and their origin. ......................................................29 
Table 4.15: Concentrations and volumes for siRNA transfection in 6-well plates using 
Oligofectamine. .............................................................................................................31 
Table 4.16: Concentrations and volumes for siRNA transfection in 12-well and 6-well plates 
using Lipofectamine RNAiMAX. .....................................................................................31 
Table 4.17. Cell numbers and incubation periods used for 3D tumoroid formation assays. ..34 
Table 4.18. Composition of stacking gel and separation gels used for SDS PAGE. ..............36 
Table 5.1: Synergistic or additive effects of combined AIIB2/chemotherapy administration in 
unirradiated 3D PDAC cultures. .....................................................................................48 
Table 5.2: Synergistic or additive effects of combined AIIB2/chemotherapy administration in 6 
Gy irradiated 3D PDAC cultures. ...................................................................................48 
Table 5.3: List of peptides used in PTK and STK arrays. ......................................................50 
Table 5.4: List of PTKs and STKs assessed by PamGene®. ................................................55 
List of Tables 
XII 
 
Table 5.5: RBE values comparing proton to photon irradiation effectiveness in PDAC cell 
lines...............................................................................................................................64 
Table 5.6: SF2 values of PDAC cell lines after photon and proton irradiation. ......................64 






Globally, cancer will overtake cardiovascular diseases as the leading cause of disease-related 
deaths in a few decades (Dagenais et al., 2020), and therapy resistance remains a major ob-
stacle in cancer cure. Despite progress in treatment approaches, pancreatic ductal adenocar-
cinoma (PDAC) is a disease with unmet needs and will become the second deadliest tumor 
entity by 2030 (Rahib et al., 2014). PDAC is highly resistant to chemo-, radio- and targeted 
therapies elicited by a highly desmoplasmic microenvironment, the mutational landscape, and 
intratumoral heterogeneity. The reasons for this bad prognosis lie in its late diagnosis at ad-
vanced, metastasized stages caused by lack of early symptoms (Juiz et al., 2019; Kleeff et al., 
2016; Vincent et al., 2011). Given the high resistance to current standard therapies, more spe-
cific and effective treatment modalities are urgently required. Two options can be considered: 
(1) more precise radiotherapy such as proton irradiation or (2) molecular-targeted strategies. 
Proton beam therapy is increasingly applied for cancer treatment. Owing to its depth-
dose-profile, proton irradiation offers benefits compared to photon irradiation. The low entrance 
dose in the tissue and the so-called spread-out Bragg peak (SOBP) facilitate a precise location 
of the dose in the tumor while sparing normal tissue (Lühr et al., 2018; Vitti & Parsons, 2019). 
However, the role of radiotherapy per se and the efficacy of proton irradiation are still under 
debate for PDAC. 
Tailored strategies demand a profound characterization of the molecular conditions 
contributing to therapy resistance. The hallmarks of cancer are elicited by genetic and epige-
netic modifications that consequently drive tumor development, progression, and resistance 
(Hanahan & Weinberg, 2011). A better understanding of the underlying molecular mechanisms 
is likely to reveal exploitable cancer targets (Blandin et al., 2015; Buckley et al., 2020). Among 
a large number of survival-advantaging mechanisms, the interaction of cells with extracellular 
matrix (ECM) via cell adhesion molecules like integrins has been shown to fundamentally reg-
ulate resistance to therapy (Cooper & Giancotti, 2019; Desgrosellier & Cheresh, 2010; Eke & 
Cordes, 2015; Seguin et al., 2015). These mechanisms are termed cell adhesion-mediated 
radio- (CAM-RR) and drug (CAM-DR) resistance (Cordes & Meineke, 2003; Damiano et al., 
1999). Disruption of cell adhesion-mediated signaling by targeting of integrins or other focal 




head and neck, breast, prostate, PDAC (Deville et al., 2020; Eke et al., 2015; Jin et al., 2019; 
L. Li et al., 2018; C. C. Park et al., 2008; Vehlow et al., 2017, 2019). These observations 
demonstrate the essential role of cell adhesion molecules for conveying radio- and chemo-
resistance. 
In cancers, including PDAC, β1 integrins are frequently overexpressed compared to 
normal tissue (Eriksen et al., 2004; Logsdon et al., 2003), a prerequisite for targeted therapies. 
In PDAC, depletion and inhibition of β1 integrins decreased tumor growth and progression and 
sensitized PDAC cells to chemo- or targeted therapies (Brannon et al., 2020; Grzesiak et al., 
2011; Grzesiak & Bouvet, 2006; Yang et al., 2018). Hence, the targeting of β1 integrins and 
the unraveling of the underlying molecular circuitry pose promising approaches to overcome 
radiochemoresistance in PDAC. 
In the first part of the work, the function of β1 integrins intrinsic and acquired radi-
ochemoresistance was investigated in PDAC cultures, and contributing molecular mecha-
nisms were unraveled. β1 integrin inhibition significantly decreased radiation survival in ther-
apy-naïve and radioresistant PDAC cultures, although the latter were found less dependent on 
β1 integrins. Mechanistically, β1 integrin inhibition downregulated the kinome activity. Interest-
ingly, the therapy-naïve cultures were more vigorously affected than the radioresistant cul-
tures. Simultaneous kinase and β1 integrin depletion enhanced radiosensitivity and uncovered 
kinases potentially interacting in β1 integrin-mediated signaling in response to radiation in ther-
apy-naïve PDAC cultures. The radioresistant counterpart remained almost insusceptible for 
double targeting. 
In the second part, the PDAC cell survival upon photon and proton irradiation was com-
paratively analyzed, and specific radiation-induced molecular changes were explored. A cell 
line-dependent higher efficacy in cell kill and more phosphoproteomic changes were uncov-
ered for proton than for photon irradiation. While radiation type-specific targeting for radiosen-
sitization failed, pharmacological inhibition of molecular targets turned out similarly efficient for 
photon and proton irradiation. A strong dependence of PDAC cell radiation survival response 






2.1 Pancreatic Ductal Adenocarcinoma 
2.1.1 Epidemiology 
Despite significant advances in treatment modalities in the last decade, pancreatic ductal ad-
enocarcinoma (PDAC) is a tumor entity of unmet needs. Pancreatic adenocarcinomas consti-
tute 90 % of pancreatic malignancies. The majority are ductal adenocarcinomas, while neuro-
endocrine or acinar tumors, among others, present less frequent neoplasms of the pancreas 
(Kleeff et al., 2016; Vincent et al., 2011). PDAC ranks fourth (Figure 2.1) in cancer-related 
deaths and is estimated to become second in the next decade (Rahib et al., 2014; Robert Koch 
Institute, 2020). In Germany of 9,190 , incident cases for females and 9,180 for males were 
reported for 2016 and are predicted to increase to approximately 10,000 cases in 2020 (Robert 
Koch Institute, 2020). 
The poor prognosis with a 5-year overall survival rate of only 7 % can be traced back 
to a late discovery of the disease at already advanced, metastasized stages due to unspecific 
or lacking symptoms, difficult imaging of early-stage tumors, and lastly, yet of immense signif-
icance, to the devastating character of PDAC. Another aggravating feature of PDAC is its pro-
nounced resistance to therapy, be it chemo-, radio- and targeted therapy (Kleeff et al., 2016; 
Orth et al., 2019). Local outgrowth into perineural and vascular tissues, early metastasis, mul-
tiple genetic and epigenetic modifications, and a highly desmoplasmic tumor stroma contribute 
to the tumor entity’s aggressiveness (Kleeff et al., 2016; Vincent et al., 2011; Waddell et al., 
2015). 
Risk factors emerge from lifestyle habits, such as tobacco smoking and other consump-
tion, nutrition, concomitant adiposis, and alcohol abuse (Bosetti et al., 2012; Genkinger et al., 
2015; Lucenteforte et al., 2012). Furthermore, other diseases, like type 2 diabetes mellitus or 
chronic inflammation of the pancreas, bear risks for pancreatic malignancies (Bosetti et al., 
2014). Patients suffering from PDAC usually belong to the group older than 50 years, with the 





Figure 2.1: Percentage of cancer-related deaths in Germany. Most frequent tumor sites subdivided by gender 
when cancer was responsible for death in Germany in 2016. Tumors of the pancreas rank four (taken from Robert 
Koch Institute (Robert Koch Institute, 2020)). 
2.1.2 Molecular mechanisms and pathophysiology 
In most cases, PDAC arises from pancreatic intraepithelial neoplasias (PanINs) undergoing 
three different stages that are frequently accompanied by acquiring gene alterations (Vincent 
et al., 2011; Waddell et al., 2015). Point mutations, methylations, homozygous deletions, or 
altered copy numbers often contribute to genetic changes. Over 90 % of PDAC patients exhibit 
activating mutations of the oncogene KRAS. Tumor suppressors are affected and inactivated 
by alterations in 50-80 % of the patients, such as the cyclin-dependent kinase inhibitor 2A 
(CDKN2A), mothers against decapentaplegic homologue 4 (SMAD4), and the tumor suppres-
sor protein 53 (TP53). The mutation of the BRCA2, a protein involved in DNA repair, is only 
present in 7 % of the patients, yet, it impacts curative regimen as poly (ADP-ribose) polymer-
ase (PARP) inhibitors can be applied (Kleeff et al., 2016; Waddell et al., 2015). 
The landscape of genetic alterations translates into altered signaling in pancreatic can-
cer. Activated signaling driven by KRAS confers a cascade that is concomitantly involved in 
growth factor receptor signaling responsible for survival and proliferation in PDAC, namely 
EGFR, IGF-1R, HGFR, TGF-β, and VEGFR, consisting of Ras and PI3K/Akt pathways (Gore 
et al., 2014; Jones et al., 2008; Kleeff et al., 2016; Matsushita et al., 2007; Stathis & Moore, 
2010). Moreover, the reinvigoration of Wnt, Hedgehog, and Notch signaling, pathways active 
under normal circumstances in developmental processes, is known to contribute to tumor pro-




Pancreatic cancer cells are, additionally to intrinsic characteristics, influenced by the 
surrounding tumor microenvironment. PDAC is characterized by a highly desmoplasmic and 
hypoxic tumor milieu. The ECM, consisting of collagen and other extracellular matrix proteins, 
is shaped by pancreatic stellate cells (PSCs), and both collagen and PSCs present modulators 
of resistance to therapies in PDAC (Hamada et al., 2012; Seymour et al., 1994; Xu et al., 2010). 
Infiltration of immune cells and the presence of endothelial and neuronal cells are further spe-
cific for the microenvironment of PDAC (Armstrong et al., 2004; Berchtold et al., 2015; Kleeff 
et al., 2016; Mantoni et al., 2011; Orth et al., 2019; Schober et al., 2014). 
2.1.3 Therapeutic management for PDAC 
Since operative removal is only applicable at early stages without metastases and a tumor size 
smaller than 2 cm, the majority of patients (80 %) are excluded from surgical resection. First-
line treatment is stage-dependent for PDAC (Kleeff et al., 2016). In 1997 a study demonstrated 
that gemcitabine was superior to 5-FU treatment in PDAC treatment regarding amelioration of 
symptoms and prolonged survival (Burris et al., 1997). Upon the FDA’s approval for gemcita-
bine as a first-line treatment, various combinational curative strategies with the nucleoside 
analogue were tested. However, the efficacy of gemcitabine monotherapy was only moderately 
increased by a multimodal administration combined with the EGFR targeting small molecule 
inhibitor erlotinib, FOLFIRINOX (consisting of leucovorin, 5-fluorouracil, irinotecan, and oxali-
platin), or albumin-bound paclitaxel (Conroy et al., 2011; Moore et al., 2007; Von Hoff et al., 
2013). Treatment with both latter agents is accompanied by severe side effects, especially 
critical for elderly and weak patients. Adjuvant chemotherapy is administered upon surgery. 
Second-line treatment depends on the first-line regimen (Kleeff et al., 2016; Neoptolemos et 
al., 2004; Orth et al., 2019). 
In most cases, PDAC patients receive radiotherapy as a palliative regimen. However, 
for locally advanced non-metastatic yet unresectable tumors, chemoradiation serves as a mul-
timodal cure, unfortunately with a poor success rate of 4 % of the PDAC patients (Buckley et 
al., 2020; Kleeff et al., 2016). Despite being rather infrequently used for PDAC, radiotherapy 
is still a therapy modality of great interest for this tumor entity, and the chronological sequence 
and feasibility of combinations of surgery, chemo- and radiotherapy have lately been debated. 
More clinical trials are demanded to evaluate optimal treatment settings (W. A. Hall & 
Goodman, 2019; Roeder, 2016). 
Since the standard treatment modalities often fail to cure PDAC patients, hope was 
placed on targeted therapies. The mutational landscape provides options for molecular ap-
proaches, yet, the most common gene alterations turned out to be extremely difficult to target, 




PI3K/Akt, mTOR (A. D. Cox et al., 2014; Kastenhuber & Lowe, 2017; Orth et al., 2019). Multi-
modal strategies of two or more combinations of drugs, radiosensitizers, and radiotherapy 
could be promising for the quite invulnerable tumor entity; however, multimodal regimens fre-
quently implicate high toxicities (Niyazi et al., 2011). 
2.2 Ionizing radiation: physical and biological effects 
Radiotherapy, using ionizing radiation, is implemented as a standard treatment modality in 
oncology, either as monotherapy or together with surgery, chemo- or targeted therapy. With 
the discovery of X-rays in 1895, Wilhelm Conrad Röntgen paved the path for tremendous med-
ical advances, enabling to image and treat diseases. X-ray radiation presents the most fre-
quently used radiation type in radiotherapy, and more than 50 % of all cancer cases should 
receive radiation as a curative regimen (Barker et al., 2015; Delaney et al., 2005; E. J. Hall & 
Giaccia, 2012; Joiner & van der Kogel, 2009). 
There are two groups of ionizing radiation: electromagnetic radiations, consisting of X- 
and γ-rays, and particulate radiations including electrons, protons, α-particles, neutrons, and 
heavy charged particles like carbon. These groups differ in their mechanisms of action. Partic-
ulate irradiations of high kinetic energy are directly ionizing, meaning they can interfere with 
atomic structures in the material they are absorbed by and produce chemical or biological 
alterations. In contrast, electromagnetic radiation is indirectly ionizing and not harmful. How-
ever, upon its absorbance in the target material, the energy is transferred and charged, harmful 
particles (= secondary electrons) are produced. Absorbed doses are given in the unit of Gray 
(Gy), equivalent to an energy absorption of 1 J/kg (E. J. Hall & Giaccia, 2012). 
The spatial distribution of ionizing events in the material differs between applied radia-
tion types and determines the biological effects. The linear energy transfer (LET) specifies the 
transferred energy per unit length of the track, usually given as kilo-electron volts (keV) per 
µm. X-rays, defined as low-LET (< 3.5 keV/µm) radiations, are considered sparsely ionizing 
radiations since ionization events along the track of the mobilized electrons are predominantly 
spatially separated. On the opposite, these events are located more closely in densely ionizing 
radiation, as it is seen for neutrons or α-particles. With an increase in LET, the biological ef-
fectiveness of radiation is also enhanced. The relative biological effectiveness (RBE) com-
pares a radiation type of interest with a reference radiation, often 250-kV X-rays. The higher 
the LET, the more frequent ionizing events occur, and the cell kill induced per Gy is enhanced 





Figure 2.2: Depth-dose-profiles of photon and proton irradiation. Illustration of the dose curves of photon and 
proton radiation in the tumor and surrounding tissues indicated by depth in tissue. The curve of photons is charac-
terized by a higher entrance dose and a slow decline of dosage already throughout the tumor and beyond, resulting 
in higher doses behind the tumors than seen for protons. The dose curve of proton beams slowly increases, reaches 
its maximum throughout the tumor by spreading out the Bragg peak, and decreases directly behind the tumor (taken 
and modified from Baumann et al. (Baumann et al., 2016)). 
Already in 1946, protons were suggested for application in radiotherapy by Dr. Robert 
Wilson. To date, only 70 facilities worldwide offer proton beam therapy; one of them is the 
University Proton Therapy Dresden. Protons belong to the group of light particles and possess 
remarkable characteristics owing to their dose distribution. The particles are sparsely ionizing 
(LET of 0.5 keV/µm) except for a densely ionizing peak (LET of max. 100 keV/µm) at the end 
of the track before they stop. This peak is called Bragg peak, and by applying various energies, 
this peak can be spread out (spread-out Bragg peak, SOBP). The SOBP enables an exact 
location of high doses in a specific area, rendering protons very attractive for radiotherapy as 
it requests high precision. Normal tissue is additionally spared by the protons’ depth dose pro-
file, as lower doses are transmitted to smaller areas of normal tissue (Figure 2.2). The RBE of 
protons is marginally higher (10 %) in comparison to X-ray irradiation; however, the value of 
1.1 is under debate (Chaudhary et al., 2014; E. J. Hall & Giaccia, 2012; Lühr et al., 2018; Vitti 
& Parsons, 2019) 
For both kinds of radiation, the DNA presents the primary cellular target (Figure 2.3). 
Biological effects result from direct or indirect actions of photons or protons. Secondary elec-
trons or recoil electrons can directly interact with the DNA. Indirect mechanisms in aqueous 
surroundings result from electrons interacting with water molecules, leading to ionization of a 
water molecule. Upon the generation of H2O+ the ion and free radical interacts in the next step 
with another water molecule. OH∙, a highly reactive hydroxyl radical, is formed and able harm 
the DNA. Indirect actions of radiation via free radicals are estimated to be responsible for two-




mutagenesis, or carcinogenesis. Irradiation-induced effects start within microseconds after ex-
posure; however, they might become noticeable only years after (E. J. Hall & Giaccia, 2012; 
Joiner & van der Kogel, 2009). 
 
Figure 2.3: Direct and indirect actions of ionizing radiation. The DNA is represented here in a simplified 
scheme. Secondary electrons, emerging from absorbed photons, interact either directly or, more frequently, indi-
rectly with the DNA. In the indirect action, free radicals are produced, for instance, from the encounter of secondary 
electrons with water, and the emerging highly reactive OH∙radicals subsequently damage the DNA (modified from 
Hall and Giaccia (E. J. Hall & Giaccia, 2012), created with BioRender.com). 
2.3 Radiation-induced DNA damage and DNA damage repair 
Clinically relevant doses between 1 and 2 Gy of ionizing irradiation can induce different kinds 
of DNA damage. These include base damages, single strand breaks (SSB), double strand 
breaks (DSB) and DNA-DNA or DNA-protein-crosslinks. Base damages are the most frequent 
events with > 1000, followed by SSBs with 1000 and DSBs present the least number of events 
with 40 upon application of 1 Gy. In general, unsuccessful DNA damage repair can induce 
mutations and loss of genetic information, potentially resulting in cancer and hereditary dis-
eases. While SSB and other DNA damages are mostly efficiently repaired, DSB breaks require 
more complex repair mechanisms and, if not repaired, are lethal for the cell. During mitosis, 
DSB are translated into chromosomal aberrations like deletions or translocations, eventually 
resulting in mitotic cell death (E. J. Hall & Giaccia, 2012). 
DNA damage response is triggered by DSBs and initiated by the recruitment of a group 
of proteins (Figure 2.4). The initial DSB sensor is the MRN complex, comprising Meiotic Re-
combination 11 (Mre11), Nijmegen breakage syndrome protein 1 (Nbs1), and Rad50. Mre11 
holds exo- and endonuclease activity and is responsible for the resection of the DNA ends. 
Rad50 binds the DNA. Furthermore, it ensures the necessary proximity of the DNA ends. Upon 
MRN complex localization in the nucleus and at the DSB site, a process guarded by Nbs1, 




ATM and Rad3 related (ATR), and DNA-dependent protein kinase catalytic subunit (DNA-
PKcs) (Blackford & Jackson, 2017; Stracker & Petrini, 2011; Uziel et al., 2003; Williams et al., 
2010). ATM phosphorylates the histone variant H2AX to γH2AX. γH2AX serves as a signal for 
mediator of DNA damage checkpoint protein 1 (MDC1). Together with the MRN complex 
MDC1 stabilizes γH2AX at the DSB site (Blackford & Jackson, 2017; Uziel et al., 2003). MDC1 
activates chromatin restructuring by other proteins, and the structural reorganization recruits 
p53 binding protein 1 (53BP1) to the DSB. 53BP1 stabilizes the MRN complex as well as ATM 
at the DSB and is activated by the latter (Blackford & Jackson, 2017; Ciccia & Elledge, 2010; 
Goodarzi & Jeggo, 2013). Radiation-induced DSBs, termed foci, can be visualized and quan-
tified by immunofluorescence staining of, for instance, 53BP1 and γH2AX (Goodarzi & Jeggo, 
2013; Löbrich & Jeggo, 2005). 
In mammalian cells, two DNA repair pathways exist (Figure 2.4), homologous recom-
bination (HR) and non-homologous end joining (NHEJ). HR is restricted to late S phase and 
G2 phase and is characterized as error-free as the sister chromatid is present serving as a 
template. NHEJ is known for rather inaccurate DNA repair and active throughout the whole 
cell cycle but dominating G0/G1 a (Goodarzi & Jeggo, 2013). 
The DNA repair process of HR proceeds as follows: Upon DSB recognition and binding 
by the MRN complex, the DNA is resected, facilitated by C-terminal binding protein interacting 
protein (CtIP), resulting in 3’ single-strand DNA overhangs. The overhangs are covered by 
RPA and HR-specific repair proteins, RAD51, RAD52 and BRCA1/2, are recruited to the dam-
age sites. BRCA1 is an antagonizer of the NHEJ-mediator 53BP1. BRCA2 follows BRCA1 and 
enables positioning of RAD51, the protein bearing an essential role in HR, on the RPA coated 
single strands. This step is accompanied by the replacement of RPA by RAD51. Rad52 attrac-
tion hinders exonucleolytic degradation and assists RAD51-driven invasion of the overhang 
into the sister chromatid – a formation called Holliday junction. Rad54 and the DNA polymerase 
enable the repair by unwinding the DNA, filling the missing sequences, and resolving the Hol-
liday junction. Finally, DNA ligases connect the filled gaps (Blackford & Jackson, 2017; 





Figure 2.4: DNA repair mechanisms. DNA DSBs are repaired either by HR, alt- or c-NHEJ. Rad51 presents a 
specific DNA repair protein for the HR, while MRN and CtIP participate both in alt-NHEJ and HR. Alt-NHEJ is 
specified by the presence of PARP, whereas c-NHEJ demands the Ku70/Ku80 (modified from Chang et al. 
(Chang et al., 2017)). 
NHEJ is classified into the classical (c-) and alternative (alt-) NHEJ. C-NHEJ does not 
require resection but binding of the Ku heterodimer. The complex, consisting of Ku80 and 
Ku70, saves the DNA ends from nucleolytic degradation and attracts DNA-PKcs to the damage 
site. After the formation of the DNA-PK holoenzyme, both autophosphorylation of DNA-PK and 
its activation by the Ku complex result in end processing by the recruitment of assisting repair 
proteins, Artemis, polynucleotide kinase 3’ phosphatase (PNK), and the DNA polymerases µ 
and λ. The c-NHEJ is finalized collectively by Ligase IV (LIG4), the X-ray repair cross comple-
menting 4 (XRCC4), and XRCC4-like factor (XLF) by ligating the filled parts (Blackford & 
Jackson, 2017; Ceccaldi et al., 2016; Goodarzi & Jeggo, 2013; Mladenov et al., 2013). 
Initially, the alt-NHEJ was considered a backup pathway in case the c-NHEJ fails to 
repair the DSB. However, there are indications for a stand-alone part in DNA repair (Ceccaldi 
et al., 2016; Chang et al., 2017). Alt- NHEJ uses microhomology present between the two DNA 
ends and functions independent of the Ku complex and DNA-PKcs. In the alt-NHEJ, the MRN 
complex and CtIP carry out DNA resection, which is almost absent in c-NHEJ. PARP, one 
central enzyme in this repair pathway, anneals the DNA and recruits the DNA polymerase θ 
(Pol θ). Pol θ synthesizes without a template, rendering the alt-NHEJ more error-prone. 
Freshly synthesized parts require the XRCC1/DNA ligase III complex for ligating the breaks 
(Ceccaldi et al., 2016; Chang et al., 2017; Goodarzi & Jeggo, 2013; Mladenov et al., 2013). 
2.4 Extracellular matrix and cell adhesion 
The extracellular matrix (ECM) comprises the non-cellular structures, consisting of water, pro-
teins, and polysaccharides, thus providing a scaffold for tissues and organs. It functions as a 
driver of various cellular processes necessary for homeostasis, differentiation, and morpho-




compositions of proteoglycans and glycoproteins: the interstitial ECM, surrounding the cells 
and serving as a scaffold for tissues, and the basement membrane, separating the epithelium 
from the stroma, i.e., the interstitial ECM. The ECM composition and its impact on cells are 
tissue dependent (Bonnans et al., 2014; Frantz et al., 2010). The ECM, mainly constituted of 
water, consists of two classes of macromolecules. The first class is fibrous proteins, including 
collagens and elastin. The second class comprises glycoproteins, such as proteoglycans, fi-
bronectin, or laminin (Mouw et al., 2014). The ECM is enriched by cytokines, growth factors, 
and hormones and steadily reconstructed predominantly by matrix-metalloproteases (MMPs) 
(Bonnans et al., 2014; Mott & Werb, 2004; Spencer et al., 2007). 
The interaction of cells with the ECM is a rudimental feature of multicellular structures 
for developmental or healing processes and a functional immune system. However, these in-
teractions can facilitate the development or severeness of diseases, such as cancer (Geiger 
& Yamada, 2011). Cellular adhesion to the ECM is an interdependent mechanism. Both cells 
and ECM undergo structural organization upon sensing and signaling processes. Cell fate is 
influenced by external events resulting in proliferation, survival, and differentiation. Reversely, 
cells impact ECM remodeling and reconstruction, for instance, by the secretion of matrix 
(Geiger & Yamada, 2011). The homeostasis of ECM composition and the resulting stiffness in 
tissues can change with pathologies, such as desmoplasia of the tumor microenvironment. 
Moreover, cancer progression can result from changes of mechanical forces and signaling 
from outside the cells (Butcher et al., 2009; Geiger & Yamada, 2011). 
Cell adhesion is mediated by various integrins and membrane receptors and consists 
of distinct shapes and formations. Integrin-mediated formations are focal complexes, focal ad-
hesions, podosomes, and invadopodia, that enable cell-ECM contact. Focal adhesions are 
restricted areas of some square µm of the cell membrane in which integrins and involved adap-
tor and signaling molecules provide the connection to the cellular actin-cytoskeleton (Burridge, 
1988; Geiger & Yamada, 2011; Hehlgans et al., 2007; Shattil et al., 2010). Integrin-independ-
ent cell-ECM contacts can be mediated by other receptors such as CD44, growth factor recep-
tors, the discoidin receptors 1 and 2 (DDR1/2), or syndecans (Frantz et al., 2010; Geiger & 
Yamada, 2011). Integrins are transmembrane cell surface receptors and represent the central 
part of cell adhesion mediating molecules. They were previously thought to principally connect 
ECM to cytoskeleton. However, today, after almost 35 years of research on integrins, the ad-
hesion receptors are known for a myriad of signaling and structural events. Information is chan-
neled by integrins alone or in concert with other cell surface receptors and via numerous adap-
tor, scaffold, and signaling proteins, collectively called the ‘integrin adhesome’. The collection 
of proteins interrelated with integrins was defined starting with literature curation and updated 




paxillin, talin-vinculin, and α-actinin-zyxin-VASP hubs are noteworthy (de Franceschi et al., 
2015; Geiger & Yamada, 2011; Horton et al., 2015, 2016; Sun et al., 2019). 
2.5 Cell adhesion molecules: integrins 
Integrins are heterodimeric receptors consisting of an α- and a β-subunit. Out of 18 α- and 8 β-
subunits, 24 different receptors evolve in mammals (de Franceschi et al., 2015; Hynes, 1987, 
2002). α and β subunits are both type I transmembrane glycoproteins; however, they differ in 
their structural composition. The basic assembly is similar, comprising a large extracellular 
domain with head and leg modules and a size of more than 700 amino acids, followed by a 
single-spanning transmembrane domain and a short cytoplasmic tail of approximately 70 
amino acids (Figure 2.5). The head of the α subunit is a seven-bladed module called β-propel-
ler. Half of the α integrins possess an α I domain within this structure. The propeller is followed 
by the leg part consisting of Thigh, Calf-1, and Calf-2 domains. Both α- and the β-integrins are 
composed of transmembrane domains and cytoplasmic tails, the latter being shorter in the α-
subunit. The head of the β integrins comprises the β I-like domain. The leg is constituted by 
the hybrid domain and the PSI-(plexin-semaphorin-integrin) domain connecting the head to 
four cysteine-rich epidermal growth factor (EGF) domains. The extracellular part ends with the 
β-tail domain located close to the membrane connected to the transmembrane module 
(Campbell & Humphries, 2011; Danen, 2013; Gahmberg et al., 2009; Liddington & Ginsberg, 
2002; Shimaoka et al., 2002; J.-P. Xiong et al., 2001). 
 
Figure 2.5: Integrin structure and activation. Integrin receptors comprise an α- and a β-subunit. Each subunit 
contains a long extracellular part, a transmembrane domain and a short cytoplasmic tail. The composition of do-
mains is unique for each subunit. Upon ligand binding or intracellular binding of adaptor proteins the receptors are 
activated and undergo a conformational change from bent to lifted (modified from Cooper and Giancotti (Cooper & 
Giancotti, 2019)). 
The receptors demonstrate differential substrate specificities (Figure 2.7). Binding of 
ECM proteins to integrins is governed by short amino acid sequences located in the large 
extracellular domain. Motifs, found in the ECM proteins, are RGD (Arg-Gly-Asp) for fibrinogen, 




GFOGER (glycine–phenylalanine–glycine–glutamicacid–arginine) for collagen, are recog-
nized (Cordes et al., 2009; Danen, 2013; de Franceschi et al., 2015). 
A particular feature of integrins is their capability to perform both ‘outside-in’ and ‘inside-
out’ signaling. The heterodimeric receptors continuously fluctuate between active and inactive 
states (Figure 2.5). Activity is conferred either extracellularly by specific ligand or metal ion 
binding or intracellularly by activators, such as the adaptor proteins talins or kindlins, binding 
to the cytoplasmic tails. Receptor activation is accompanied by conformational changes from 
a bent “OFF” status via an extended position towards a lifted “ON” status, defined by low and 
high affinities towards ligands, respectively (Bouvard et al., 2013; Calderwood et al., 2013; 
Hynes, 2002; Liddington & Ginsberg, 2002; Shattil et al., 2010; Shimaoka et al., 2002; Sun et 
al., 2019). ‘Outside-in’ signaling provides a connection of the ECM with the cell and the cyto-
skeleton. Since integrins lack intrinsic kinase activity, a complex of structural proteins, such as 
paxillin and talin, adaptor proteins like p130Cas, and kinases such as the focal adhesion kinase 
(FAK) is recruited. Altogether this interplay conveys signaling cascades or mechanotransduc-
tion. The signaling directions are strongly entangled with each other and entail alterations in 
proliferation, survival, differentiation, apoptosis, migration, and invasion of cells (Bouvard et 
al., 2013; Hehlgans et al., 2007; Humphries et al., 2019; Miyamoto et al., 1995; Shattil et al., 
2010). Circulating cells, like blood cells, demand the possibility of integrin inactivation. In ad-
herent cells, however, inactive receptors might even bear regulatory functions in focal adhe-
sion assembly. Proteins involved in integrin inactivation, such as filamin, prevent adaptor pro-
teins from binding to the cytoplasmic domain of integrins. The inactive status of integrins is 
stabilized subsequently by other inactivators, such as SHANK-associated RH domain-interact-
ing protein (SHARPIN) and integrin cytoplasmic domain-associated protein 1 (ICAP1) 
(Bouvard et al., 2013; Sun et al., 2019). Integrin heterodimers can cluster into oligomers. This 
integrin clustering influences adhesion lifetime, outside-in signaling, and therapy resistance 
among other processes and may even be regulated by the activity status of the receptors 





Figure 2.6: Integrin-mediated signaling in cancer. Upon ligand or adaptor protein binding, integrin-mediated 
signaling is activated and supported by the integrin adaptor proteins such as paxillin. Due to the lack of intrinsic 
kinase activity, kinases like integrin-linked kinase (ILK) or FAK are recruited. Signaling proteins like Src or AKT are 
involved in signal transmission, influencing survival, proliferation, or apoptosis, resulting in therapy resistance. 
Crosstalk with growth factor receptors, such as RTKs, is known to affect both receptors mutually (modified from 
Cordes et al. (Cordes et al., 2009), created with BioRender.com). 
Since signaling axes are not unique for integrins but shared with other receptors, such 
as growth factor receptors (GFRs) and in particular receptor tyrosine kinases (RTKs), a mutual 
interplay between receptors can occur (Figure 2.6). The interrelation of integrins and GFRs is 
heterogeneous and can be direct – upon GFR embedding in integrin clusters or growth factor 
binding by integrin receptors – and indirect by growth factor-induced integrin activation. Addi-
tionally, cross-phosphorylation events are known to occur. Collectively, the collaboration en-
sues enhanced activation of downstream kinases such as Src, MAPK, or Akt. Besides, cell 
membrane expression of the receptors or their respective ligands can be regulated by the 
other. Increased cell survival and migration of tumor cells are consequences of this crosstalk 
(Cordes et al., 2009; de Franceschi et al., 2015; Desgrosellier & Cheresh, 2010; Eke et al., 
2015; Hamidi & Ivaska, 2018; Ivaska & Heino, 2011; Seguin et al., 2015; J. Xiong et al., 2013). 
Cell adhesion and the resulting signaling events are highly dynamic processes and 
demand trafficking and recycling of integrins. Endocytosis of integrins into early and late en-
dosomes or lysosomes is either clathrin- or caveolin-dependent. Several conditions are known 
to impact endocytosis: the type of adhesion, the activity status of the receptor, heterodimer 
constitution, composition of the cytoskeleton involved, and adaptor or scaffolding proteins pre-
sent at the focal adhesion sites. Trafficking of integrins is essentially mediated by small 
GTPases, namely Rho, Rab and Arf GTPases. Integrin recycling, in contrast to degradation, 
is the main traffic event. Trafficking and recycling of integrins is a sensitive system. For in-




adhesions and promote invasion and migration (de Franceschi et al., 2015; M. R. Morgan et 
al., 2013). 
2.6 β1 integrins 
2.6.1 Role in physiology and cancer 
The β1 subunit is ubiquitously expressed and presents the major subgroup of integrins con-
tributing to 12 out of the 24 integrin receptor combinations (Figure 2.7). In combination with 
various α integrin subunits, β1 integrins serve as receptors for ECM proteins like collagens, 
laminins, and fibronectins (Bellis, 2004; Humphries et al., 2006; Hynes, 2002). 
β1 integrins are vital proteins, which becomes apparent in knockout mice (Fässler & 
Meyer, 1995). Embryogenesis is hampered upon absent β1 integrin-mediated laminin-1 ex-
pression, resulting in a lack of basement membrane formation and ectoderm differentiation. 
Upon implantation and basement membrane development, β1 integrins contribute cell type-
dependently to proliferation, migration in normal tissue development, and cell function; how-
ever, loss of the receptors is not lethal (Brakebusch & Fässler, 2005). 
 
 
Figure 2.7: The family of integrin receptors. The constitution of integrin receptors defines ligand affinity. β1 in-
tegrins present the subunit most engaged in receptor formation and thus are part of the groups of RGD-binding, 
laminin-binding, and collagen-binding receptors (modified from Hynes (Hynes, 2002)). 
Alternative splicing can impact the protein functions of β1 integrins. Differing variants 
demonstrate differential tissue expression and specificities for adaptor proteins (Soto-Ribeiro 
et al., 2019). The NPXY motif is essential for signaling processes and is located in the cyto-
plasmic tail. While splice variants β1A and D possess the NPxY motif, variant β1B is unable to 
contribute to signaling due to the absence of the c-terminal part of variant β1A (Cordes et al., 




The expression of β1 integrins and distinct receptors comprising β1 integrins is either 
upregulated in several cancer types, like HNSCC and breast cancer, or linked to tumor pro-
gression and poor patient survival. Intriguingly, in tumors, often those ECM proteins bound by 
receptors comprising the β1 integrin subunit are overexpressed. However, opposing observa-
tions, like the characterization of α2β1 receptor in breast cancer as beneficial, i.e., tumor sup-
pressive, point out specific functions of β1 integrins in different tumor entities (Desgrosellier & 
Cheresh, 2010; Eriksen et al., 2004; Howe & Addison, 2012; E. S. Yao et al., 2007). Conse-
quently, thorough further investigations of β1 integrins and their role in cancer are demanded. 
The value of β1 integrins as a prognostic marker has been investigated in various tumor 
entities. For PDAC, no such value was shown for the patients’ overall survival (Bottger et al., 
1999), contrary to its presence in metastatic melanoma, adenocarcinoma of Berret’s esopha-
gus and serous adenocarcinomas of the ovary (Bottger et al., 1999; Müller-Klingspor et al., 
2001; Vihinen et al., 2000). In a retrospective study of Cordes et al., overall survival, loco-
regional control, or lack of distant metastasis of HNSCC patients receiving primary ra-
dio(chemo)therapy were independent of β1 integrin expression, limiting its function as a bi-
omarker in HNSCC (Cordes et al., 2018). 
Various studies demonstrated that β1 integrins mediate cancer progression and ther-
apy resistance. However, the mechanisms and channeling of signals strongly depend on the 
tumor entity or even the analyzed cancer cell lines. Altered expression and activation of β1 
integrins promote independence from anoikis, a cell death mechanism induced upon loss of 
cell-ECM contact, and entails activation of survival signaling and, consequently, tumor pro-
gression (Blandin et al., 2015; Howe & Addison, 2012; Ivanova et al., 2013; Pan et al., 2018). 
β1 integrins are involved in tumor aggressiveness, manifested by metastasis and invasion. 
These processes include transmission of the receptors via exosomes, thus, driving metastasis 
in certain tumor entities. Furthermore, alterations in expression between metastases compared 
to the primary tumors were observed. Interactions of the receptors with ligands such as fibron-
ectin together with GFR crosstalk and subsequent signaling resulting in cell survival, metasta-
sis, and invasion point out the significant role of β1 integrins, although contrary, inhibitory 
mechanisms have been observed (Barrow-McGee et al., 2016; Blandin et al., 2015; Hamidi et 
al., 2016; Hoshino et al., 2015; Howe & Addison, 2012; Navab et al., 2016; Pan et al., 2018). 
Numerous investigations attributed β1 integrins a crucial role in resistance towards ra-
dio-, chemo- or targeted therapy in cancer cells originating from various tumor entities. 
(Carbonell et al., 2013; Cordes, Hansmeier, et al., 2003; Dickreuter et al., 2016; Eke, Deuse, 
et al., 2012; Eke, Dickreuter, et al., 2012; Eke, Schneider, et al., 2013; C. C. Park et al., 2008). 
The increase in radiosensitivity in HNSCC cells, conferred cell line-dependently by targeting 
of β1 integrins, was enhanced by concomitant EGFR targeting in vitro and in vivo (Eke et al., 




was as effective as single irradiation with 8 Gy (Park 2008). The therapy sensitizing potential 
of β1 integrin targeting was also demonstrated for anti-angiogenic bevazucimab and doxoru-
bicin in glioblastoma and T-cell acute lymphoblastic leukemia cells, respectively (Berrazouane 
et al., 2019; Carbonell et al., 2013). 
2.6.2 Targeting β1 integrins in clinical studies 
As discussed in the previous section, targeting of β1 integrins in preclinical studies demon-
strated an efficient increase in radio- and chemosensitivity or their combination in various tu-
mor entities, rendering β1 integrins a promising target for clinical interventions. In the preclini-
cal studies, β1 integrins are blocked specifically; thus, various heterodimeric receptors are 
affected simultaneously (Figure 2.7). However, the inhibitors tested in clinical trials until now 
target one specific receptor heterodimer, the fibronectin receptor α5β1, and address cancer 
cure by suppressing angiogenesis. Volociximab (M200), a humanized monoclonal antibody, 
failed in ovarian cancer to be beneficial in a PII trial. In contrast, its use in other tumor entities, 
such as pancreatic cancer, here combined with gemcitabine, or lung cancer provided favorable 
results with moderate side effects (Almokadem & Belani, 2012; Barkan & Chambers, 2011; 
Bell-McGuinn et al., 2011; Besse et al., 2013). The peptide ATN-161, an antagonist of α5β1, 
was well tolerated in phase I clinical trials in patients with solid tumor and should be combined 
in a phase II trial with irradiation and chemotherapy in HNSCC patients, but progress reports 
are missing (Alday-Parejo et al., 2019; Barkan & Chambers, 2011; Cianfrocca et al., 2006; D. 
Cox, 2020). 
Clinical targeting of other integrin receptors aVβ3 and aVβ5 with cilengitide provided 
promising results in phase II clinical trials as monotherapy or as combinational therapy in glio-
blastoma and pancreatic cancer, among other entities. Disappointingly, the desired efficacy 
was not achieved in phase III. In general, integrin targeting strategies faced some challenges: 
agonist instead of antagonist properties of the drugs and conformational changes resulting in 
interactions with other cell surface receptors provoked the failure of some targeting options. 
These malfunctions underpin the need for novel targeting strategies. Addressing the intracel-
lular domain or exploiting integrin signaling by targeting downstream molecules is under de-
bate and gives hope to observe the outstanding preclinical effects in future in the patients 
(Alday-Parejo et al., 2019; D. Cox, 2020; D. Cox et al., 2010; Stupp et al., 2014). 
2.7 Cell adhesion and cancer therapy resistance 
In vitro studies are often conducted with cells growing in plastic. However, when grown on the 
ECM protein fibronectin, both cancer cells of various tumor entities such as glioblastoma, pan-
creatic cancer, or breast cancer cells, among others, and normal cells, like fibroblasts, were 




Cordes & Meineke, 2003). Cell-ECM or cell-cell contacts are drivers for resistance, and the 
resulting resistance mechanisms are conflated in the terms cell adhesion-mediated radiore-
sistance (CAM-RR) or cell adhesion-mediated drug resistance (CAM-DR) (Cordes & Meineke, 
2003; Damiano et al., 1999). Cell adhesion to fibronectin resulted in higher resistance towards 
EGFR targeting with cetuximab alone and in combination with irradiation (Eke, Storch, et al., 
2013). Moreover, various studies revealed that cancer cells embedded in a more physiological 
3D matrix rich in laminin were not only more resistant to radio- and chemotherapy but, further-
more, demonstrated differing gene and protein expression in 3D compared to 2D culture con-
ditions (Eke & Cordes, 2011; Le Beyec et al., 2007; Lelièvre, 2009; Zschenker et al., 2012). 
While 2D cultured adherent cells grow flat-shaped, in 3D conditions, a round cell shape can 
be observed accompanied by alterations in the actin-cytoskeleton structures (Eke & Cordes, 
2011). Furthermore, 3D cultured squamous cell carcinoma cells demonstrated remarkable 
similarity in protein phosphorylation to the corresponding cells in in vivo tumor xenografts. This 
underpins the potential of 3D cell culture model to imitate physiological growth conditions (Eke, 
Schneider, et al., 2013). 
Integrins bear a crucial role in CAM-RR and CAM-DR (Figure 2.6). 3D cellular growth 
conditions enhanced and stabilized β1 integrin clustering and resulted in radioresistance in 
mouse embryonic fibroblasts (Babel et al., 2017). Additionally, other receptors, e.g. RTKs, and 
numerous focal adhesion proteins are involved in cell adhesion-mediated resistance. The re-
sulting signaling cascades impinge DNA repair, cell cycle, cytoskeletal organization, and cell 
death mechanisms like apoptosis. Consequently, changes in cell survival, differentiation, pro-
liferation, or motility affect the resistance (Cordes & Van Beuningen, 2003; Dickreuter et al., 
2016; Eke et al., 2015; Eke, Storch, et al., 2013; Eke & Cordes, 2015). Recently, the collagen 
receptor and tyrosine kinase discoidin receptor 1 (DDR1) was found to mediate radiochemo-
resistance via an autophagy-related signaling cascade in glioblastoma cells (Vehlow et al., 
2019). 
Additionally, other microenvironmental factors contribute to treatment failure. Soluble 
factors found in the tumor surrounding such as cytokines or growth factors or other non-cancer 
cells, like cancer-associated fibroblasts, are known resistance-drivers Furthermore, 
desmoplasia – often found in PDAC – hampers an adequate drug delivery due to the high 
density of ECM proteins (Henke et al., 2020; Meads et al., 2009; Schober et al., 2014; Whatcott 
et al., 2015). 
The contents of sections 4.2.7, 5.2 and 6.7 have been published in similar form by Görte et al. 
(Görte et al., 2020) and are adapted according to Erratum/Corrigendum submitted to Cancers 
on May 11th in 2021. 
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3 Hypothesis and Aims 
The hypothesis of the first work package is that β1 integrins bear an essential role in conferring 
both intrinsic and acquired radiochemoresistance in PDAC and that its targeting elicits an in-
creased efficacy of therapies. The hypothesis of the second work package is that proton and 
photon irradiation affect PDAC cell survival differentially and that thereupon induced unique 
molecular alterations can be exploited for a radiation type-specific radiosensitization. 
The aims of the first work package are to investigate the effect of β1 integrin inhibition 
combined with radiochemotherapy on the cell survival of therapy-naïve and radioresistant 
PDAC cultures and to reveal the underlying molecular mechanisms. Consequently, the impact 
of β1 integrin inhibition on the kinome in therapy-naïve and radioresistant PDAC cultures is 
assessed, and significantly deregulated kinases are identified for both cell types. Kinases in-
terrelated in the β1 integrin signaling associated with radiation survival response are unraveled 
in therapy-naïve and radioresistant PDAC cultures. 
The second work package aims to comparatively determine the radiation survival in 
PDAC cultures upon photon and proton exposure and unravel contributing molecular pro-
cesses. Therefore, phosphoproteomic changes upon photon and proton irradiation are as-
sessed in PDAC cultures, and alterations unique for each radiation type are identified. Radia-
tion survival upon targeting radiation type-specifically altered molecules with biologicals com-
bined with each radiation types is evaluated in PDAC cultures.
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4 Materials and Methods 
4.1 Materials 
4.1.1 Devices 
Table 4.1. Devices used for biochemical, molecular-biological or cell culture applications. 
Device Type Company 
Autoclave V-65 Systec, Wettenberg, GER 
Barometer  Conrad Electronics, Hirschau, GER 
Bio Imaging System  Genius Syngene Syngene, Cambridge, GB 
Centrifuge 5415R (for 15, 50 ml reac-tion tubes) Eppendorf, Hamburg, GER 
Centrifuge 
S415R (for 1,5 ml Safe-Lock 
reaction tubes) Eppendorf, Hamburg, GER 
Dosimeter PTW Unidos PTW, Freiburg, GER 
Film welding tool Dual Electronic Jencons-PLS, London, GB 
Freezer, -20 °C KX1011 Liebherr, Ochsenhausen, GER 
Freezer, -80 °C  Heraeus Holding GmbH, Hanau, GER 
Fridge  Liebherr, Ochsenhausen, GER 
Ice machine AT-10 Scotsman, London, GB 
Imager Fusion FX Vilber, Collégien, F 
Incubator cell culture HeraCell Heraeus Holding GmbH, Hanau, GER 
Incubator for liquids  Heraeus Holding GmbH, Hanau, GER 
Inverted Microscope Axiovert 25 Carl Zeiss, Jena, GER 
Laser Scanning Microscope LSM 980 with Airycan 2 Carl Zeiss, Jena, GER 
Microwave  Sharp Electronics (Europe) GmbH, Hamburg, GER 
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Device Type Company 
pH-meter ph Level 1 inoLab, Weilheim, GER 
Power Supply EPS601 Amersham, Freiburg, GER 
Precision scale LE244S-0CE Sartorius, Göttingen, GER 
Rotary shaker CERTOMAT®IS B. Braun Melsungen AG, Melsun-gen, GER 
Scale BL 1500S Sartorius, Göttingen, GER 
Semi Dry Blotter TE77 Amersham, Freiburg, GER 
Shaker Polymax 1040, 2040 Heidolph, Schwabach, GER 
Shaker KS260 basic IKA, Staufen, GER 
Stirrer, incl. heating MR3001 Heidolph, Schwabach, GER 
Sterile work bench Clean Air  Heraeus Holding GmbH, Hanau, GER 
Tecan Microplate-Reader Genios Pro Tecan, Crailsheim, GER 
Thermomixer comfort 1.5 ml Eppendorf, Hamburg, GER 
Vacuum pump Vacusafe comfort VacuSafe IBS Integra Bioscience, Chur, CH 
Vertical gel-electrophoresis 
chamber incl. accessory parts SE250 Hoefer, San Francisco, USA 
Vortex mixer Reax control VWR, Darmstadt, GER 
Water bath SW22 Julabo Labortechnik GmbH, Seel-bach, GER 
X-ray device Y.TU320 Yxlon, Kopenhagen, DK 
 
4.1.2 Materials 
Table 4.2. Materials used for biochemical, cell culture or molecular-biological applications. 
Material Company 
Cell culture flasks; T-25, T-75, T-175 cm2 Corning Life Science, Wiesbaden, GER 
Cell culture plates, 96-Well, flat bottom Corning Life Science, Wiesbaden, GER 
Cell culture plates; 6-, 12-, 24-Well BD, Heidelberg, GER 
Cell culture plates; 60 mm, 100 mm BD, Heidelberg, GER 
Cell scraper; 40 cm BD, Heidelberg, GER 
Centrifuge tubes; 15 ml, 50 ml Greiner Bio-one GmbH, Frickenhausen, GER 
Coverslips, 12 mm, round Glaswarenfabrik Karl Hecht KG, Sondheim, GER 




Cryovials Biochrom, Berlin, GER 
Glass pasteurpipets Brand GmbH u. Co. KG, Wertheim, GER 
Hamilton-Syringe, 100 µl Hamilton Bonaduz AG, Bonaduz, CH 
Hamilton-Syringe, 10 µl Hamilton Bonaduz AG, Bonaduz, CH 
Instrument case Roth, Karlsruhe, GER 
Insulin syringe, 0.3 mm x 12 mm Braun, Melsungen, GER 
Labory bottles Schott AG, Mainz, GER 
Nitrocellulose membrane Protran; 0.2 µm Schleicher & Schuell, Dassel, GER 
Microscopy slides, Superfrost Roth, Karlsruhe, GER 
Pipette tips with filter, sterile; 10-1000 µl Sarstedt, GER 
Pipettes; 1, 5, 10, 25 ml BD, Heidelberg, GER 
Pipette controller, accu jet pro Brand, Herrenberg, GER 
Reaction tube, Safe Lock; 1.5 ml, 2 ml Eppendorf, Hamburg, GER 
Reaction tube rack Rotilab, Roth, Karlsruhe, GER 
Staining chamber Roth, Karlsruhe, GER 
Whatman filterpaper; 3 mm Bender-Hobein, Zürich, CH 
 
4.1.3 siRNA 
In the RNA interference (RNAi) screen in section 5.1.6 ON-TARGETplus SMARTpool™ small 
interfering (si) RNAs (Dharmacon, a Horizon Discovery Group company, Lafayette, USA) for 
gene silencing of the listed genes in Figure 5.10 and a non-specific SMARTpool™ siRNA were 
used. 
Table 4.3. SiRNAs used to silence the indicated genes. Corresponding sequences are shown. 
siRNA Sequence (Sense) Company 
ITGB1#1 5‘-GGAACCCUUGCACAAGUGAtt-3‘ MWG Eurofins, Ebersberg, GER 
ITGB1#2 5‘-GGAUAUUACUCAGAUCCAAtt-3‘ MWG Eurofins, Ebersberg, GER 
ITGB1#3 5‘-GGAAUGUUCCUAUUUUAACtt-3‘ MWG Eurofins, Ebersberg, GER 
Nonspecific siRNA 5’-AAAACAGUUGCGCAGCCUGAAtt-3’ MWG Eurofins, Ebersberg, GER 
 




Ethanol (for Hydroxy-Tamoxifen), human IgG1 (for Ontruzant, Enzo), rat IgG1 (for AIIB2, Santa 
Cruz Biotechnology), rat IgG2a (for mAb13, Invivogen, Toulouse, FR), mouse IgG1 (for 
TS2/16, R&D Systems) and DMSO (for all other inhibitors) were used as controls. 
Table 4.4. Inhibitors used in cell culture experiments. 
Inhibitor Target Company 
AIIB2, rat, monoclonal β1 integrin 
Produced at OncoRay, Group 
of Molecular and Cellular Radi-
obiology 
CD 29 (mAb13) β1 integrin Merck, Darmstadt, GER 
CD29 (TS2/16), mouse, 
monoclonal 
β1 integrin ThermoFisher Scientific, Erlan-gen, GER 
KU55933 ATM Calbiochem, San Diego, CA, USA 
Prexasertib Chk1 Selleckchem, Houston, TX, USA 
NU7026 DNA-PK Selleckchem, Houston, TX, USA 
Tarceva® EGFR Roche, Basel, Switzerland 
Hydroxy-Tamoxifen ER-α Sigma Aldrich, Taufkirchen, GER 
Ontruzant® HER2 MSD SHARP & DOHME GMBH, Haar, GER 
SB203580 MAPK Selleckchem, Houston, TX, USA 
AMG232 MDM2 Axon Medchem, Groningen, NL 
PD98059 MEK Selleckchem, Houston, TX, USA 
LY294002 PI3K Selleckchem, Houston, TX, USA 
Olaparib PARP 
Cell Signaling, Frankfurt a. M., 
GER 
B02 Rad51 Axon Medchem, Groningen, NL 
Axitinib VEGFR Sigma Aldrich, Taufkirchen, GER 
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4.1.5 Chemotherapeutic agents 
Table 4.5. Chemotherapeutics used in cell culture experiments.  
Chemotherapeutic agent Company 
Cisplatin Hexal AG, Holzkirchen, GER 
Gemcitabine Accord Healthcare GmbH, München, GER 
Taxol Sigma Aldrich, Taufkirchen, GER 
 
4.1.6 Protein ladders 
The PageRuler Unstained (ThermoFisher Scientific, Erlangen, GER) and the Trident Pres-
tained Protein Ladder (Genetex, Irvine, USA) were applied as protein ladders for SDS gel 
electrophoresis. 
4.1.7 Method kits 
Table 4.6. Method kits used for biochemical applications. 
Kit Application Company 
BCA Protein Assay Kit Determination of protein concentration Pierce, Bonn, GER 
ECL Western Blotting 
Detection Reagents Western blot detection 
Amersham, Freiburg, 
GER 
Venor®GeM OneStep Mycoplasma test Minerv Biolabs, Berlin, GER 
 
4.1.8 Primary antibodies 
Table 4.7. Primary antibodies used for Western blot or immunofluorescence stainings.  
Antibody Application Dilution Company 
β-Actin, Klon AC-15, 
mouse, monoclonal Western blot 1:20000 
Sigma Aldrich, Taufkirchen, 
GER 
β1 Integrin, rabbit, mono-
clonal Western blot 1:5000 Abcam, Cambridge, UK 
β1 Integrin, mouse, mon-
oclonal Immunofluorescence 1:100 
Calbiochem, San Diego, CA, 
USA 
p-Chk1 Ser345, rabbit, 
monoclonal Western blot 1:1000 
Cell Signaling, Frankfurt a. M., 
GER 
Chk1 mouse, monoclo-
nal Western blot 1:1000 
Cell Signaling, Frankfurt a. M., 
GER 
p-ER-α, Ser118, mouse, 
monoclonal Western blot 1:500 
Cell Signaling, Frankfurt a. M., 
GER 
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Antibody Application Dilution Company 
ER-α, rabbit, monoclonal Western blot 1:500 Cell Signaling, Frankfurt a. M., GER 
p-HER2, Tyr1248, rabbit 
polyclonal Western blot 1:1000 
Cell Signaling, Frankfurt a. M., 
GER 
HER2, rabbit, monoclo-
nal Western blot 1:1000 
Cell Signaling, Frankfurt a. M., 
GER 
For F-Actin fluorescence staining Alexa Fluor® 488 Phalloidin (1:500; Life Technologies GmbH, 
Darmstadt, GER) was used. 
4.1.9 Secondary antibodies 
Table 4.8. Secondary antibodies used for Western blot or immunofluorescence stainings. 
Antibody Application Dilution Company 
Anti-mouse IgG, HRP con-
jugated Western blot 1:5000 Pierce, Bonn, GER 
Anti-rabbit IgG, HRP con-
jugated Western blot 1:5000 Pierce, Bonn, GER 
Alexa Fluor®594, Anti-
mouse IgG Immunofluorescence 1:200 
Life Technologies GmbH, 
Darmstadt, GER 
 
4.1.10 Solutions for cell biological applications 
Table 4.9. Solutions and compositions used for cell biological applications. 
Substance Composition Company 
1x PBS  Sigma Aldrich, Taufkirchen, GER 
1x Trypsin/EDTA (4 °C) Sigma Aldrich, Taufkirchen, GER 
1 % Agarose 
1 g Agarose  
ad 100 ml ddH2O 
Sigma Aldrich, Taufkirchen, GER 
10 nM Non-Essential Amino 
Acid Solution (NEAA) (4 °C) Sigma Aldrich, Taufkirchen, GER 
80 % Ethanol 800 ml Ethanol, denatured, 99 % ad 1 l ddH2O 
Berkel, Berlin, GER 
 
Cell culture medium  
DMEM with GlutaMAX™ 
(supplemented with 10 % 
FCS, 1 % NEAA) 





10 mg/ml, in DMEM 
BD, Heidelberg, GER 
Materials and Methods 
26 
 
Substance Composition Company 
Basement Membrane High 




5 mg/ml, in complete Medium 
(4 °C) 
Fetal Calf Serum (FCS) Heat inactivated prior to use: 30 min at 56 °C (- 20 °C) 




Life Technologies, Karlsruhe, 
GER 
Oligofectamine™  Life Technologies, Karlsruhe, GER 
OptiMEM with GlutaMAX™ (4 °C) Life Technologies, Karlsruhe, GER 
 
4.1.11 Solutions for protein-biochemical and molecular-biological applica-
tions 
Table 4.10. Solutions and compositions used for protein-biochemical and molecular-biological applications. 
Substance Composition Company 
10 % Ammonium persulfate 
(APS) 
1 g APS 
ad 10 ml ddH2O (- 20 °C) 
AppliChem GmbH, Darmstadt, 
GER 
10x Blotting buffer  
(Maniatis-SDS) 
29 g Glycine 
58 g Tris 
ad 1 l ddH2O 
Roth, Karlsruhe, GER 
Roth, Karlsruhe, GER 
1x Blotting buffer 
100 ml 10x Blotting buffer 
200 ml Methanol 
ad 1 l ddH2O 
Roth, Karlsruhe, GER 
 
5 % BSA solution 
0.5 g Bovine Serum Albumin  
ad 10 ml PBST (4 °C) 
Serva, Heidelberg, GER  
25x CompleteTM protease 
inhibitor cocktail 
1 Tablet 
ad 2 ml ddH2O (- 20 °C) 
Roche Diagnostics GmbH, 
Mannheim, GER 
0.5 M EDTA (pH 8) 
7.306 g EDTA (Titriplex) 
ad 50 ml ddH2O 
Merck, Darmstadt, GER 
HALT™ Protease Inhibitor 




itor Cocktail (100x)  
ThermoFisher Scientific, Er-
langen, GER 
10x Kinome Buffer  Cell Signaling, Frankfurt a.M., GER 
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Substance Composition Company 
5 % Milk powder  
5 g skimmed milk powder 
ad 100 ml 1x PBS (4 °C) 
AppliChem GmbH, Darmstadt, 
GER 
Modified 3x RIPA buffer (< 
0.1 % SDS, < 50 mM Tris) 
0.6 ml Tris-HCl (pH 7.4) 
0.15 ml NP-40 
0.135 ml (10 % SDS) 
0.45 ml 5 M NaCl 
0.03 ml 0.5 M EDTA 
ad 5 ml ddH2O 
(4 °C) 
AppliChem GmbH, Darmstadt, 
GER 
Fluka, München, GER 
AppliChem GmbH, Darmstadt, 
GER 
Merck, Darmstadt, GER 
Roth, Karlsruhe, GER 
5 M NaCl 
14.61 g NaCl 
ad 50 ml ddH2O 
Roth, Karlsruhe, GER 
500 mM NaF 
2.1 g NaF 
ad 100 ml ddH2O (- 20 °C) 
Sigma Aldrich, Taufkirchen, 
GER 
200 mM Na3VO4 
3.678 g Na3VO4 
ad 100 ml ddH2O (- 20 °C) 
Sigma Aldrich, Taufkirchen, 
GER 
20x PBS (pH 7.4) 
160 g NaCl 
4 g KCl 
36 g Na2HPO4 
4.8 g KH2PO4 
ad 1 l ddH2O 
Merck, Darmstadt, GER 
Merck, Darmstadt, GER 
Merck, Darmstadt, GER 
Merck, Darmstadt, GER 
 
1x PBS 
50 ml 20x PBS 
ad 1 l ddH2O 
 
PBS/0 05 % Tween20 
(PBST) 
0.5 ml Tween 20 
ad 1 l 1x PBS 
Serva, Heidelberg, GER 
6x Reducing electrophore-
sis loading dye 
5 ml Glycerol 
0.925 g DTT 
1.2 g SDS 
3.5 ml Tris 
1.2 mg Bromophenol blue 
ad 10 ml ddH2O (- 20 °C) 
Roth, Karlsruhe, GER 
AppliChem GmbH, Darmstadt, 
GER 
Roth, Karlsruhe, GER 
Roth, Karlsruhe, GER 
AppliChem GmbH, Darmstadt, 
GER 
3x RIPA buffer 
7.5 ml Tris-HCl (pH 7.4) 
1.5 ml NP-40 
3.75 ml 10% SDS 
4.5 ml 5 M NaCl 
0.3 ml 0.5 M EDTA 
ad 50 ml ddH2O 
(4 °C) 
AppliChem GmbH, Darmstadt, 
GER 
Fluka, München, GER 
AppliChem GmbH, Darmstadt, 
GER 
Merck, Darmstadt, GER 
Roth, Karlsruhe, GER 
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Substance Composition Company 
10 % SDS 
100 g SDS 
ad 1 l ddH2O 
Roth, Karlsruhe, GER 
10x SDS running buffer 
30.3 g Tris 
144.1 g Glycine 
10 g SDS 
ad 1 l ddH2O 
Roth, Karlsruhe, GER 
Roth, Karlsruhe, GER 
Roth, Karlsruhe, GER 
1x SDS running buffer 
100 ml 10x SDS running buffer 
ad 1 l ddH2O 
 
20x TBS 
121 g Tris 
175.2 g NaCl 
ad 1 l ddH2O 
Roth, Karlsruhe, GER 
 
TBS/0.0 5% Tween20 
(TBST) 
0.5 ml Tween 20 
ad 1 l 1x TBS 
Serva, Heidelberg, GER 
3 M Tris buffer (pH 8.8) 
181.71 g Tris 
ad 1 l ddH2O 
Roth, Karlsruhe, GER 
 
4.1.12 Solutions for immunofluorescence stainings 
Table 4.11. Solutions and compositions used for immunofluorescence stainings. 
Substance Composition Company 
0.25 % Triton X-100 125 µl Triton X-100 
ad 50 ml 1x PBS 
Roth, Karlsruhe, GER 
1 % BSA 0.5 g Bovine serum albumin (BSA) 
ad 50 ml 1x PBS 
Sigma Aldrich, Taufkirchen, 
GER 
3 % Formaldehyde 1 ml 37% Formaldehyde  
ad 11 ml 1x PBS 
Merck, Darmstadt, GER 
 
4.1.13 Additional solutions and chemicals 
Table 4.12. Additional solutions and chemicals used for biochemical or molecular-biological applications. 
Substance Company 
30 % Acrylamide bis-acrylamide solution (29:1) Serva, Heidelberg, GER 
Agarose, Type-A Sigma Aldrich, Taufkirchen, GER 
Dimethyl sulfoxide (DMSO) AppliChem GmbH, Darmstadt, GER 
Ethanol, denatured, 99 % Merck, Darmstadt, GER 
Formaldehyde, 37 % Merck, Darmstadt, GER 




Glycerol Roth, Karlsruhe, GER 
Isopropyl alcohol Merck, Darmstadt, GER 
Ponceau S Sigma Aldrich, Taufkirchen, GER 
ProLong Diamant Antifade Mountant with DAPI Life Technologies, Karlsruhe, GER 
Tetramethylethylene-diamine (TEMED) Merck, Darmstadt, GER 
 
4.1.14 PC programs 
Table 4.13. PC programs for data analysis and presentation. 
Program Company 
GraphPad Prism 8 GraphPad Software Inc., San Diego, USA 
Fiji (Image J) 
National Institutes of Health, Bethesda, Mary-
land, USA 
Fusion FX7 Edge Vilber, Collégien, FRA 
Magellan 5.0 Software Tecan, Crailsheim, GER 
Microsoft Office 2010 Microsoft Corp., Redmond, WA, USA 
ZEN 3.1 (blue edition) Carl Zeiss GmbH Jena, GER 
 
4.2 Methods 
4.2.1 Cell lines 
In this work, human pancreatic cancer cell lines from various origins were used (Table 4.14). 
The cell lines BxPC3, MiaPaCa2, Panc-1, and Patu8902 were purchased from the American 
Type Culture Collection (ATCC). Colo357 cell line was a kind gift from Chr. Pilarsky (University 
Erlangen-Nürnberg, Germany). Radioresistant cell lines of MiaPaCa-2 cells were generated 
(see section 4.2.6) at OncoRay. 
Table 4.14: Pancreatic cancer cell lines and their origin. 
Cell line Origin 
BxPC-3 Adenocarcinoma 
Colo357 
Adenosquamous carcinoma; derived from 
metastatic site: Celiac axis lymph node 
MiaPaCa-2 Carcinoma 
Panc-1 Epithelioid carcinoma; derived from ductus 
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Cell line Origin 
Patu8902 Adenocarcinoma 
 
4.2.2 Cell culture and passaging 
All cell lines were adherently grown in the corresponding cell culture vessel in cell culture me-
dium (composition in section 0) under standard cell culture conditions (37 °C, 8.5 % CO2, 
pH 7.4). At a confluency of 70-80 % cells were used for experiments or passaged every 3-4 
days. Upon washing the cells 1x with PBS cells were detached with Trypsin/EDTA and incu-
bation at 37 °C. Upon entire detachment of the cells complete DMEM was added and the cells 
were subcultured in ratios of 1:5 to 1:20 into fresh cell culture vessels. In all experiments, 
asynchronously growing cells were used. All cells tested negative for Mycoplasma by using a 
mycoplasma detection kit. 
4.2.3 Cell freezing and thawing 
At a confluency of 80-90 % cells were detached as described in section 4.2.2 and then centri-
fuged at 130 x g for 3 min at room temperature. The medium was discarded, and cells were 
carefully resolved in cryo medium. Depending on the cell culture vessel the cell suspension 
was distributed into 3-7 cryovials in a volume of 1 ml. First, cells were transferred into a freezing 
container with isopropanol for a controlled cooling to -80 °C. For short term storage cells were 
kept at -80 °C, liquid nitrogen was used for long term storage. 
Cells were thawed and immediately transferred into a tube containing fresh complete 
DMEM. After centrifugation at 130 x g for 3 mins at room temperature, the cell pellet was re-
suspended in fresh complete DMEM and transferred into a cell culture vessel for culture. 
4.2.4 siRNA knockdown 
RNA interference can specifically impede the expression of target proteins (Elbashir et al., 
2001). siRNA was used to knock down various target proteins in this work. For transfection, 
5 x 104 cells in 0.5 ml or 3 x 105 cells in 2 ml medium were plated in 12- or 6-well plates, re-
spectively. 24 h after seeding, cells were transfected. Depending on the experiment two differ-
ent transfection conditions were used. 
For the transfection using Oligofectamine, nonspecific control siRNA (siC) or specific 
siRNA were diluted in OpitMEM. An Oligofectamine/OptiMEM dilution was prepared in a dif-
ferent reaction tube (Table 4.15). After an incubation time 10 min of the two dilutions, the siRNA 
and the Oligofectamine dilutions were mixed and incubated for additional 20 min. In the mean-
time, cells were washed with OptiMEM. Finally, 800 μl OptiMEM per 6-well was added. Trans-
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fection of cells was performed using 200 μl (6-well) transfection mix. Following an 8 h incuba-
tion period under standard cell culture conditions, 1 ml of OptiMEM supplemented with 20 % 
FCS was added per well. 24 h after transfection, cells were used for experiments. 
Table 4.15: Concentrations and volumes for siRNA transfection in 6-well plates using Oligofectamine. 
C   siRNA dilution Oligofectamine dilution 
 csiRNA cfinal siRNA OptiMEM Oligofectamine OptiMEM 
6-well 
plate 20 µM 20 nM 1 µl 184 µl 4 µl 11 µl 
 
For the transfection of siRNA SMARTpool™ Lipofectamine RNAiMAX was used. For 
single knockdown, nonspecific control siRNA (siC) or specific siRNA SMARTpool were diluted 
in OptiMEM. For double knockdown, twice the volume of nonspecific control siRNA (siC) or 
two specific siRNA SMARTpools were diluted in OptiMEM. A Lipofectamine RNAiMAX/Opti-
MEM dilution was prepared in a different reaction tube (Table 4.16). After an incubation time 
10 min of the two dilutions, the siRNA and the Oligofectamine dilutions were mixed and incu-
bated for additional 20 min. In the meantime, cells were washed with OptiMEM. Finally, 1 ml 
and 2 ml OptiMEM per 12- and 6-well was added, respectively. Transfection of cells was per-
formed using 100 µl (12-well) and 260 μl (6-well) transfection mix. Following a 4-5 h incubation 
period under standard cell culture conditions, one third of the transfection solution was re-
placed by fresh complete DMEM (330 µl per 12-well or 750 µl per 6-well). 24 h after transfec-
tion, cells were used for experiments. 
Table 4.16: Concentrations and volumes for siRNA transfection in 12-well and 6-well plates using Lipofectamine 
RNAiMAX. 
C   siRNA dilution Lipofectamine dilution 











2 µM 10 nM 
5 µl + 
5 µl 40 µl 2 µl 48 µl 
6-well 
plate 20 µM 10 nM 1.3 µl 128.7 µl 5 µl 125 µl 
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4.2.5 Inhibitor treatment and chemotherapy 
Specific inhibitory or activating antibodies, inhibitors and chemotherapies were applied alone 
or in combination prior to irradiation. Cells were seeded for the 3D tumoroid formation assay 
(in section 4.2.8) and 24 h later complete medium enriched with anti- β1 integrin antibodies 
(AIIB2, TS2/16, mAb13; 10 µg/ml), pharmacological inhibitors for ATM (10 µM), Chk1 (1 and 
3 nM; EC10 for Colo357 and MiaPaCa-2), DNA-PK (10 µM), EGFR (10 µM), ER-α (10 µM), 
HER2 (Ontruzant: 2 µg/ml, Lapatinib: 1 µM),MAPK (10 µM), MAPK (10 µM), MDM2 (10 µM), 
MEK (20 µM), MRNcomplex (10 µM), PI3K (10 µM), PARP (10 µM), Rad51 (10 µM) and 
VEGFR (1 µM) or the chemotherapies gemcitabine (15 nM and 40 nM, EC10 for Colo357 and 
(RR-) MiaPaCa-2, respectively), cisplatin (0.015 nM and 0.7 nM; EC10 for Colo357 and (RR-) 
MiaPaCa-2, respectively) and taxol (0.9 nM and 1.5 nM, EC10 for Colo357 and (RR-) MiaPaCa-
2, respectively) with the indicated concentrations. Ethanol (for Hydroxy-Tamoxifen), the re-
spective IgG controls (for AIIB2, mAb13, TS2/16 and Ontruzant), complete DMEM (for chemo-
therapies) and DMSO (for all other inhibitors and Taxol) were used as controls. Chemothera-
pies and pharmacological inhibitors were carefully removed after 24 h and replaced by fresh 
complete DMEM. Schematic treatment illustrations are presented in Figure 5.2, Figure 5.6, 
Figure 5.12 and Figure 5.16. 
4.2.6 Generation of radioresistant PDAC cell lines 
The radioresistant (RR-) MiaPaCa-2 (RR-MiaPaCa-2) cell line was generated by fractionated 
radiation. 2-Gy irradiation was applied 5x per week for four weeks resulting in a total dose of 
40 Gy. The RR-MiaPaCa-2 cell line was generated with the technical assistance from Julie 
Wolfgang. During the course of fractionated radiation, cells were passaged when a confluency 
of 70-80 % was achieved. After the four weeks, cells were cultured for stock preparation and 
frozen. Acquired resistance was determined using the 3D tumoroid formation assay. Subse-
quently, the surviving fractions were compared to the therapy-naïve corresponding cell lines. 
4.2.7 Radiation exposure 
The content of this section has been published in similar form by Görte et al. (Görte et al., 
2020). 
4.2.7.1 Photon irradiation 
Cells were irradiated at room temperature using 2, 4, or 6 Gy single doses of 200-kVp X-rays 
(Yxlon Y.TU 320; Yxlon; dose rate of 1.3 Gy/min at 20 mA) filtered with 0.5 mm Cu. The ab-
sorbed dose was measured using a Semiflex ionization chamber (PTW Freiburg; Freiburg, 
Germany). Cells in tissue culture plates were irradiated horizontally both for tumoroid formation 
assays (96-well plates) and whole-cell lysates (24-well plates). 
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4.2.7.2 Proton irradiation 
Proton irradiation (low-LET of 3.7 keV/µm) was performed at the horizontal fixed-beam beam 
line in the experimental hall of the University Proton Therapy Dresden (UPTD). For 150 MeV 
protons, a dedicated beam shaping system consisting of a double-scattering device and a 
ridge filter provides a laterally extended 10 × 10 cm2 proton field and a SOBP of 26.3 mm 
(90 % dose plateau) in water. Cells in tissue culture plates were irradiated at room temperature 
using two different setting to assure mid-SOBP position. For tumoroid formation assays 96-
well plates were placed perpendicular to beam axis (90 °), whereas for whole-cell lysates 24-
well plates were positioned at 42 ° relative to beam axis to avoid destruction of 3D structure. 
For absolute dosimetry, a Markus ionization chamber (PTW) readout by an Unidos dosemeter 
(PTW) at sample position was applied. Details of absolute dosimetry and beam control are 
given in Beyreuther and colleagues (Beyreuther et al., 2019). 
4.2.8 3D tumoroid formation assay 
The tumoroid formation (TF) assay represents the colony formation assay in 3D culture condi-
tions. The colony formation assay is the gold standard in radiobiology to assess the reproduc-
tive integrity of cells upon exposure to genotoxic stress (Puck Marcus 1956), such as radiation, 
chemotherapy, or others. Cells are considered clonogenic, if they are able to undergo mitosis 
five or more times and form colonies consisting of at least 50 cells, since they maintained the 
capacity to divide indefinitely (Joiner & van der Kogel, 2009). The plating efficiency is the per-
centage of seeded cells that form colonies, indicating the basal cell survival (E. J. Hall & 
Giaccia, 2012). Upon exposure of the cells to genotoxic stress, such as radiation, the percent-
age of surviving cells (surviving fraction) is calculated with the following formula: 
 =  
 
  ∙  
 
The results are presented as dose survival curves showing mean ± SD of at least three 
experiments. The dose is plotted on a linear scale and surviving fraction on a logarithmic scale 
(Puck et al., 1956). 
Assessment of clonogenicity was performed by plating single cells (Table 4.17) em-
bedded in 3D laminin-rich extracellular matrix (lrECM) in 96-well cell culture plates coated with 
50 μl of 1 % agarose to avoid cell adhesion (Eke et al., 2009; Storch et al., 2010). Depending 
on the cell line (Table 4.18) a certain cell number was seeded per well in a volume of 100 μl 
culture medium containing 0.5 mg/ml lrECM. Cells were incubated for 24 h for matrix polymer-
ization at standard cell culture conditions. 100 μl of cDMEM or cDMEM containing inhibitors or 
chemotherapies were carefully added on top (Details in 4.2.5). Cells were left unirradiated or 
were exposed to single radiation doses of 2, 4, 6 Gy. After the cell line specific growth period 
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(Table 4.17) cells were fixed with 50 μl of 3 % Formaldehyde and stored at 4 °C. Colonies with 
more than 50 cells were counted by using the inverted microscope. 
Table 4.17. Cell numbers and incubation periods used for 3D tumoroid formation assays. 
Cell line Cell numbers/well Incubation [d] 
BxPC-3 3000 8 
Colo357 1500 9 
(RR-)MiaPaCa-2 3000 8 
Panc-1 3000 7 
Patu8902 6000 8 
 
The relative biological effectiveness of proton compared to photon irradiation was calculated 
as follows: 
=   
The doses (D) were calculated as follows: data points were fitted in the linear-quadratic 
formula and the values for α and β were taken from the fitted curve. D was then solved at a SF 
of 50 % from the following formula: 
=   
4.2.9 Total protein extracts, SDS-PAGE and Western Blotting 
4.2.9.1 Cell lysates 
For protein isolation upon siRNA-mediated knockdown, cells leftover after seeding for tumoroid 
formation were seeded in 6-well plates in 2D conditions. 24 h after seeding (48 h after siRNA 
transfection), the cell culture medium was discarded, and cells were washed with ice cold 1x 
PBS. After thorough removal of PBS, the cell culture plate was kept on ice and 80 µl of 1x 
complete RIPA buffer containing phosphatase and protease inhibitors was used to lyse the 
cells. With the use of a cell scraper lysates were collected and transferred into a 1.5 ml Ep-
pendorf tube. For all other experiments demanding protein isolation, 3D culture conditions 
were used. Therefore, 500,000 cells were seeded in 0.5 µg/ml lrECM in one well of a 24-well 
plate coated with 250 µl of 1 % agarose. 24 h later cells were lysed. For lysis upon treatment 
cells were processed 1 h after treatment or left untreated. Cells were isolated in a volume of 
200 µl from the 24-well using a 1000 µl pipette. The cell suspension was transferred into a 
1.5 ml Eppendorf tube containing 100 µl of 3x complete RIPA containing phosphatase and 
protease inhibitors. After lysis of 30 min on ice, mechanical lysis was achieved by using an 
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insulin syringe and drawing the lysate carefully up 3x into the syringe avoiding bubbles. Upon 
1 h on ice, the lysates were centrifuged at 16,000 x g for 20 min at 4 °C. The supernatant was 
collected and the pellet containing cellular debris was discarded. 
For 2D lysates, the protein concentration was determined in 96-well plates using BCA 
Protein Assay Kit, protein standards and a calibration curve. Lysates were diluted 1:10 in RIPA 
buffer and a BSA concentration series (0.0 µg/µl – 2.0 µg/µl) was prepared. The reagent was 
added, and the plate was incubated for 30 min at 37 °C. Subsequently, the absorption was 
measured. Protein concentrations were calculated using the standard curve. For 3D lysates, 
equal protein concentrations were assessed by carrying out an SDS-PAGE and Western Blot. 
β-actin was quantified and, if necessary, volumes were adjusted for detection of the target 
protein. 
4.2.9.2 SDS-Polyacrylamide gel electrophoresis (SDS-PAGE) 
The SDS-PAGE was developed in 1970 by Laemmli and enables the separation of proteins of 
a cell lysate according to their molecular weight. For the preparation of the polyacrylamide gels 
the Hofer Mini gel casting system was used. Depending on the molecular weight of the ana-
lyzed proteins the acrylamide concentration in the separation gels was chosen (8-10 %, Table 
4.18). The stacking gels always contained the same concentration (Table 4.18). 
Whole cell lysates were prepared at a concentration of 50 µg of protein (2D lysates) 
and approximately 20 µl of 3D lysates. 6x loading dye (6:1) was added and incubated at 99 °C 
for 5 min to denature protein structures. 5 μl of protein ladders were used. Electrophoresis was 
carried out using a current of 25 mA per gel in a vertical gel electrophoresis chamber. 
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ddH2O 1.63 ddH2O 2.16 1.83 
0.5 M Tris/HCl pH 6.8 0.72 3 M Tris/HCl pH 8.8 1.25 1.25 
Acryl amide 30 % 0.5 Acryl amide 30 % 1.33 1.67 
50 % Glycerol 0.06 50 % Glycerol 0.10 0.10 
10 % SDS 0.03 10 % SDS 0.05 0.05 
10 % APS 0.06 10 % APS 0.10 0.10 
TEMED 0.0048 TEMED 0.004 0.004 
 
4.2.9.3 Western Blot 
Semi-dry blotting was used to transfer the electrophoretically separated proteins from the gel 
onto a nitrocellulose membrane. Proteins transferred onto the nitrocellulose membrane can be 
visualized based on specifically binding of primary antibodies to the target proteins and sub-
sequent binding of HRP-conjugated secondary antibodies. In detail, upon removal of the stack-
ing gel, the gel was put between 6 layers of Whatman filter paper and one sheet of nitrocellu-
lose membrane, as illustrated in Figure 4.1, that were shortly pre-incubated in 1x blotting buffer. 
The transfer of proteins was conducted using a current of 0.8 mA/cm2 membrane for 2-3 h, 
depending on the molecular weight of the protein of interest. Subsequently, proteins were 
stained with PonceauS solution and the nitrocellulose membranes were cut according to the 
size of target proteins. After cutting, PonceauS was removed by washing the membranes with 
1x PBS. To prevent unspecific antibody binding, the membranes were blocked for 1 h in 5 % 
milk powder or 5 % BSA solution as recommended by antibody manufacturers. After blocking, 
the membranes were incubated with the specific primary antibodies over night at 4 °C. Upon 
membrane washing for 4x for 10 min in PBST, the incubation with secondary antibodies for 
1.5 h at RT followed. Finally, membranes were washed in PBST (5 x 10 min) and PBS (1 x 10 
min) and incubated for 3 min with the ECL Western Blotting Detection system. The signal was 
detected using the imaging system Fusion FX. 




Figure 4.1: Scheme of semi-dry blotting. 
4.2.9.4 Analysis of protein expression and phosphorylation 
Densitometric analysis was performed for quantification of total or phosphorylated proteins 
using Fiji. Protein band intensity was quantified and normalized to β-Actin (for total protein and 
phospho-protein) and for analysis of phosphorylations further to total protein expression. 
4.2.10 Kinome analysis 
Kinome analysis in PDAC cells upon β1 integrin inhibition by AIIB2 was performed using phos-
pho-tyrosine kinase (PTK) and serine-threonine kinase (STK) microarrays (PamGene). The 
PTK and STK PamChip® assays consist of 196 and 144 peptide sequences, respectively 
(https://pamgene.com/technology/). Upon coating 12-well plates with 500 μl of 1 % agarose, 
1.5 x 106 cells in 0.5 mg/ml lrECM were plated per well, three wells per condition. After 24 h 
cells were treated with AIIB2 or control IgG. For whole cell lysates cells were lysed with 5x 
kinase buffer, supplemented with 5x HALT™ phosphatase and protease inhibitor cocktail. 
100 µl of the cells were harvested from the lrECM from each well using a 1000 µl pipette and 
transferred to one 1.5 ml Eppendorf tube containing 100 μl of 5x kinome buffer. After 30 min, 
the mechanical lysis was carried out using an insulin syringe, followed by an incubation on ice 
for 30 min. The lysates were centrifuged for 20 min at 16,000 x g at 4 °C. The supernatant was 
transferred to a new 1.5 ml Eppendorf tube. The samples were transferred in triplicates to 
Genomics and Proteomics Core Facility Microarray Unitcenter at DKFZ (Heidelberg, Germany) 
on dry ice. The analysis of kinase activity was performed on a Pamstation 12 System 
(Pamgene). Briefly, after 2 % BSA in water for 30 cycles blocking the arrays were washed 3x 
with PK assay buffer. Phosphorylated peptides were measured using primary (PTK) and pri-
mary and secondary (STK) fluorescence labeled antibodies. Imaging of arrays was performed 
using the PamChip® station with a 12-bit CCD camera. BioNavigator software (PamGene In-
ternational BV) was applied for data analysis of the images obtained from the phosphorylated 
arrays. A list of significantly phosphorylated peptides was generated of AIIB2-treated to IgG-
treated samples. Peptide phosphorylation data was analyzed with GeneGo, PhosphoSite and 
other databases and KinMap using various ranking and scoring methods to assess putative 
down- or upregulated kinases. 
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4.2.11 Phosphoproteome analysis 
The Phospho Explorer Antibody Microarray was conducted by Full Moon BioSystems Inc. as 
published (Klapproth et al., 2018) to analyze protein expression and specific phospho-sites 1 h 
after 6-Gy photon or proton irradiation. The array consists of antibodies against 342 proteins 
and 606 phospho-sites. For whole cell lysates 10 x 104 Colo357 and MiaPaCa-2 cells were 
seeded in 0.5 mg/mL lrECM in 24-well plates coated with 250 µl of 1 % agarose. Two wells 
per condition were seeded. After 4 days of culture, cells were harvested in a volume of 200 µl 
using a 1000 µl pipette 1 h after exposure to 6-Gy photon or proton irradiation or unirradiated. 
3D protein extracts were prepared as described in section 4.2.9.1 using modified 3x complete 
RIPA containing phosphatase and protease inhibitors and transferred to Full Moon BioSystems 
Inc. on dry ice. At Full Moon BioSystems Inc. proteins were labelled with biotin and placed on 
preblocked microarray slides. Detection of total and phosphorylated proteins was conducted 
using Cy3-conjugated streptavidin. Expression of phosphorylated proteins was normalized to 
the corresponding total protein expression. For analysis, protein phosphorylation was normal-
ized to corresponding total protein expression. Proteins with phosphorylation site changes of 
at least a 30 % decrease or 50 % increase (arbitrary cut-off) were considered relevant and 
selected, and changes in both cell lines comparatively analyzed 
4.2.12 Fluorescence microscopy 
The technique of immunofluorescence is used to visualize the localization of proteins of inter-
est. As for Western blot, specific primary and secondary antibody reactions are used. In this 
method, a fluorophore-coupled secondary antibody is used for detection. Using a laser scan-
ning microscope, the localization of the protein can be visualized. 
To determine the localization of β1 integrins in PDAC cell lines, 50 x 105 cells were 
seeded on coverslips. 24 h after seeding, the cells were fixed with 3 % Formaldehyde. Subse-
quently, the cells were washed three times with 1x PBS and permeabilized with 0.25 % Triton-
X-100/PBS for 10 min followed by three 1x PBS washing steps. Cells were blocked with 1 % 
BSA/PBST for 1 h. The primary antibody was incubated for 2 h at room temperature. After 
washing three times with 1x PBS and cells were incubated with fluorophore-coupled secondary 
antibodies or fluorophore-coupled-Phalloidin (for F-actin staining) for 1 h in the dark. Cells were 
washed with 1x PBS and mounted on microscope slides using ProLong Diamant Antifade 
Mountant with DAPI. Images were acquired using the LSM 980 with Airyscan 2 and the Soft-
ware ZEN 3.1 blue edition (Zeiss). 
4.2.13 Statistics 
Means ± SD of at least three independent experiments were calculated. For statistical signifi-
cance analysis of 3D tumoroid formation capacity two-sided Student’s t-test was performed 
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with Excel (Microsoft) or one-way ANOVA followed by post-hoc analysis using Tukey’s correc-
tion was executed in Prism 8 (GraphPad, San Diego, CA, USA) and a P value of less than 






5.1 The role of β1 integrins in radiochemoresistance of 3D, matrix-
based PDAC cell cultures 
5.1.1 β1 integrin mRNA expression and survival analysis on publicly avail-
able PDAC patient data 
Cell adhesion molecules of the integrin family, particular β1 integrins, are known to mediate 
therapy resistance in head and neck squamous cell carcinoma, breast cancer, laryngeal can-
cer, and other tumor entities (Eke, Deuse, et al., 2012; L. Li et al., 2018; C. C. Park et al., 
2008). 
 
Figure 5.1: β1 integrin mRNA overexpression in PDAC patient samples correlates with poor prognosis. (A) 
Comparative analysis of β1 integrin mRNA expression between PDAC and normal pancreas using Oncomine data 
base (www.oncomine.org, (Badea et al., 2008; Logsdon et al., 2003)). (B) Kaplan-Meier plot of PDAC patients with 
tumors expressing low and high β1 integrin mRNA levels, data provided by OncoLnc using TCGA PDAC patient 
survival data (www.oncolnc.org, (Anaya, 2016)). 
Expression analysis of β1 integrin in PDAC using two studies of publicly available data 
sets (Figure 5.1A) demonstrated β1 integrin mRNA levels to be significantly higher in PDAC 
when compared to normal pancreas (Badea et al., 2008; Logsdon et al., 2003). Interestingly, 
Kaplan-Meier survival analysis links the overexpression to significantly poorer survival of 
PDAC patients (Figure 5.1B), indicating β1 integrins to bear a critical role in tumor progression 




5.1.2 Effect of β1 integrin inhibition in combination with photon irradiation 
on 3D PDAC tumoroid growth 
In this work radioresistant (RR) PDAC cell lines and their parental, untreated counterparts, 
termed therapy-naïve (TN), serve to resemble therapy resistance resulting from cellular heter-
ogeneity of tumors, in order to elicit the potential function of β1 integrins in radioresistance in 
PDAC. 
 
Figure 5.2: β1 integrin inhibition confers radiosensitization in therapy-naïve and radioresistant 3D PDAC 
cell cultures. (A) Experimental design and treatment setup for 3D PDAC tumoroid growth analysis. (B) Repre-
sentative bright-field images of unirradiated and 6-Gy photon irradiated antibody-pretreated 3D PDAC tumoroids, 
scale bar: 100 µm. (C) 3D tumoroid formation capacity of unirradiated TN- and RR-MiaPaCa-2 cells 1-h pretreated 
with indicated antibodies. (D) 3D MiaPaCa-2 tumoroid formation capacity upon 1-h antibody pretreatment combined 
with photon irradiation. (E) Violin blots presenting specifically 3D tumoroid growth formation capacity after 6-Gy 
irradiation of antibody-pretreated TN- and RR-3D MiaPaCa-2 cell cultures from D. (F) Immunoblots on whole cell 
lysates showing β1 integrin knockdown efficiencies of three different siRNAs in TN- and RR-MiaPaCa-2 cells. Actin 
served as loading control. (G) Normalized basal 3D tumoroid formation of 3D TN- and RR-MiaPaCa-2 cell cultures 
upon knockdown of β1 integrin with three different siRNAs. (H) Normalized 3D tumoroid formation of 3D TN- and 
RR-MiaPaCa-2 cell cultures upon knockdown of β1 integrin with three different siRNAs and 6-Gy irradiation. All 




The study was commenced by antibody-mediated (AIIB2) inhibition of β1 integrins com-
bined with photon irradiation in therapy-naïve and radioresistant MiaPaCa-2 cell cultures 
grown under more physiological 3D conditions (Figure 5.2A). With only marginal effects on 
basal tumoroid formation (Figure 5.2B, C) AIIB2 mediated a significant reduction of 3D tumor-
oid growth in combination with irradiation in the analyzed cell line and the radioresistant coun-
terpart (Figure 5.2B, D). Radiosensitization resulting from β1 integrin inhibition was greater in 
the therapy-naïve cell cultures, demonstrating an enhancement of more than 7-fold upon 6-Gy 
irradiation. Intriguingly, AIIB2 lowered the tumoroid formation capacity after 6 Gy in the radio-
resistant cell cultures to a level superimposable to the intrinsic (IgG-treated) capacity of the 
parental counterpart (Figure 5.2D, E). Results upon siRNA-mediated knockdown of β1 integ-
rins confirmed the radiosensitization observed for AIIB2 in therapy-naïve and radioresistant 3D 
MiaPaCa-2 cell cultures and underpin the indicated critical role of β1 integrins in the radiation 
survival response of both therapy-naïve and radioresistant PDAC cultures. 
Subsequently, the susceptibility for AIIB2 was investigated in two additional therapy-
naïve PDAC cell lines. Cell line-dependently, yet in every case significant, an AIIB2-mediated 
decrease in tumoroid growth upon irradiation was observed. Except for Colo357, basal survival 
was not strongly affected (Figure 5.3A, B). In Colo357 cell lines, siRNA-mediated knockdown 
of β1 integrins provided confirmatory results (Figure 5.3C-E). The PDAC cell lines showed 
differing degrees of AIIB2-induced radiosensitization with Colo357 cell lines being the least 
susceptible cell lines with a 2-fold enhancement (Figure 5.3B) and the parental MiaPaCa-2 
being the most sensitive cell line for β1 integrin inhibition (Figure 5.2D). 
Characterization of β1 integrins in the radiation response in therapy-naïve and radiore-
sistant 3D PDAC cell cultures was pursued further by applying the β1 integrin activating anti-
body TS2/16 with 6-Gy irradiation. Interestingly, a trend towards or a significant increase in 
tumoroid growth of therapy-naïve 3D Colo357 and MiaPaCa-2 cultures was disclosed upon 
irradiation, respectively, but not when left unirradiated (Figure 5.3F, G). Apparently, the radio-
resistant counterpart was unaffected by β1 integrin activation upon irradiation (Figure 5.3G). 
mAb13, another β1 integrin inhibitory antibody, mirrored the responsiveness to AIIB2 in both 
the most sensitive and resistant cell lines, MiaPaCa-2 and Colo357, validating previous results 






Figure 5.3: β1 integrin comprises critical role in radiation response in a panel of 3D PDAC cell cultures. (A) 
3D PDAC tumoroid formation capacity of unirradiated Colo357 and Patu8902 1- h pretreated with indicated anti-
bodies. (B) 3D tumoroid formation capacity of Colo357 and Patu8902 cells upon 1-h antibody pretreatment com-
bined with 6-Gy photon irradiation. (C) Immunoblots on whole cell lysates showing β1 integrin knockdown efficien-
cies of three different siRNAs in Colo357 cells. Actin served as loading control. (D) Normalized basal 3D tumoroid 
formation of 3D Colo357 cell cultures upon knockdown of β1 integrin with three different siRNAs. (E) Normalized 
3D tumoroid formation of 3D Colo357 cell cultures upon knockdown of β1 integrin with three different siRNAs and 
6-Gy irradiation. (F, H) 3D tumoroid formation capacity of unirradiated Colo357 and TN- and RR-MiaPaCa-2 cells 
1-h pretreated with indicated antibodies. (G, I) 3D tumoroid formation capacity of Colo357 and TN- and RR-Mi-
aPaCa-2 cells upon 1-h antibody pretreatment combined with 6-Gy photon irradiation. All results show mean ± SD 





5.1.3 β1 integrin protein expression and localization in PDAC cell cultures 
β1 integrins seem to convey a pivotal role both in therapy-naïve and radioresistant 3D PDAC 
cell culture models, demanding a more detailed characterization in the panel. Protein expres-
sion analysis of β1 integrins in the 3D cultured PDAC cell line panel revealed a cell line-de-
pendent expression pattern, with a strong expression of both mature and immature forms of 
β1 integrins in Colo357 and Patu8902 and a predominant expression of the immature form of 
β1 integrins in the therapy-naïve and radioresistant MiaPaCa-2 cell lines (Figure 5.4A, B). La-
ser-scanning microscopy of immunofluorescence staining visualized a cell line-dependent lo-
calization of β1 integrins in the nucleus, the cytosol and membrane bound (Figure 5.4C). β1 
integrin expression patterns by Western blot technique could not be linked to its cellular local-
ization determined by microscopy, yet, for a precise characterization further experiments are 
needed (Figure 5.4A-C). 
 
Figure 5.4: β1 integrin protein expression and localization vary in PDAC cell cultures. (A) Immunoblots on 
whole cell lysates from the 3D cultured PDAC cell line panel showing immature and mature β1 integrin. Actin served 
as loading control. (B) Densitometry of normalized immature and mature forms of β1 integrin shown in A illustrated 
in stacks relative to total expression. (C) Confocal microscopy of immunofluorescence stained β1 integrin (white) in 
a panel of 2D cultured TN- and RR-PDAC cell lines. Co-staining with Phalloidin (F-Actin, red) and DAPI (nucleus, 





Next, the relationship of the β1 integrin expression pattern and the susceptibility to its 
targeting upon irradiation in the therapy-naïve 3D PDAC cell cultures was investigated. Re-
gression analyses revealed that (i) intrinsic radiosensitivity or (ii) AIIB2-mediated radiosensi-
tivity of the cell lines were neither linked significantly to (a) total, (b) mature nor (c) immature 
β1 integrin expression of each cell line. (Figure 5.5A, B). The extent of enhancement of radio-
sensitization upon AIIB2 significantly correlated with the (b) mature β1 integrin expression, 
indicating a lower degree of sensitization with higher expression of the mature form (Figure 
5.5C). 
 
Figure 5.5: Mature β1 integrin expression correlates with sensitizing enhancement upon AIIB2 and irradia-
tion in 3D TN-PDAC cultures. Regression analyses of (A) tumoroid formation capacity after 6-Gy irradiation of 
IgG-treated (intrinsic radiosensitivity) TN-PDAC cell lines against total, mature and immature expression of β1 in-
tegrin, (B) tumoroid formation capacity after 6-Gy irradiation of AIIB2-treated TN-PDAC cell lines against total, ma-
ture and immature expression of β1 integrin and (C) enhancement ratio (tumoroid formation capacity after IgG 
treatment and 6-Gy irradiation / tumoroid formation capacity after AIIB2 treatment and 6-Gy irradiation) of TN-PDAC 
cell lines against total, mature and immature expression of β1 integrin. Coefficient of correlation was calculated with 




5.1.4 Effect of β1 integrin targeting in combination with radiochemother-
apy on 3D PDAC tumoroid growth 
Chemotherapy is used as first-line treatment of locally advanced and metastatic PDAC and 
gemcitabine, a nucleoside-analogue, the microtubule inhibitor taxol or oxaliplatin, inhibiting 
DNA replication, are frequently administered (Kleeff et al., 2016). Consequently, the sensitizing 
potential of AIIB2 sequentially applied with chemotherapy alone or in combination with irradia-
tion was analyzed. 
Both the least and most sensitive cell lines to AIIB2, Colo357 and MiaPaCa-2, respec-
tively, and the corresponding radioresistant cell line were investigated. Chemo- or radiochemo-
therapy-treated therapy-naïve and radioresistant 3D MiaPaCa-2 and Colo357 cultures re-
mained largely refractory for AIIB2 (Figure 5.6B, D). Cell line-dependently the multiple inter-
ventions together with irradiation showed synergistic effects for AIIB2 and taxol in therapy-
naïve and for AIIB2 and cisplatin in radioresistant MiaPaCa-2 cultures (Figure 5.6C; Table 5.1 
and Table 5.2). Radiochemotherapy-treated Colo357 cultures revealed synergistic, however, 
non-significant effects when applying AIIB2 with gemcitabine (Figure 5.6E; Table 5.1 and Table 







Figure 5.6: Chemosensitivity and radiochemosensitivity remain largely unaltered upon β1 integrin target-
ing. (A) Experimental design and treatment setup for 3D PDAC tumoroid growth analysis. (B, D) 3D tumoroid 
formation capacity of unirradiated TN- and RR-MiaPaCa-2 and Colo357 cells 2-h pretreated with indicated antibod-
ies and 1-h pretreated with EC10 of indicated chemotherapies. (C, E) 3D tumoroid formation capacity of TN- and 
RR-MiaPaCa-2 and Colo357 cells upon 2-h pretreatment with indicated antibodies and 1-h pretreatment with indi-
cated chemotherapies combined with 6-Gy photon irradiation. All results show mean ± SD (n = 3; one-way ANOVA 





Table 5.1: Synergistic or additive effects of combined AIIB2/chemotherapy administration in unirradiated 
3D PDAC cultures. Calculation of synergistic and additive effects was performed as published by Yan et al. (Yan 
et al., 2010) using surviving fractions and the formula S = r(a, b) – r(a0,b) x r(a, b0); a: AIIB2, b: drug. Synergistic 
effects are highlighted in red. Additive effects are highlighted in blue. 
Cell line Chemotherapy Value 
Colo357 Taxol 0.925014476 
MiaPaCa-2 Taxol 1.05530234 
RR-MiaPaCa-2 Taxol 0.999202552 
Colo357 Gemcitabine 0.741231489 
MiaPaCa-2 Gemcitabine 0.920366657 
RR-MiaPaCa-2 Gemcitabine 0.909807011 
Colo357 Cisplatin 0.768235294 
MiaPaCa-2 Cisplatin 0.943014706 
RR-MiaPaCa-2 Cisplatin 0.953177258 
 
Table 5.2: Synergistic or additive effects of combined AIIB2/chemotherapy administration in 6 Gy irradiated 
3D PDAC cultures. Calculation of synergistic and additive effects was performed as published by Yan et al. (Yan 
et al., 2010) using surviving fractions and the formula S = r(a, b) – r(a0,b) x r(a, b0); a: AIIB2, b: drug. Synergistic 
effects are highlighted in red. Additive effects are highlighted in blue. 
Cell line Chemotherapy Value 
Colo357 Taxol 0.112747312 
MiaPaCa-2 Taxol -0.103425421 
RR-MiaPaCa-2 Taxol 0.084441906 
Colo357 Gemcitabine -0.125 
MiaPaCa-2 Gemcitabine 0.004663732 
RR-MiaPaCa-2 Gemcitabine 0.086145295 
Colo357 Cisplatin 0.162530656 
MiaPaCa-2 Cisplatin 0.017081965 






5.1.5 Impact of β1 integrin targeting on kinase activity in 3D therapy-naïve 
and radioresistant PDAC cultures 
Given the strong radiosensitizing effect of β1 integrin targeting in three therapy-naïve and one 
radioresistant PDAC cell lines, a better understanding of the underlying potentially differing 
mechanisms present upon its inhibition in PDAC cell models was sought. Broad-spectrum ki-
nase activity analyses (PamGene®) of phospho-tyrosine kinases (PTKs) and serine/threonine 
kinases (STKs) in the 3D therapy-naïve and radioresistant MiaPaCa-2 cell cultures revealed 
predominantly less peptide phosphorylation intensities (PPIs) 1 h after inhibition of β1 integrin 
in comparison to the control, illustrated by mainly negative PPI Δ values (Figure 5.7A and B; 
Table 5.3). This was observed for both analyzed cell lines, yet a slightly higher peptide phos-
phorylation intensity was detected in the radioresistant cell line (Figure 5.7C). 
 
Figure 5.7: β1 integrin inhibition decreases peptide phosphorylation events both in therapy-naïve and radi-
oresistant 3D PDAC cultures. Peptide phosphorylation analyses of (A) PTK array (PamGene® technology) and 
(B) STK Array (PamGene® technology) in 3D TN- and RR-MiaPaCa-2 cultures 1 h after AIIB2 and IgG treatment 
depicted in heatmaps (generated with https://software.broadinstitute.org/morpheus/; raw data in n = 3; measured 
PPI; list in Table 5.3) and Δ values of PPI (PPIAIIB2 - PPIIgG) shown in waterfall blots. (C) Distribution of positive and 




Table 5.3: List of peptides used in PTK and STK arrays. Peptides detected in the PTK and STK arrays listed in 
the order of the PPI Δ values for the corresponding analyzed cell line. 
PTK STK 
TN-MiaPaCa-2 RR-MiaPaCa-2 TN-MiaPaCa-2 RR MiaPaCa-2 
B3AT_39_51 K2C8_425_437 KS6A1_374_386 ART_025_CXGLRRWSL
GGLRRWSL 
LYN_501_512 ANXA2_17_29 CDC2_154_169 GYS2_1_13 




MK12_180_189_M182B STAT4_714_726 E1A_ADE05_212_224 MP2K1_287_299 
CD3E_193_205 CD3Z_135_147 NCF1_321_333 ANDR_785_797 
YES_420_432 LAT_194_206 NR4A1_344_356 RBL2_655_667 
MK14_173_185 EPOR_419_431 VTNC_390_402 PLEK_106_118 
CD79A_181_193 FGFR1_761_773 CREB1_126_138 CDK7_163_175 
KIT_930_942_C942S ANXA1_14_26 NCF1_296_308 CA2D1_494_506 
STAT4_714_726 INSR_992_1004 NFKB1_330_342 PTK6_436_448 
RASA1_453_465 ERBB2_870_882 VASP_271_283 ESR1_160_172 
FAK1_569_581 MPZL1_236_246 CFTR_761_773 ERBB2_679_691 
CD3Z_117_129 EGFR_1103_1115 MARCS_152_164 ANXA1_209_221 
PGFRB_768_780 P85A_600_612 TY3H_65_77 BAD_112_124 
EPHA1_774_786 CDK4_11_23 MPIP1_172_184 LIPS_944_956 
ARAF_297_307 IRS1_890_902 F263_454_466 NMDZ1_890_902 
CDK1_9_21 PDPK1_369_381 DCX_49_61 KS6A1_374_386 
NTRK2_696_708 ARAF_297_307 KCC2G_278_289 BAD_93_105 
FGFR1_761_773 CD28_185_197 RB_803_815 NOS3_1171_1183 
PTN11_580_590 EPHB1_771_783 GPR6_349_361 KIF2C_105_118_S106G 
ZAP70_313_325 LYN_391_403 MPIP3_208_220 CSF1R_701_713 
MK08_181_191 PTN11_580_590 ACM1_444_456 GRIK2_708_720 
IRS2_626_638 EPHA2_765_777 GBRB2_427_439 CDN1A_139_151 
ENOG_37_49 RON_1346_1358 PTN12_32_44 TOP2A_1463_1475 
PLCG2_1191_1203_C12
00S 
EPOR_361_373 TOP2A_1463_1475 KPB1_1011_1023 
PECA1_708_718 TEC_512_524 VASP_150_162 NCF1_296_308 
VGFR2_1046_1058 PTN6_558_570 CDK7_163_175 RS6_228_240 
PDPK1_2_14 CD3E_193_205 MYPC3_268_280 RB_803_815 
PTN6_558_570 EPHA1_774_786 ACM5_494_506 KCNA6_504_516 




CD3Z_105_117 CD3Z_105_117 STK6_283_295 MYPC3_268_280 
MPZL1_236_246 AKT1_320_332 RAF1_253_265 RYR1_4317_4329 
JAK3_974_986 VGFR2_1046_1058 PLM_76_88 H32_3_18 




P85A_600_612 VGFR2_989_1001 KPCB_19_31_A25S CREB1_126_138 
PECA1_706_718 MK10_216_228 CDN1A_139_151 REL_260_272 





TN-MiaPaCa-2 RR-MiaPaCa-2 TN-MiaPaCa-2 RR MiaPaCa-2 
RET_1022_1034 YES_420_432 KIF2C_105_118_S106G CFTR_730_742 
MBP_198_210 ERBB2_1241_1253 RAP1B_172_184 GPR6_349_361 
CDK2_8_20 IRS2_626_638 KPB1_1011_1023 CENPA_1_14 
TEC_512_524 MET_1228_1240 ACM5_498_510 F263_454_466 
EGFR_1103_1115 PGFRB_768_780 STMN2_90_102 H2B1B_ 27_40 
TYK2_1048_1060 ZAP70_485_497 H2B1B_ 27_40 ACM5_494_506 
PAXI_111_123 ZAP70_313_325 BAD_93_105 VTNC_390_402 
ZAP70_485_497 EGFR_1165_1177 CA2D1_494_506 KCNA2_442_454 
PDPK1_369_381 CDK1_9_21 CFTR_730_742 GBRB2_427_439 
PLCG1_764_776 EPHA7_607_619 FRAP_2443_2455 E1A_ADE05_212_224 
HAVR2_257_267 PLCG1_764_776 PLEK_106_118 NCF1_321_333 
EPHA2_765_777 FGFR2_762_774 KCNA3_461_473 VASP_271_283 
FES_706_718 TYK2_1048_1060 GYS2_1_13 ACM4_456_468 
PGFRB_771_783 CD3Z_116_128 CAC1C_1974_1986 BAD_69_81 
FRK_380_392 PTN6_531_541 DESP_2842_2854 RAP1B_172_184 
41_654_666 HAVR2_257_267 KAP2_92_104 PTN12_32_44 
LCK_387_399 PGFRB_1014_1028 ESR1_160_172 MPIP1_172_184 
PRRX2_202_214 BTLA_252_262 NOS3_1171_1183 SCN7A_898_910 
EPHA7_607_619 PGFRB_709_721 CENPA_1_14 MPIP3_208_220 
MET_1228_1240 PGFRB_771_783 BAD_69_81 PPR1A_28_40 
CDK4_11_23 FRK_380_392 SCN7A_898_910 KAP3_107_119 
FER_707_719 JAK3_974_986 REL_260_272 ADRB2_338_350 
PGFRB_1002_1014 PTN11_57_67 H32_3_18 CGHB_109_121 
GAB2_638_648 PECA1_708_718 CD27_212_224 FRAP_2443_2455 
EGFR_1165_1177 ENOG_37_49 CGHB_109_121 NFKB1_330_342 
FGFR2_762_774 RET_1022_1034 ADDB_706_718 VASP_150_162 
RB_804_816 JAK1_1027_1039 NMDZ1_890_902 STK6_283_295 
PAXI_24_36 CTNB1_79_91 CSF1R_701_713 KAP2_92_104 
CTNB1_79_91 CD3Z_117_129 ADRB2_338_350 MARCS_152_164 
PGFRB_709_721 LAT_249_261 PTK6_436_448 ACM5_498_510 
MK03_199_208 CBL_693_705 KCNA2_442_454 TY3H_65_77 
VGFR1_1040_1052 KIT_930_942_C942S BAD_112_124 NR4A1_344_356 
JAK2_563_577 MK12_178_190 RS6_228_240 EPB42_241_253 
LAT_249_261 FES_706_718 RYR1_4317_4329 DESP_2842_2854 
PGFRB_572_584 FER_707_719 ANXA1_209_221 CAC1C_1974_1986 
LYN_391_403 CD3Z_77_89 PPR1A_28_40 KCNA1_438_450 




EPOR_419_431 CD3E_182_194 ANDR_785_797 CD27_212_224 
CD28_185_197 FAK1_569_581 RBL2_655_667 PLM_76_88 
K2C6B_53_65 PAXI_111_123 KCNA1_438_450 RAF1_253_265 
MUSK_548_560 CALM_95_107 ERBB2_679_691 DCX_49_61 








































































The changes on molecular level induced by inhibition of β1 integrins were biostatisti-
cally analyzed by PamGene® and putative upstream PTKs and STKs altered in activity were 
identified. Without exception, the kinase profiling demonstrated reduced PTK and STK activi-
ties upon β1 integrin targeting in the therapy-naïve and radioresistant cell models (Figure 5.8A, 
B and Figure 5.9A, B). Strongly affected kinases differed between therapy-naïve and radiore-
sistant MiaPaCa-2 cell cultures (Figure 5.8, Figure 5.9D, E). The PTK JAK1 and the STK 
DAPK3 were affected strongly by β1 integrin inhibition in therapy-naïve MiaPaCa-2 cultures. 
In contrast, FLT1 (PTK) and CK1ε (STK) were the most deregulated kinases in the radiore-
sistant counterpart (Figure 5.8A, B). PTKs were downregulated to a higher degree after β1 
integrin inhibition than STKs (Figure 5.8A, B and Figure 5.9A, B). The extent of downregulation 
after AIIB2 is much greater in the therapy-naïve than in the radioresistant cell cultures, mani-
fested by kinase activity values of -2.64 vs. -0.55 for PTKs and -1.22 vs. -0.97 for STKs, re-
spectively (Figure 5.8A, B and Figure 5.9A, B; Table 5.4). Comparative examination of the IgG-
treated therapy-naïve and radioresistant MiaPaCa-2 cell lines suggested a lower basal kinase 






Figure 5.8: Putative kinases deregulated upon β1 integrin inhibition in therapy-naïve and radioresistant 3D 
PDAC cultures. (A) Comparative upstream kinase analysis of Top 15 PTKs showing median final score (evaluated 
from specificity, significance scores and peptide size) plotted against kinase activity of PTKs for 3D TN- and RR-
MiaPaCa2 cultures of AIIB2 vs. IgG. (B) Comparative upstream kinase analysis Top 15 STKs showing median final 
score (evaluated from specificity, significance scores and peptide size) plotted against kinase activity of STKs for 
3D TN- and RR-MiaPaCa2 cultures of AIIB2 vs. IgG. All results shown are n = 3. Kinase activity analyses based on 
data from Figure 5.7 and were performed by PamGene® Technology. 
Comparative analysis of the top 20 candidates revealed only seven PTKs and five 
STKs overlapping between the cell models (Figure 5.9D), suggesting varying cellular re-
sponses caused by AIIB2 administration. Significant and specific deregulations upon β1 integ-
rin inhibition, stated by high median final score, were found for the top 15 of PTKs and top 6 of 





Figure 5.9: β1 integrin targeting affects kinase activity differentially in therapy-naïve PDAC cultures and 
their radioresistant counterpart. (A) Superimposed waterfall blots demonstrating putative PTK and STK activity 
in AIIB2-treated 3D TN- and RR-MiaPaCa-2 cultures (kinase names in Table 5.4). (B) Violin blots illustrating mean 
kinase activities in of PTKs and STKs in AIIB2-treated 3D TN- and RR-MiaPaCa-2 cultures. (C) Violin blots pre-
senting mean kinase activities of PTKs and STKs in IgG-treated 3D RR- in comparison to TN-MiaPaCa-2 cell cul-
tures. (D) Venn diagrams deciphering similarities of Top 20 PTKs and STKs sorted by median final score in 3D TN- 
and RR-MiaPaCa-2 cultures after AIIB2 treatment. (E) Venn diagrams comparing in Top 15 PTK and Top 6 STK 
ordered by median final score in AIIB2-treated 3D TN- and RR-MiaPaCa-2 cultures. Kinase activity analyses based 
on data from Figure 5.7 and were performed by PamGene® Technology. 
Table 5.4: List of PTKs and STKs assessed by PamGene®. Names of putative PTKs and STKs in the order of 
kinase activities measured in 3D TN-MiaPaCa-2 cultures as shown in Figure 5.9A. 
# PTK STK # PTK STK 
1 JAK1~b DAPK3 2 FLT1 MSK2 
3 FLT4 CDK6 4 Fer CDK4 
5 TRKB GSK3[beta] 6 JAK2 PKD1 
7 Fes CDK3 8 ITK AurA/Aur2 
9 KDR RSK1/p90RSK 10 Ret IKK[alpha] 
11 BTK NuaK1 12 Ron CaMK4 
13 EGFR CDK5 14 TRKC PKG1 




# PTK STK # PTK STK 
17 Srm p70S6K[beta] 18 Brk CHK1 
19 Mer CDKL2 20 HER4 SGK1 
21 HER2 CDKL1 22 ALK HGK/ZC1 
23 FRK PRKY 24 FAK2 PKA[alpha] 
25 TRKA DCAMKL1 26 Syk ARAF 
27 EphA3 PKC[gamma] 28 Met MSK1 
29 EphA2 BRAF 30 Etk/BMX PKC[epsilon] 
31 Axl PKC[delta] 32 Yes PKC[alpha] 
33 DDR1 CDK9 34 TEC RSK2 
35 EphA4 Akt2/PKB[beta] 36 CSK PKG2 
37 FmS/CSFR Akt1/PKB[alpha] 38 ZAP70 AurB/Aur1 
39 EphA5 PRKX 40 Src PKN1/PRK1 
41 TXK PKC[eta] 42 EphA8 RAF1 
43 FAK1 mTOR/FRAP 44 PDGFR[alpha] AMPK[alpha]1 
45 BLK CaMK2[alpha] 46 LTK PKC[iota] 
47 HCK Pim2 48 FLT3 PKC[theta] 
49 PDGFR[beta] PKC[zeta] 50 HER3 Pim1 
51 CTK Pim3 52 Fyn ATR 
53 FGFR1 ROCK1 54 EphA1 IKK[beta] 
55 Tyro3/Sky CK2[alpha]1 56 Lck MAPKAPK2 
57 Lyn MAPKAPK3 58 RYK SGK2 
59 InSR PKC[beta] 60 FGFR4 p70S6K 
61 IGF1R PFTAIRE1 62 Kit CK1[epsilon] 
63 FGFR2 PAK1 64 FGFR3 PCTAIRE2 






































































5.1.6 Identification of PTKs and STKs putatively involved in β1 integrin-in-
duced radiation response in 3D PDAC cultures 
In both the therapy-naïve and radioresistant 3D MiaPaCa-2 cell cultures, albeit less in the lat-
ter, the inhibition of β1 integrins manifested in an overall decrease of kinase activity. Hence, a 
potential interconnection of significantly and specifically deregulated kinases (Figure 5.10E) 
with the strongly diminished radiation survival upon β1 integrin inhibition was sought in each 
cell model. 
Depletion of the top 15 PTKs and top 6 STKs in a RNAi knockdown screen, targeting 
β1 integrin and each kinase alone or in combination with β1 integrin, affected tumoroid growth 
only moderately and target-dependently under both knockdown conditions in therapy-naïve 
and radioresistant 3D MiaPaCa-2 cultures (Figure 5.10A). In this setup, single knockdown of 
β1 integrin led to an enhancement of radiosensitization of 2-fold in therapy-naïve and of 1.3-
fold in radioresistant 3D MiaPaCa-2 cultures (Figure 5.10C). The tumoroid formation capacity 
upon single knockdown of the kinases and 6-Gy irradiation was decreased kinase- and cell 
line-dependently. In therapy-naïve 3D MiaPaCa-2 cell cultures double knockdown with β1 in-
tegrins in combination with irradiation enhanced the reduction of tumoroid growth (Figure 
5.10B). The double targeting resulted in an ER up to 3.7-fold (Figure 5.10C). In contrast, in the 
radioresistant cultures upon simultaneous kinase and β1 integrin targeting provided only a 
maximal enhancement of 1.6-fold (Figure 5.10B, C). Lower influence of co-targeting β1 integrin 
in radioresistant 3D MiaPaCa-2 cell cultures was further illustrated by comparing the efficacies 
of single and double knockdown after irradiation of each kinase (Figure 5.11A). Collectively, 
these results indicate differential molecular events entangled in the radiation response in ther-





Figure 5.10: Single and double RNAi knockdown screen of PTKs and STKs with β1 integrin reveals kinase- 
and cell line-dependent radiosensitization. (A) Normalized basal 3D tumoroid formation of 3D TN- and RR-
MiaPaCa-2 cell cultures upon single and double siRNA-mediated knockdown with SMARTpools. (B) Normalized 
3D tumoroid formation of 3D TN- and RR-MiaPaCa-2 cell cultures upon single and double siRNA-mediated knock-
down with SMARTpools and 6-Gy irradiation. (C) Enhancement ratios (tumoroid formation capacity upon siC and 
6 Gy / tumoroid formation capacity upon knockdown and 6 Gy) depicted as dots. All data ordered by ERs of double 
knockdown found for TN-MiaPaCa-2 cell cultures, gene names are given. All results show mean ± SD (n ≥ 3; two-





Aiming at unravelling mechanistic details of β1 integrin signaling related to radiore-
sistance in PDAC, the RNAi screen in therapy-naïve 3D MiaPaCa-2 cell cultures revealed 
three molecules worth to consider, namely extracellular signal-regulated kinase 2 (MAPK1, 
Erk2), Casein kinase I isoform delta (CSNK1D, CK1δ) and protein kinase D1 (PRKD1, PKD1). 
Showing (i) the same degree of radiosensitization both upon single and double knockdown 
together with β1 integrin (Figure 5.11A) and (ii) falling in a range of 20 % deviation from the β1 
integrin knockdown-induced reduction of tumoroid growth (Figure 5.11B), a potentially shared 
signaling axis of these proteins with β1 integrin can be deduced. However, detailed investiga-
tions are necessary here as well as for putative bypass signaling mechanisms or additive ef-
fects indicated by higher efficacy of double targeting. A lack of a β1 integrin depletion-induced 
shift in sensitization in radioresistant counterpart renders interrelations rather vague (Figure 
5.11A, B). 
Kinases mediating, under double depletion and 6 Gy, an ER similar to or higher than 
the one upon β1 integrin depletion in the radioresistant 3D MiaPaCa-2 cultures were connected 
to various pathways. Predominantly growth factor receptor signaling, in detail the VEGF, EGFR 
and FGF signaling, was linked to these kinases, accompanied by immune response, vascular 
system and other non-cancerous diseases or hormonal signaling (Figure 5.11C). Potential 






Figure 5.11: Radioresistant 3D MiaPaCa-2 cultures are less susceptible for single and double depletion of 
β1 integrin together with PTKs or STKs than their therapy-naïve counterpart. (A) Efficacy of single vs. double 
targeting indicated by log2 values calculated from fold changes (TF 6 Gy upon single knockdown / TF 6 Gy upon 
double knockdown), ordered by ER of double knockdown of each cell line. (B) Deviation of single and double kinase 
depletion from single β1 integrin depletion indicated by fold changes (TF 6 Gy upon single β1 integrin knockdown / 
TF 6 Gy upon single or double knockdown of indicated kinase), in the order of double knockdown fold changes of 
each cell line, colored bars indicate a deviation of ± 20 %, big dots illustrate similar fold changes. (C) Overrepre-
sentation test of kinases found to induce an ER ≥ 1.3 when depleted in combination with β1 integrin and 6-Gy 
irradiation in 3D RR-MiaPaCa-2 cultures (http://geneontology.org/). All results obtained from n ≥ 3, raw data from 
Figure 5.10. 
5.1.7 Effect of β1 integrin inhibition in combination with proton irradiation 
on 3D PDAC tumoroid growth 
This study provided evidence for a significant role of β1 integrins in therapy resistance upon 
photon exposure in both therapy-naïve and radioresistant 3D PDAC cultures and details of 
molecular underlying events have been elicited. In the next step of this work, clinically trans-




tumor entity demanding particular caution when radiotherapy is applied. Proton beam irradia-
tion offers local precision, hence, advances photon irradiation in terms of sparing normal tis-
sue. Consequently, the efficacy of the inhibition of β1 integrins in combination with proton irra-
diation was investigated. 
 
Figure 5.12: Proton irradiation induced reduction of 3D tumoroid growth is augmented cell line-dependently 
by β1 integrin targeting. (A) Experimental design and treatment setup for 3D PDAC tumoroid growth analysis. (B) 
3D tumoroid formation capacity of unirradiated PDAC cell lines 1-h pretreated with indicated antibodies. (C) 3D 
PDAC tumoroid formation capacity upon 1-h antibody pretreatment combined with proton irradiation of PDAC cell 
lines. All results show mean ± SD (n = 3; two-sided t test; *, P < 0.05; **, P < 0.01; ***, P < 0.001). 
In three therapy-naïve 3D PDAC cell cultures and the radioresistant 3D MiaPaCa-2 
cultures a superimposable AIIB2-mediated cytotoxicity was observed in the setup for proton 
irradiation and the inhibition of β1 integrins resulted in a non- or less significant reduction of 
tumoroid growth upon proton irradiation (Figure 5.12B, C). Interestingly, the susceptibility of 
the radioresistant 3D MiaPaCa-2 cultures for AIIB2 was greater for protons than photons (Fig-
ure 5.12C, Figure 5.2). Intriguingly, intrinsic (IgG) sensitivity of the analyzed 3D Colo357 and 
MiaPaCa-2 cultures differed towards photons and protons with the radioresistant cell model 
being as sensitive to protons as the parental one (Figure 5.2, Figure 5.3 and Figure 5.12C). 
These observations stimulated to pursue a comparative investigation of radiation survival and 




5.2 Comparative proton and photon irradiation of 3D, matrix-based 
PDAC cell cultures 
5.2.1 Effect of proton and photon irradiation on 3D PDAC tumoroid growth 
Sections 5.2.1 to 5.2.5 have been published in similar form by Görte et al. (Görte et al., 2020) 
and are adapted according to Erratum/Corrigendum submitted to Cancers on May 11th in 2021. 
To date little is known concerning effectiveness, molecular mechanisms, and proton beam 
radiosensitization in PDAC. In order to fill gaps of knowledge in detail, first, a comparative 
tumoroid growth analysis upon photon and proton irradiation in a panel of five human PDAC 
cell lines grown in physiological lrECM was conducted (Figure 5.13A). While basic tumoroid 
formation was similar for the experimental photon and proton irradiation setup, varying intrinsic 
radiosensitivities towards photon irradiation were observed with MiaPaCa-2 being the most 
sensitive and Colo357 the most resistant cell line (Figure 5.13B-D; values for relative biological 
effectiveness (RBE) and surviving fraction of 2 Gy (SF2) are shown in Table 5.5 and Table 
5.6, respectively). In general, the degree of radiosensitivity towards photon irradiation differs 
to the one found for proton irradiation. Apart from BxPC-3 cells, tested PDAC cell lines demon-
strated either a significantly higher sensitivity to protons than photons or showed a trend to-
wards higher sensitivity to protons that resulted in reduced tumoroid growth (Figure 5.13D). 
Collectively, the obtained data revealed a greater reduction in PDAC tumoroid growth upon 





Figure 5.13: Proton irradiation tends to be more effective in reducing PDAC tumoroid growth than photon 
irradiation. (A) Experimental set-up for examining 3D PDAC tumoroid growth. (B) Representative bright-field im-
ages of unirradiated, 6-Gy photon and 6-Gy proton irradiated 3D PDAC tumoroids, scale bar: 100 µm. (C) 3D 
tumoroid formation capacity without irradiation. (D) 3D PDAC tumoroid growth after irradiation with 2, 4 or 6 Gy of 
photons and protons. Cell lines are ordered by increasing resistance to photon irradiation. Results show mean ± 
SD (n = 3; two-sided t-test; *, P < 0.05; **, P < 0.01). Reproduced from Görte et al. (Görte et al., 2020) and adapted 




Table 5.5: RBE values comparing proton to photon irradiation effectiveness in PDAC cell lines. 







Table 5.6: SF2 values of PDAC cell lines after photon and proton irradiation. 




MiaPaCa-2 0.69 0.61 
Panc-1 0.58 0.34 
BxPC-3 0.56 0.61 
Patu8902 0.70 0.51 
Colo357 0.73 0.51 
 
5.2.2 Effect of proton and photon irradiation on phosphoproteome of 3D 
PDAC cultures 
One aim of the study was to unravel potential differences in the molecular mechanisms causing 
the observed differential effectiveness between proton and photon irradiation in PDAC cell 
cultures. Hence, a screening in form of a broad-spectrum phosphoproteome analysis was per-
formed (Figure 5.14A). 3D lrECM grown Colo357 and MiaPaCa-2 cell lines were chosen as 
models due to differences in their intrinsic radiosensitivity towards photon irradiation (Mi-
aPaCa-2 most sensitive, Colo357 most resistant). Generally, the phosphorylation patterns dif-
fered between proton and photon irradiation (Figure 5.14B, C; Table 5.7). Interestingly, more 
increases and decreases in phosphorylation were detected in both 3D PDAC cell cultures upon 
proton irradiation than photons according to the set cut-offs of ≥ 50 % and ≥ 30 %, respectively 
(Figure 5.14D). Among the detected 584 phosphorylation sites of 331 proteins from the array, 
6 out of 37 and 10 out of 34 showed an overlapping ≥ 30 % decrease between protons and 
photons in Colo357 and MiaPaCa2 cells (Figure 5.14E). A common ≥ 50 % increase after pro-
ton and photon irradiation was detectable for 10 out of 69 and 23 out of 76 protein phosphor-





Figure 5.14: Phosphoproteome of 3D PDAC cell cultures is differentially affected by proton and photon 
irradiation. (A) Experimental set-up of phosphoproteome analysis; Alterations of phosphorylation sites upon irra-
diation are categorized into three ranges: (i) ≥ 30 % decrease, (ii) ≥ 50 % increase, (iii) ≤30% decrease + ≤ 50% 
increase. The latter is defined as ‘no change’. Data falling into the categories (i) and (ii) are plotted as (B) heatmaps 
and (C) waterfall blots after normalization to unirradiated controls (n = 1) (peptide names given in Table 5.7. (D) 
Percentage of phospho-sites among all detected 584 phospho-sites showing ≥ 30 % decrease or ≥ 50 % increase 
in phosphorylation after irradiation in indicated cell lines. Modified from Görte et al. (Görte et al., 2020). 
Table 5.7: List of altered phosphorylation sites upon irradiation. Phospho-sites categorized into (i) ≥ 30 % 
decrease and (ii) ≥ 50 % increase upon irradiation, as demonstrated in Figure 5.14, are listed in the order of pho-
ton-induced changes for each analyzed cell line. 
Colo357 MiaPaCa-2 
Ret (Phospho-Tyr905) GluR1 (Phospho-Ser849) 
c-Jun (Phospho-Thr93) Chk1 (Phospho-Ser317) 
Raf1 (Phospho-Ser259) IRS-1 (Phospho-Ser312) 





Myc (Phospho-Thr358) c-Jun (Phospho-Ser243) 
Smad1 (Phospho-Ser187) Cortactin (Phospho-Tyr421) 
CaMK2A (Phospho-Thr286) 4E-BP1 (Phospho-Thr45) 
p38 MAPK (Phospho-Tyr182) p44/42 MAPK (Phospho-Thr202) 
JAK2 (Phospho-Tyr221) CREB (Phospho-Ser133) 
B-RAF (Phospho-Thr598) GAP43 (Phospho-Ser41) 
JunB (Phospho-Ser79) Merlin (Phospho-Ser10) 
Chk1 (Phospho-Ser317) EGFR (Phospho-Tyr1110) 
Merlin (Phospho-Ser10) HDAC8 (Phospho-Ser39) 
VEGFR2 (Phospho-Tyr1214) LCK (Phospho-Tyr393) 
SHP-2 (Phospho-Tyr542) PDGFR beta (Phospho-Tyr751) 
ATF2 (Phospho-Thr69/51) NFkB-p105/p50 (Phospho-Ser337) 
Synuclein alpha (Phospho-Tyr125) PPAR-gamma (Phospho-Ser112) 
p53 (Phospho-Ser6) Synuclein alpha (Phospho-Tyr125) 
VASP (Phospho-Ser157) IR (Phospho-Tyr1361) 
PKC delta (Phospho-Ser645) STAT5A (Phospho-Ser780) 
Rel (Phospho-Ser503) 14-3-3 theta/tau (Phospho-Ser232) 
BLNK (Phospho-Tyr96) p53 (Phospho-Ser6) 
BCR (Phospho-Tyr177) 4E-BP1 (Phospho-Thr36) 
Myc (Phospho-Ser62) HSP27 (Phospho-Ser82) 
KIT (Phospho-Tyr936) NFkB-p65 (Phospho-Ser529) 
P90RSK (Phospho-Thr359/Ser363) VASP (Phospho-Ser157) 
HSP27 (Phospho-Ser82) Tau (Phospho-Ser396) 
ICAM-1 (Phospho-Tyr512) p44/42 MAPK (Phospho-Tyr204) 
Estrogen Receptor-alpha (Phospho-Ser167) IGF1R (Phospho-Tyr1165/1166) 
MEK1 (Phospho-Thr291) Gab1 (Phospho-Tyr627) 
GABA-RB (Phospho-Ser434) VAV1 (Phospho-Tyr174) 
FKHR (Phospho-Ser256) GSK3 beta (Phospho-Ser9) 
HDAC8 (Phospho-Ser39) P70S6K-beta (Phospho-Ser423) 
AMPK1/AMPK2 (Phospho-Ser485/491) E2F1 (Phospho-Thr433) 
Shc (Phospho-Tyr349) BTK (Phospho-Tyr223) 
LKB1 (Phospho-Thr189) STAT6 (Phospho-Tyr641) 
MARCKS (Phospho-Ser163) Integrin beta-3 (Phospho-Tyr773) 
LIMK1 (Phospho-Thr508) BCL-XL (Phospho-Thr47) 
IR (Phospho-Tyr1361) Tau (Phospho-Thr205) 





NFkB-p65 (Phospho-Ser276) HER4/ErbB4 (Phospho-Tyr1284) 
Rac1/cdc42 (Phospho-Ser71) mTOR (Phospho-Thr2446) 
FAK (Phospho-Tyr861) Estrogen Receptor-alpha (Phospho-Ser118) 
Ras-GRF1 (Phospho-Ser916) DAPP1 (Phospho-Tyr139) 
SYK (Phospho-Tyr525) Lamin A (Phospho-Ser22) 
Integrin beta-3 (Phospho-Tyr785) Smad2/3 (Phospho-Thr8) 
IL-4R/CD124 (Phospho-Tyr497) BCR (Phospho-Tyr360) 
SAPK/JNK (Phospho-Tyr185) Ezrin (Phospho-Tyr353) 
c-Jun (Phospho-Ser243) STAM2 (Phospho-Tyr192) 
Raf1 (Phospho-Ser43) A-RAF (Phospho-Tyr301/302) 
ATF4 (Phospho-Ser245) PDK1 (Phospho-Ser241) 
AKT1 (Phospho-Tyr474) Vinculin (Phospho-Tyr821) 
Histone H2A.X (Phospho-Ser139) Catenin delta-1 (Phospho-Tyr228) 
EGFR (Phospho-Tyr1069) Tau (Phospho-Thr181) 
JunD (Phospho-Ser255) PLD1 (Phospho-Ser561) 
Src (Phospho-Tyr529) c-Jun (Phospho-Tyr170) 
IRS-1 (Phospho-Ser636) HER2 (Phospho-Thr686) 
HNF4 alpha (Phospho-Ser313) MEK1 (Phospho-Ser221) 
Zap-70 (Phospho-Tyr319) VASP (Phospho-Ser238) 
Catenin beta (Phospho-Ser33) IkB-alpha (Phospho-Ser32/36) 
GSK3 alpha (Phospho-Ser21) HDAC4 (Phospho-Ser632) 
HER2 (Phospho-Tyr1248) M-CSF Receptor (Phospho-Tyr561) 
MEK1 (Phospho-Ser221) NMDAR1 (Phospho-Ser897) 
Stathmin 1 (Phospho-Ser37) Paxillin (Phospho-Tyr31) 
GluR1 (Phospho-Ser863) DARPP-32 (Phospho-Thr34) 
PKC zeta (Phospho-Thr410) Ret (Phospho-Tyr905) 
Src (Phospho-Tyr418) Caspase 9 (Phospho-Ser196) 
Tau (Phospho-Ser235) Pyk2 (Phospho-Tyr402) 
HSP90B (Phospho-Ser254) Catenin beta (Phospho-Ser33) 
p27Kip1 (Phospho-Thr187) MEF2A (Phospho-Thr312) 
PAK3 (Phospho-Ser154) HSP27 (Phospho-Ser78) 
p53 (Phospho-Ser15) Smad3 (Phospho-Ser213) 
Kv1.3/KCNA3 (Phospho-Tyr135) Estrogen Receptor-alpha (Phospho-Ser104) 
p53 (Phospho-Thr18) CrkII (Phospho-Tyr221) 
P70S6K (Phospho-Ser424) Elk1 (Phospho-Thr417) 





SP1 (Phospho-Thr739) Caspase 9 (Phospho-Tyr153) 
Smad2/3 (Phospho-Thr8) eNOS (Phospho-Ser1177) 
Integrin beta-4 (Phospho-Tyr1510) HDAC1 (Phospho-Ser421) 
HSP90B (Phospho-Ser226) Smad3 (Phospho-Ser425) 
Catenin beta (Phospho-Thr41/Ser45) AKT1S1 (Phospho-Thr246) 
Cyclin D1 (Phospho-Thr286) SP1 (Phospho-Thr739) 
EEF2 (Phospho-Thr56) NFkB-p100/p52 (Phospho-Ser869) 
NFkB-p65 (Phospho-Thr435) PKC delta (Phospho-Ser645) 
ETK (Phospho-Tyr40) HER2 (Phospho-Tyr1221/Tyr1222) 
Abl1 (Phospho-Tyr204) GSK3 alpha (Phospho-Ser21) 
STAT4 (Phospho-Tyr693) Synaptotagmin (Phospho-Thr202) 
GluR1 (Phospho-Ser849) MKK4/SEK1 (Phospho-Thr261) 
Synaptotagmin (Phospho-Thr202) IKK-gamma (Phospho-Ser31) 
BRCA1 (Phospho-Ser1457) MAP3K8/COT (Phospho-Thr290) 
BTK (Phospho-Tyr223) EGFR (Phospho-Tyr1172) 
c-Jun (Phospho-Ser63) Estrogen Receptor-alpha (Phospho-Ser106) 
CDK2 (Phospho-Thr160) SHP-2 (Phospho-Tyr580) 
MSK1 (Phospho-Thr581) NFkB-p105/p50 (Phospho-Ser927) 
IKK-alpha/beta (Phospho-Ser180/181) LYN (Phospho-Tyr507) 
DAPP1 (Phospho-Tyr139) ATP1A1/Na+K+ ATPase1 (Phospho-Ser23) 
Tau (Phospho-Thr212) STAT4 (Phospho-Tyr693) 
JunB (Phospho-Ser259) FAK (Phospho-Tyr397) 
EGFR (Phospho-Tyr1110) Rel (Phospho-Ser503) 
IRS-1 (Phospho-Ser312) Ras-GRF1 (Phospho-Ser916) 
CDC25C (Phospho-Ser216) Shc (Phospho-Tyr349) 
Cortactin (Phospho-Tyr421) FAS (Phospho-Tyr291) 
Elk1 (Phospho-Thr417) GluR2 (Phospho-Ser880) 
VEGFR2 (Phospho-Tyr1175) Rb (Phospho-Ser780) 
HDAC1 (Phospho-Ser421) Abl1 (Phospho-Tyr204) 
 4E-BP1 (Phospho-Ser65) 
 BRCA1 (Phospho-Ser1457) 
 SYK (Phospho-Tyr525) 
 Raf1 (Phospho-Ser296) 






A more rigorous analysis focused on phosphorylation sites with an increase of 50 % or 
higher aiming for identifying potential radiosensitizing targets specific for either protons or pho-
tons or both. For photons, Merlin (p-Ser10) was the only shared unique candidate among 39 
phospho-sites in 3D Colo357 and MiaPaCa-2 cell cultures (Figure 5.15A). Upon proton irradi-
ation, Catenin β (p-Ser33), Smad2/3 (p-Thr8) and GSK3-α (p-Ser21) among 68 unique phos-
pho-sites emerged in both cell lines (Figure 5.15A). Overlapping among 30 phospho-sites for 
proton and photon irradiation were p53 (p-Ser6), Synuclein (p-Tyr125) and VASP (p-Ser157) 
(Figure 5.15A). Given the fact that these protein phosphorylations either inhibit the enzymatic 
activity (GSK3α), induce ubiquitination (Merlin) or lack specific clinically relevant inhibitors 
(Synuclein, VASP), the data was reanalyzed on the protein level instead of the phosphorylation 
level (≥ 50 % increase; Figure 5.15B). 
 
Figure 5.15: Identification of cell line-overlapping protein alterations induced by proton and photon irradi-
ation. (A) Venn diagram analysis indicating overlapping and specific alterations of phospho-sites after photon or 
proton irradiation. (B) Venn diagram analysis comparing proteins altered by ≥ 50 % increase in phosphorylation of 
Colo357 and MiaPaCa-2 cell lines either specifically after photons and protons or by both kinds of irradiation. (C) 
Phospho-site alterations with ≥ 50 % increase in phosphorylation (fold change; displayed data start at 1.5) in 6-Gy 




In summary, proton irradiation led to greater changes in phosphorylation events than 
photon irradiation in 3D PDAC cell cultures and the conducted analysis revealed a strikingly 
different pattern of phosphorylation events for proton- and photon irradiation. 
5.2.3 Exploitation of radiation type-specific phosphoproteomic changes to 
increase radiosensitivity of 3D PDAC cultures 
After obtaining the list of all proteins showing a ≥50% increase in phosphorylation that entailed 
enhanced enzymatic activity, the next step was to search for both radiation type-specific and 
non-specific targets (Figure 5.15C). Out of this set of proteins, druggable targets were chosen 
for which inhibitors are already clinically applied or are being tested in clinical trials (Figure 
5.15C). One target specifically altered after either photon irradiation (estrogen receptor α, ER-
α), proton irradiation (HER2), or both photon and proton irradiation (Chk1) was chosen (Figure 
5.15C). Hydroxy-tamoxifen was used to deactivate ER-α, the inhibitory antibody trastuzumab 
(Ontruzant®) and the small molecule inhibitor lapatinib were applied for HER2 and prexasertib, 
a small molecule inhibitor, for Chk1. 
Concerning basal tumoroid growth after treatment, only moderate effects were found 
in both analyzed cell lines, Colo357 and MiaPaCa-2 (Figure 5.16B). In combination with irra-
diation, however, Tamoxifen enhanced Colo357 and MiaPaCa-2 cell sensitivity towards 6-Gy 
photons by 1.2- and 1.6-fold, respectively (Figure 5.16C). The sensitivity towards 6-Gy protons 
was only elevated in MiaPaCa-2 cells by 1.4-fold (Figure 5.16C). In contrast, trastuzumab 
failed to radiosensitize the tested PDAC cell lines to photons and protons (Figure 5.16C). In 
contrast, treatment with lapatinib sensitized significantly both analyzed cell lines towards irra-
diation with photons and protons (Figure 5.17A, B). The enhancement ratios were greater for 
Colo357 cells (1.3 for photons; 1.4 for protons) than for MiaPaCa-2 (1.1 for photons; 1.2 for 
protons) (Figure 5.17B). Intriguingly, prexasertib elicited radiosensitization to photons and pro-
tons both in Colo357 and MiaPaCa-2 cells. The resulting enhancement ratios for Colo357 and 
MiaPaCa-2 cells were 1.5 and 1.6, respectively, for photons and 1.3 in both cell lines for pro-
tons (Figure 5.16C). These findings suggest targeting of ER-α and Chk1 to convey slightly 
higher radiosensitizing efficacy to photons in relation to protons, whereas targeting of HER2 
tends to increase the efficacy for protons (Figure 5.16D). To note, the phosphorylation and 
expression of these targeted proteins after irradiation remained unchanged for ER-α and HER2 
(Figure 5.18B-E) in contrast to Chk1 showing a hyperphosphorylation at its activating phospho-





Figure 5.16: Photon and proton irradiated 3D PDAC cell cultures differentially respond to tamoxifen, 
trastuzumab and prexasertib. (A) Experimental design and treatment setup for 3D PDAC tumoroid growth anal-
ysis. (B) 3D tumoroid formation capacity of unirradiated Colo357 and MiaPaCa-2 cells treated with tamoxifen, 
trastuzumab or prexasertib (experimental set-up shown in). (C) Normalized 3D tumoroid formation capacity upon 
1-h pretreatment with tamoxifen, trastuzumab or prexasertib in combination with 6-Gy photon or proton irradiation. 
Enhancement ratio (tumoroid formation capacity after 6 Gy control treatment/tumoroid formation capacity after 6 
Gy inhibitor treatment) are indicated as blue triangles. (D) Differences in the radiosensitizing efficacy of inhibitors 
visualized by Δ values of normalized tumor formation capacity (tumoroid formation capacity after 6 Gy of protons - 
tumoroid formation capacity after 6 Gy of photons). All results show mean ± SD (n = 3; two-sided t test; *, P < 0.05; 





Figure 5.17: Photon and proton irradiated 3D PDAC cell cultures differentially respond to lapatinib. (A) 3D 
tumoroid formation capacity of unirradiated Colo357 and MiaPaCa-2 cells treated with lapatinib (experimental set-
up shown in Figure 5.16). (B) Normalized 3D tumoroid formation capacity upon 1-h pretreatment with lapatinib in 
combination with 6-Gy photon or proton irradiation. Enhancement ratio (tumoroid formation capacity after 6 Gy 
control treatment/tumoroid formation capacity after 6 Gy inhibitor treatment) are indicated as blue triangles. (C) 
Differences in the radiosensitizing efficacy of inhibitors visualized by Δ values of normalized tumor formation ca-
pacity (tumoroid formation capacity after 6 Gy of protons - tumoroid formation capacity after 6 Gy of photons). All 






Figure 5.18: Photon and proton irradiation differentially affect the phosphorylation status of Chk1, ER-α 
and HER2 of 3D PDAC cell cultures. (A, B, C) Immunoblots on whole cell lysates from 0-Gy (Co) or 6-Gy photon 
or 6-Gy proton irradiated Colo357 and MiaPaCa-2 cells showing total and phosphorylated forms of Chk1, ER-α and 
HER2. β-Actin served as loading control. (D) Densitometry of normalized total forms of Chk1, ER-α and HER2 from 
A, B and C. (E) Fold change of phosphorylated forms of Chk1, ER-α and HER2 from A, B and C. All results show 
mean ± SD (n = 3). Reproduced from Görte et al. (Görte et al., 2020). 
Taken together, despite detectable changes in protein phosphorylation in the phospho-
proteome analysis, the objective to therapeutically exploit these differences uniquely for PDAC 





5.2.4 Comparative proton and photon irradiation combined with pharma-
cological inhibitors in 3D PDAC cultures 
Subsequently, a screen with inhibitors deactivating either RTK signal transduction (EGFRi, 
MAPKi, MEKi, PI3Ki, VEGFRi) or DNA repair processes (ATMi, DNA-PKi, MDM2i, 
Mre11/Rad50/Nbs1 protein complex (MRNcomplexi), PARPi, Rad51i) was conducted. While 
3D tumoroid growth of Colo357 cells was diminished upon EGFRi, VEGFRi and Rad51i, Mi-
aPaCa-2 tumoroid growth remained unaffected (Figure 5.19A). Cell line dependently, signal 
transduction inhibitors elicited 3D tumoroid growth reduction in both tested cell lines upon irra-
diation (Figure 5.19B). PI3Ki showed the strongest effect in both cell lines (Figure 5.19B). In-
terestingly, Colo357 and MiaPaCa-2 cells responded differently to MRNcomplexi upon proton 
irradiation relative to photons (Figure 5.19B). Pretreatment with Rad51i led to a radioprotection 
in MiaPaCa-2 cells (Figure 5.19B). In contrast, PARPi, DNA-PKcsi and ATMi presented most 
efficient regarding reduction of tumoroid growth (Figure 5.19B). The similarity of the radiosen-
sitizing efficacy of the different signal transduction and DNA repair inhibitors for photons and 
protons is visualized in Figure 5.19C.  
In conclusion, effective signal transduction inhibitors such as PI3Ki and DNA repair 
inhibitors were found as radiation type-independent radiosensitizers. Notably, the screen 






Figure 5.19: Targeting of signal transduction and DNA repair enzymes sensitizes PDAC cell cultures to 
photon and proton irradiation. (A) 3D tumoroid formation capacity of unirradiated Colo357 and MiaPaCa-2 cells 
1-h pretreated with indicated pharmacological inhibitors (experimental set-up shown in Figure 5.16). (B) Normalized 
3D PDAC tumoroid formation capacity upon 1-h inhibitor pretreatment combined with 6-Gy photon or proton irradi-
ation. Data in the order of cell line-specific inhibitor efficacy after photon irradiation. Enhancement ratio (tumoroid 
formation capacity after 6 Gy control treatment/tumoroid formation capacity after 6 Gy inhibitor treatment) are indi-
cated as blue triangles. (C) Differences in the radiosensitizing efficacy of inhibitors visualized by Δ values of nor-
malized tumor formation capacity (tumoroid formation capacity after 6 Gy of protons - tumoroid formation capacity 




5.2.5 Comparative proton and photon irradiation combined with DNA dam-
age repair inhibition on 3D PDAC tumoroid growth 
The DNA damage response, in general, plays a pivotal role in tumor cell survival and the as-
sociated DNA repair enzymes are considered as ideal therapeutic targets. To confirm the dif-
ferent DNA repair inhibitor efficacies for radiosensitization the larger PDAC cell line panel was 
analyzed. Single pharmacological inhibition of Rad51, PARP, DNA-PK and ATM indeed ech-
oed the results observed in the Colo357/MiaPaCa-2 cell model screen (Figure 5.20A). Overall, 
and similar to the data of the screen, the following increasing 3D PDAC tumoroid reduction for 
photons as well as protons was discovered: Rad51i < PARPi < DNA-PKcsi < ATMi (Figure 
5.20B). Although differing in their absolute values among tested PDAC cell lines, the discrep-
ancies between photons and protons turned out to be minor ranging between approximately -
0.2 to 0.3 (Figure 5.20C). This notion is also visualized in Figure 5D, in which the enhancement 
ratios of all conditions are plotted. Moreover, these results are underpinned by taking together 
the differences in the radiation response to photons and protons of the whole PDAC cell line 
panel. Indicative by Δ values close to zero, the reduction in tumoroid growth after HR and 
NHEJ inhibition presented largely independent from radiation type (Figure 5.20E). 
Conclusively, the data generated in this PDAC cell line panel revealed the classical and 






Figure 5.20: Targeting NHEJ associated enzymes seems generally potent to sensitize 3D PDAC cell cultures 
to photon and proton irradiation. (A) 3D tumoroid formation capacity of unirradiated indicated PDAC cells treated 
with indicated DNA repair inhibitors (experimental set-up shown in Figure 5.16). (B) Normalized 3D PDAC tumoroid 
formation capacity upon 1-h inhibitor pretreatment combined with 6-Gy photon or proton irradiation. (C) Differences 
in in the radiosensitizing efficacy of inhibitors visualized by Δ values of normalized tumor formation capacity (tumor-
oid formation capacity after 6 Gy of protons - tumoroid formation capacity after 6 Gy of photons). (D) Enhancement 
ratio (tumoroid formation capacity after 6 Gy control treatment/tumoroid formation capacity after 6 Gy inhibitor treat-
ment) of each cell line analyzed in B after photon and proton irradiation plotted logarithmically. (E) Analysis of 
differences in the radiosensitizing efficacy of indicated inhibitors showing violin blots of summarized Δ values of 
tumoroid formation capacity from all PDAC cell lines. All results show mean ± SD (n = 3; two-sided t test; *, P < 
0.05; **, P < 0.01; ***, P < 0.001). Reproduced from Görte et al. (Görte et al., 2020) and adapted according to 





PDAC is a highly therapy-resistant tumor, and despite great advances in treatment modalities, 
patient survival is still very poor (Kleeff et al., 2016). The extraordinary resistance to therapy 
presents a significant obstacle for improving the bad prognosis. Uncovering the molecular cir-
cumstances responsible for intrinsic and acquired resistance is likely to improve current stand-
ard therapies and lead to novel targeting strategies. In more physiological 3D PDAC cell cul-
tures, this work implemented two different preclinical approaches to tackle resistance to ther-
apy in PDAC. This study expands the knowledge of CAM-RR in PDAC by unraveling the func-
tion of β1 integrins and the underlying mechanisms driving therapy resistance. Furthermore, 
indications for targeting strategies are provided by in-depth analyses of the efficacies of photon 
and proton irradiation with and without the addition of biologicals in 3D PDAC cell cultures. 
In the first part, the role of β1 integrins in radioresistance was investigated in therapy-
naïve and radioresistant 3D PDAC cultures. It was demonstrated that (i) the overexpression of 
β1 integrin mRNA in PDAC in comparison to normal pancreas correlated with poorer patient 
survival, (ii) β1 integrin targeting significantly radiosensitized both therapy-naïve and radiore-
sistant 3D PDAC cultures to photon and proton irradiation, (iii) the protein expression pattern 
was not decisive for targeting susceptibility of the cell lines, (iv) β1 integrin inhibition marginally 
sensitized the analyzed 3D PDAC cell cultures to radiochemotherapy, (v) the β1 integrin inhi-
bition resulted in an overall downregulation of kinase activities in both therapy-naïve and radi-
oresistant 3D PDAC cultures, (vi) the combinational kinase depletion together with β1 integrins 
elicited a substantial enhancement of radiosensitivity in therapy-naïve 3D cultures, however, 
not in the radioresistant counterpart, (vii) Erk2, PKD1 and CK1δ are potential effector mole-
cules in the β1 integrin-mediated signaling cascade activated in the radiation survival response 
in PDAC. 
In the second part, a comparative analysis of the efficacy of proton and photon irradia-
tion regarding cell kill was conducted and the respective induced molecular alterations were 
investigated in 3D PDAC cultures. This study revealed that (i) protons induce a higher cell kill 
in a cell line-dependent manner, (ii) more phosphoproteomic changes are caused by proton 
than photon irradiation, but (iii) the exploitation of these molecular changes fails to induce ra-




transduction and DNA repair molecules is similar for photon and proton irradiation, and (iv) the 
3D PDAC cultures strongly and homogeneously depend on c- and alt-NHEJ. 
In summary, this work performed in more physiological 3D PDAC cell culture models 
demonstrates that both photon and proton radiotherapy combined with tailored therapies pre-
sent promising treatment strategies to overcome the resistance of this cancer type. 
6.1 β1 integrins mediate radioresistance in therapy-naïve and radi-
oresistant 3D PDAC cell cultures 
Integrins are key players of CAM-RR and CAM-DR in various tumor entities (Cordes et al., 
2006; Cordes & Meineke, 2003; Eke, Deuse, et al., 2012; Jin et al., 2019; Koppenhagen et al., 
2017). In PDAC, owing to its highly desmoplasmic microenvironment (Kleeff et al., 2016), cell 
adhesion is likely to be exploitable for sensitizing to therapies. The overexpression of β1 integ-
rins on mRNA level in tumor tissue (Badea et al., 2008; Logsdon et al., 2003) and the correla-
tion of a high mRNA expression of β1 integrins with poorer patient survival indicate a crucial 
role of the adhesion receptors in tumor aggressiveness. Indeed, various studies demonstrated 
β1 integrins to contribute to tumor progression and metastasis in PDAC (Grzesiak et al., 2011; 
Grzesiak & Bouvet, 2006; H. Yao et al., 2011). Corroborative data of an in vivo study by Grze-
siak et al. showed lowered primary tumor growth upon β1 integrin depletion in an orthotopic 
mouse model (Grzesiak et al., 2011). Furthermore, β1 integrins were shown to participate in 
resistance mechanisms towards targeted therapy like cetuximab or MEK inhibition in PDAC 
cell lines (Brannon et al., 2020; Y. J. Kim et al., 2017). However, regarding the role of β1 in-
tegrins in radiochemoresistance in PDAC, little data exist to date. Previous work studied cave-
olin-1-mediated radioresistance in MiaPaCa-2 cell lines and found siRNA-mediated knock-
down of ITGB1 to effectively mediate radioresponsiveness without affecting basal clonogenic-
ity (Hehlgans et al., 2009). Hence, the idea of β1 integrins to bear a role in radioresistance in 
PDAC is fostered. 
In the first part of the present work, blocking β1 integrins in a heterogeneous panel of 
four therapy-naïve and radioresistant 3D PDAC cell cultures, using inhibitory antibodies (AIIB2, 
mAb13) or RNAi-mediated silencing of β1 integrins in combination with irradiation – both pho-
ton and proton – resulted in a significant radiosensitization in all four PDAC cell lines. The 
enhancement of radiosensitization was cell line dependent. Targeting β1 integrins scarcely 
affected basal cell survival. To the best of one’s knowledge, this is the first work studying CAM-
RR to proton irradiation by β1 integrin inhibition in PDAC and to unravel a similar radiosensi-
tizing potential of the β1 integrin targeting for proton and photon irradiation. An increase in 
radiosensitivity for photons upon β1 integrin targeting has also previously been demonstrated 




squamous cell carcinoma (HNSCC) (Eke et al., 2015; Harryman et al., 2017; L. Li et al., 2018; 
C. C. Park et al., 2006). Furthermore, several groups observed a β1 integrin inhibition-medi-
ated radiosensitization upon AIIB2 administration combined with irradiation in xenograft mod-
els for breast and prostate cancer (Goel et al., 2013; C. C. Park et al., 2008). The RNAi-induced 
degree of radiosensitization was different than what could be observed upon AIIB2. This find-
ing is similar to observations in HNSCC cell lines and possibly depends on β1 integrin expres-
sion or differential underlying molecular mechanisms of the targeting strategies (Eke, 
Dickreuter, et al., 2012). 
Intratumoral heterogeneity is known to modulate intrinsic and acquired therapy re-
sistance in several cancer types, including PDAC (Juiz et al., 2019; Ligorio et al., 2019; Marine 
et al., 2020; Peng et al., 2019). AIIB2 significantly radiosensitized the radioresistant cell model 
superimposable to the intrinsic radiosensitivity of the therapy-naïve counterpart. Strikingly, 
while the antibody-mediated activation of β1 integrin fostered the radioresistance in the ther-
apy-naïve cell lines, the radioresistant 3D cultures remained unaffected. The fact that all ana-
lyzed PDAC cell lines were found susceptible for β1 integrin targeting indicates that the tumor 
heterogeneity can be tackled by this treatment approach. Simultaneously, these findings sug-
gest an independence of β1 integrins for the response to radiation in a model for acquired 
radioresistance in PDAC. Intriguingly, in the radioresistant MiaPaCa-2 cultures, both IgG con-
trol and AIIB2 treatment caused almost the same response to proton radiation as in the ther-
apy-naïve counterpart. This finding suggests that a specific resistance to photon radiation does 
not imply a resistance to other radiation kinds. Hence, acquired resistance to protons and if 
the effect exists vice versa need to be investigated. Presumably, these observations underly 
yet unknown molecular alterations induced by each irradiation type. 
The cell line-dependent efficacies of AIIB2 in radiosensitization to photon irradiation 
were hypothesized to be related to β1 integrin protein expression. With an increase of the 
mature β1 integrin expression a decrease of the extent of AIIB2-induced radiosensitization 
could be observed. Intriguingly, β1 integrin expression of total, mature or immature forms could 
neither be related with the tumoroid formation capacities of the 3D PDAC cultures after irradi-
ation nor after AIIB2-treatment combined with irradiation. Transcript variants and consequently 
differential signaling might be a conceivable reason for differing sensitivities towards β1 integ-
rin targeting in the analyzed PDAC cell line panel. Various transcript variants of β1 integrins 
exist, known to bear differential affinities for adaptor proteins resulting in altered signaling 
(Soto-Ribeiro et al., 2019). Moreover, glycosylation is discussed to differentially affect the reg-
ulation of β1 integrins (Bellis, 2004). However, to evaluate the importance of these (post-)trans-




The expression of β1 integrins did not differ between the therapy-naïve and radiore-
sistant cell lines, which suggests that the distinct AIIB2 efficacies do not rely on antibody sat-
uration in the radioresistance cell model. However, radiation exposure itself can impact the 
expression of β1 integrins and consequently the targeting effectiveness of AIIB2. Yao et al. 
found an irradiation-induced increase of membranous β1 integrin expression in the PDAC cell 
lines BxPC-3, MiaPaCa-2, and Panc-1 (H. Yao et al., 2011). In line, similar changes in expres-
sion were shown in cancer cells originating from other entities. Cordes et al. observed an ad-
hesion-dependent enhancement of β1 integrin expression upon irradiation in lung cancer cell 
lines (Cordes et al., 2002). In prostate cancer cell lines, Eke et al. revealed a sustained upreg-
ulation of β1 integrins on protein level after fractionated irradiation with 10 Gy (Eke et al., 2018). 
In contrast, β1 integrins were found downregulated upon photon and also proton radiation ex-
posure in melanoma cells (Jasińska-Konior et al., 2017). In line, a fractionated high dose reg-
imen of 25 Gy lowered β1 integrin protein expression in prostate cancer cell lines (Simon et 
al., 2005) and a lower expression of β1 integrins upon proton irradiation was observed in a 
colon carcinoma cell line (Ha et al., 2015). In the present work, β1 integrin (membranous) 
expression upon irradiation was not studied. Although the targeting efficacy was similar for 
proton and photon irradiation, transient alterations in β1 integrin expression upon both irradia-
tion types display potential determinants of AIIB2 susceptibility in the 3D PDAC cell cultures, 
especially the radioresistant counterparts.  
Consequently, these results clearly demonstrate that β1 integrins pose robust targets 
to overcome radioresistance in PDAC, even in heterogeneous tumors. The results indicate that 
the radiosensitization provided by β1 integrin inhibition may render photon- and proton-based 
radiotherapy more feasible for PDAC in a clinical scenario. Furthermore, β1 integrin targeting 
promises the potency to tackle the challenging inter- and intratumoral heterogeneity. From the 
translational point of view, the results suggest that photon and proton radiotherapy combined 
with β1 integrin targeting presents an effective therapeutic approach for PDAC. However, the 
radiosensitizing efficacy of β1 integrin-targeted intervention may be comprised if radioresistant 
clones arise during the course of radiotherapy. Various integrin targeting strategies, including 
those aiming at β1 integrins, failed in clinical trials (Alday-Parejo et al., 2019; D. Cox, 2020). 
However, the presented preclinical results underpin the potential of β1 integrins as targets, 
even in heterogeneous radioresistant tumors. Detailed investigations of the underlying mech-
anisms may prevent clinical failure and need to be unraveled in order to achieve successful 





6.2 Chemo- and radiochemosensitivity is independent of β1 integ-
rins in 3D PDAC cultures 
Another feature of PDAC is an early and frequent development of resistance to chemotherapy 
as consequence of cell adhesion-mediated drug resistance and the desmoplasmic tumor mi-
croenvironment (Schober et al., 2014). Thus, it was hypothesized that inhibition of β1 integrins 
in combination with (radio)chemotherapy benefits the efficacy of gemcitabine, taxol and cis-
platin. Against the expectations, the therapy-naïve and radioresistant 3D cultured PDAC cell 
lines were indifferent to the AIIB2 administration combined with the gemcitabine, taxol, and 
cisplatin. This is in contrast to Yang et al., who showed that β1 integrins confer resistance to 
gemcitabine via Akt signaling and that protein expression of β1 integrins in gemcitabine-re-
sistant AsPC-1 cells was increased in PDAC cell lines and patient samples (Yang et al., 2016, 
2018). Other studies demonstrated chemoresistance to be β1 integrin-dependent in varying 
tumor entities with different chemotherapies (Baltes et al., 2020; Berrazouane et al., 2019; M. 
Y. Kim et al., 2016; Vallo et al., 2017). For instance, in gemcitabine- and cisplatin-resistant 
urothelial cancer cell lines, an upregulated expression of β1 integrin was detected (Vallo et al., 
2017). The 3D cell culture model used in this work and the associated cell adhesion-mediated 
therapy resistance (Cordes & Meineke, 2003; Storch et al., 2010; Zschenker et al., 2012) are 
likely to result in a higher chemoresistance despite β1 integrin inhibition in the here analyzed 
PDAC cell lines. Accordingly, Beer et al. observed a higher cell viability upon cisplatin admin-
istration in PDAC cell lines cultured in a collagen-containing cyclic olefin polymer than under 
2D conditions (Beer et al., 2017). Similarly, in breast cancer cell lines, the investigation of CAM-
DR revealed a β1 integrin- and collagen I-dependent sensitization to various chemotherapies. 
Depending on the drug, β1 integrins conveyed chemoresistance either by the regulation of 
ATP-binding cassette transporter activity, which is responsible for cellular export of drugs, or 
by pro-survival signaling (Baltes et al., 2020). In this work, the EC10 for each drug was admin-
istered. Applying higher doses like EC20 or EC50 might alter the outcome. However, upon β1 
integrin inhibition combined with irradiation a synergistic or additive enhancement of the drug 
efficacy was determined cell line- and drug-dependently the 3D PDAC cell cultures. This ob-
servation underpins the significance of β1 integrins and the underlying signaling in radiation 
response in PDAC, since no effects on cell survival upon β1 integrin inhibition were observed 
under basal, unirradiated conditions. Nonetheless, the enhancement degree was marginal. 
Collectively, the results suggest that chemosensitivity is independent of β1 integrin 
functions. An enhanced cell line-dependent chemosensitivity is conferred upon combined β1 
integrin inhibition and irradiation in 3D cultured PDAC cell lines. Contradictory findings in other 
studies may result from the different cell culture conditions, which highlights the need for phys-




6.3 β1 integrin inhibition regulates kinome activity differentially in 
therapy-naïve and radioresistant 3D PDAC cell cultures 
Integrins lack an intrinsic enzymatic activity, and the integrin ‘adhesome’, consisting of a pleth-
ora of adaptor proteins and kinases, contributes to the integrin-mediated cell adhesion and 
associated signaling (Horton et al., 2015, 2016; Hynes, 2002). In clinical trials, direct targeting 
of integrins failed due to various reasons. Thus, a detailed elucidation of the β1 integrin signal-
ing cascade in PDAC and the alterations present in acquired radioresistance is essential to 
unravel novel translatable targets. Kinome profiling was used to assess kinase activities on the 
basal level and upon β1 integrin inhibition in the therapy-naïve and radioresistant 3D MiaPaCa-
2 cultures. A lower basal kinase activity was unraveled in the radioresistant cultures than in 
the therapy-naïve counterpart. The AIIB2 administration entailed a homogeneous decrease in 
the kinase activity after one hour in both therapy-naïve and radioresistant 3D PDAC cell cul-
tures. However, the latter demonstrated weaker responses to the treatment, suggesting an 
independence of the β1 integrin signaling in the radioresistant MiaPaCa-2 cell line. Apart from 
the degree of deregulation, the affected kinases upon AIIB2 were mostly differing in the ther-
apy-naïve and radioresistant cell cultures. This indicates differences in the β1 integrin signaling 
in the therapy-naïve and radioresistant cell cultures. Both the lower basal kinase activities and 
differing deregulations of kinases induced by the β1 integrin inhibition present molecular con-
ditions that may be explanatory for the lower degree of sensitization upon β1 integrin inhibition 
combined with photon irradiation observed in the two radioresistant PDAC cell lines. 
Several kinases are known to collaborate essentially in cell adhesion-mediated re-
sistance (Eke & Cordes, 2015; Horton et al., 2016). Interestingly, those kinases that were un-
covered to contribute to the β1 integrin signaling in PDAC, head and neck cancer or glioblas-
toma cell lines, such as FAK, c-Jun N-terminal kinase 1 (JNK1), Akt, c-Abl, or Src (Dickreuter 
et al., 2016; Eke et al., 2015; Eke, Deuse, et al., 2012; Y. J. Kim et al., 2017; Koppenhagen et 
al., 2017; Vehlow et al., 2017), were not significantly affected upon blocking of β1 integrins in 
neither of the analyzed 3D PDAC cell cultures. However, the observation in PDAC cell lines, 
including the MiaPaCa-2 cell line, were generated in 2D cultures (Y. J. Kim et al., 2017). These 
findings suggest differing kinases to be part of the β1 integrin signaling axis depending on the 
tumor entity and even the used cell culture conditions within the same cancer type. 
Altogether, the obtained results indicate that differing kinome activities, both intrinsic 
and upon β1 integrin inhibition, form the basis for the distinct outcomes upon various treat-
ments between the therapy-naïve and radioresistant 3D PDAC cultures. Canonical kinases 
often present in the β1 integrin signaling, were not affected in the analyzed cell model. This 




an observation that requires particular attention. The importance of tumor type-specific pre-
clinical evaluations must be emphasized here to unravel effective targeting strategies and to 
consequently prevent failure in the clinic. 
6.4 Erk2, PKD1, and CK1δ potentially participate in β1 integrin sig-
naling in therapy-naïve 3D PDAC cultures 
The top kinases downregulated upon β1 inhibition in the therapy-naïve and radioresistant 3D 
MiaPaCa-2 cultures were hypothesized to be part of the β1 integrin-mediated response to ra-
diation. Consequently, a depletion should elicit radiosensitization. The simultaneous depletion 
with β1 integrins should provide further information for a shared signaling axis. For the chosen 
candidates, a cell line- and kinase-dependent role in cell survival in response to radiation was 
unraveled in the therapy-naïve and radioresistant 3D MiaPaCa-2 cell cultures. Double target-
ing of Erk2, CK1δ, and PKD1 with β1 integrin resulted in no additional or only marginal en-
hancement compared to single targeting of both molecules in the therapy-naïve MiaPaCa-2 
cell line. Additionally, the single knockdown of these kinases achieved a radiosensitizing effect 
comparable to the single β1 integrin depletion. The results were rather unclear to be indicative 
for such mechanistic analyses in the radioresistant 3D MiaPaCa-2 cell cultures. Nonetheless, 
Erk2 and CK1δ single depletion and PKD1 single and double targeting were effectively reduc-
ing tumoroid growth when combined with irradiation. 
Erk1 and Erk2, predominantly located in the Ras signaling axis, are well-known medi-
ators of many crucial cellular processes such as survival, proliferation, motility, and differenti-
ation. If these processes are disturbed, for instance upon KRAS mutation, these kinases pre-
sent critical contributors to diseases like cancer (Kleeff et al., 2016; Lavoie et al., 2020). In line 
with this work, Estrada-Bernal et al. observed that Erk2 depletion or inhibition of MEK, up-
stream of Erk, significantly radiosensitized PDAC cell lines upon photon or proton irradiation 
due to hampered HR and NHEJ (Estrada-Bernal et al., 2015). Interestingly, in radioresistant 
breast cancer cell lines, an upregulation in Erk1 and Erk2 phosphorylation was discovered on 
the basal level in comparison to the parental cell lines. Furthermore, upon 2-Gy irradiation, Erk 
phosphorylation increased more rapidly in the radioresistant cell lines (Gray et al., 2019). A 
downregulation of Erk1 and Erk2 activities upon β1 integrin inhibition as observed in the ki-
nome profiling in the radioresistant 3D MiaPaCa-2 cell cultures implies similarly a higher basal 
activity. Erk2 and Erk1 activities were unaffected upon AIIB2, suggesting that the activity of 
Erk2 may be stress-induced, i. e. radiation-induced, in the therapy-naïve 3D MiaPaCa-2 cell 
cultures. Independent of the response to radiation, a regulation of Erk kinases by β1 integrins 




model, Brannon et al. demonstrated cell adhesion-mediated resistance to MEK inhibition, re-
sulting from a β1 integrin-conferred increase in Erk phosphorylation (Brannon et al., 2020). 
This is in line with the obtained results in the radioresistant 3D cultures. Sheng et al. revealed 
that the staining intensities of fibronectin, β1 integrin, and p-Erk correlated with the stages of 
the tumors of pancreatic cancer patients (Sheng et al., 2017) underpinning the interrelation of 
β1 integrins and Erk2 in PDAC. However, the inhibition of β1 integrin provoked an EGFR-
related bypass mechanism including the activation of Erk1/2 (Eke et al., 2015). These obser-
vations stress out that translating the findings in one tumor entity to another is difficult. 
Interestingly, PKD1 is closely related to Erk2. PKD1 contributes to the activation of 
MEK/Erk signaling by activating the Ras competitor RIN1 (Sundram et al., 2011). In PDAC, a 
relationship between PKD1 and Erk1/2 in Panc-1 cells was unraveled, supporting DNA syn-
thesis (Guha et al., 2002, 2003). In line with these findings, the viability of Colo357 cells was 
increased by PKD1 overexpression, and the clonogenic capacity was lost upon its depletion in 
Panc-1 cells (Ochi et al., 2011; Trauzold et al., 2003). These results further demonstrate the 
significance of Erk2 and PKD1 in PDAC. However, the potential interplay of PKD1 in β1 integrin 
signaling in response to radiation is a novel finding of this work. 
CK1δ is known to be involved in tumor progression and, moreover, associated with 
DNA repair, cell cycle, and apoptosis (Knippschild et al., 2005; Schittek & Sinnberg, 2014). In 
PDAC cell lines, CK1δ was found highly expressed, and targeting CK1δ in vitro and in vivo 
resulted in pro-apoptotic and anti-proliferative effects in PDAC (Brockschmidt et al., 2008). 
Vena et al. revealed that CK1δ targeting resulted in a chemosensitization in PDAC cell lines 
(Vena et al., 2020). Moreover, loss of CK1δ resulted in genomic instability, which was further 
enhanced by concomitant application of genotoxic drugs. Furthermore, the kinase affected the 
cell cycle by regulation of Chk1 (Greer et al., 2017). In HNSCC, it was demonstrated that 
β1 integrins mediate DNA repair (Dickreuter et al., 2016). The results of this work indicate a 
potential involvement in DNA repair and cell cycle of β1 integrins in cooperation with CK1δ in 
response to radiation in PDAC. The present work indicates a novel role of CK1δ in the β1 in-
tegrin-mediated response to radiation in PDAC. 
To the best of one’s knowledge, this present study is the first to implement Erk2, PKD1, 
and CK1δ in the context of β1 integrin signaling in response to radiation exposure in PDAC. 
However, validation is mandatory and uncovering details of the cascade remains elusive and 
will be part of future work. By uncovering Erk2, PKD1, and CK1δ as participating signal medi-





6.5 Multitargeting approaches highly efficient in the therapy-naïve 
3D PDAC cell cultures 
The salience of the increased radiosensitivity upon the simultaneous depletion of the specific 
kinases with β1 integrin in the therapy-naïve 3D MiaPaCa-2 cultures, demonstrates that tar-
geting efficacies can be extremely potentiated when combined with β1 integrin inhibition and 
radiation. Single targeting strategies can trigger the activation of bypass mechanisms that are 
hampered upon double targeting. Putatively, both β1 integrin and kinase depletion can evoke 
the activation of other signaling molecules to retain pro-survival signaling. Consequently, an 
increase in kinase activities upon AIIB2 would be expected. However, the presence of these 
adaptational mechanisms might not be mirrored yet in the kinome profiling analyzing the con-
ditions 1 h after β1 integrin inhibition. 
Adaptation and bypass mechanisms are induced upon targeted therapies, resulting in 
resistance. The crosstalk of integrins with GFRs can be involved in bypass mechanisms, caus-
ing altered expression levels of both receptors, and consequently altered signaling cascades 
(Barrow-McGee et al., 2016; da Silva et al., 2019; Ivaska & Heino, 2010). The blocking of 
β1 integrins resulted in EGFR hypersignaling as a bypass signaling event in HNSCC (Eke et 
al., 2015). Reciprocally, the resistance to EGFR inhibition induced bypass mechanisms via β1 
integrin signaling in lung and pancreatic cancer (Kanda et al., 2013; Y. J. Kim et al., 2017). 
Lesniak et al. revealed that trastuzumab efficacy was bypassed by β1 signaling in HER2-pos-
itive breast cancer cell lines (Lesniak et al., 2009). In squamous cell lung carcinoma, an inter-
action of the soluble splice variant of VEGFR1-13 with β1 integrins resulted in an activation of 
VEGFR1 and 2 signaling and thus affected the response to anti-angiogenic drugs (Abou 
Faycal et al., 2018). Likewise, β1 integrins can be interrelated with non-receptor kinases. For 
instance, the inhibition of the JNK in glioblastoma increased the β1 integrin expression (Vehlow 
et al., 2017). To which extent adaptational mechanisms are present and hit in the double tar-
geting strategy, or if rather synergistic or additive effects are illustrated here, remains to be 
investigated. 
In summary, the increase in radiosensitivity caused by β1 integrin targeting can be fur-
ther potentiated in the therapy-naïve 3D PDAC cell cultures, underpinning the extraordinary 
dependence on β1 integrins of PDAC cultures upon radiation exposure. Multitargeting ap-
proaches could be based on the targeting of β1 integrins together with molecules known to 
hold a role in adaptation and bypass signaling, such as GFRs. This targeting strategy com-
bined with radiotherapy might increase treatment response in PDAC. Nonetheless, the cyto-





6.6 Acquired radioresistance results in resistance to targeted ther-
apies in 3D PDAC cell cultures 
Intriguingly, in the radioresistant 3D MiaPaCa-2 cultures the double targeting did not evoke a 
shift in the sensitizing enhancement or even the same extent of sensitization as in the therapy-
naïve counterpart upon single β1 integrin depletion. These observations illustrate a tremen-
dous resistance to therapy of the radioresistant 3D cultures and especially indicate an inde-
pendence of or more resistant to the targeting of β1 integrins. However, on the basal level the 
kinases were only marginally downregulated upon AIIB2, a circumstance potentially explana-
tory for the absence of an increased radiosensitivity upon double targeting. Nevertheless, a 
considerable enhancement in radiosensitization was achieved upon double targeting of β1 
integrins and kinases related to GFR signaling. However, single targeting strategies of GFRs, 
especially the EGFR, were mostly inefficient in the therapy-naïve and radioresistant 3D PDAC 
cultures. General investigations on radioresistance comparable to the here performed broad-
spectrum kinome analysis in PDAC are scarce and even absent in 3D culture conditions, ag-
gravating the evaluation of the obtained results. Concomitantly, the significance of the gained 
knowledge is underlined. 
GFRs are known to bear a fundamental role in cell adhesion-mediated radioresistance 
(Eke, Storch, et al., 2013; Eke & Cordes, 2015; Vehlow et al., 2019). Functions of GFRs and 
a potential connection to radioresistance will be discussed here, whenever possible for PDAC. 
A comparative proteomic analysis of parental and generated radioresistant MiaPaCa-2 cell 
lines disclosed altered protein expression patterns that resulted in an increased activation of 
GFR and cytokine signaling in the radioresistant cell line (Nguyen et al., 2020). A shift in total 
protein expression was also observed in a breast cancer cell model investigating radioresistant 
and parental cell lines, indicated by a loss of ER-α expression and an increased EGFR ex-
pression (Gray et al., 2019). Alterations of protein expression levels of GFRs could potentially 
entail observed distinctions in kinase activities in the therapy-naïve and radioresistant 3D 
PDAC cultures. 
The EGFR deactivation induced by ibrutinib, lapatinib, or afatinib was reported to radi-
osensitize pancreatic cancer cells cell line-dependently (Huguet et al., 2016; Kimple et al., 
2010; Tan et al., 2020). In vivo, the chemoradiation (gemcitabine) response of BxPC-3 xeno-
grafts in athymic nude mice was invigorated when combined with erlotinib or cetuximab (M. A. 
Morgan et al., 2008). A clinical phase II study demonstrated an encouraging 1-year survival of 
PDAC patients when gemcitabine-based chemoradiotherapy, together with oxaliplatin and 
capecitabine, was combined with cetuximab, an intervention well tolerated by the patients 
(Crane et al., 2011). Although the receptors of the VEGFR family displayed considerable de-




single depletion of the VEGFR family members did not increase the radiosensitivity in these 
cells. In contrast to the absence of radiosensitization upon VEGFR depletion in this work, the 
VEGFR and PDGFR inhibition by sunitinib revealed promising results in vitro and in vivo. 
Sunitinib enhanced both the radiation-induced decrease of colony formation in MiaPaCa-2 and 
Panc-1 cells and a tumor growth delay in a subcutaneous Capan-1 xenograft (Cuneo et al., 
2008). A study by Zhang et al. showed that FGFR mediates pro-survival signaling in PDAC 
cells and the small molecule inhibitor dovotinib induced pro-apoptotic signaling cell line-de-
pendently (Zhang et al., 2014). In contrast to the findings of others, a significance of these 
GFRs for the response to radiation emerged only upon a combinational targeting with β1 in-
tegrins and irradiation in the radioresistant and, interestingly, also in the therapy-naïve 3D cul-
tures. The radioresistant 3D PDAC cultures most likely carry more molecular alterations that 
result in such an extraordinary resistance to therapies like combined β1 integrin/GFR targeting. 
The necessity for further detailed molecular characterization of the radioresistant cell cultures 
to efficiently unravel sore points and further potentially contributing processes will be discussed 
in the next section. 
In intrinsically radioresistant murine PDAC cell lines, an enhanced FAK activity was 
revealed by Wiechmann et al in comparison to the intrinsically radiosensitive cell lines. More-
over, only the radioresistant cell lines were effectively radiosensitized upon FAK inhibition and 
upon inhibition of DNA repair induced by Chek1 inhibition (Wiechmann et al., 2020). Addition-
ally, acquired radioresistance could be related to DNA repair. A global kinome analysis of MCF-
7 wild type and radioresistant MCF-7 breast cancer cell lines demonstrated that upregulated 
and hyperactivated proteins in the latter were proteins associated with cell cycle- and DNA 
repair (Guo et al., 2015). It must be highlighted here that kinases involved in DNA repair, such 
as DNA-PK or ATM, are not included in the kinome profiling. Furthermore, for β1 integrins, a 
role in DNA repair was unraveled with FAK and JNK as contributors in HNSCC, and JNK and 
ATM in glioblastoma (Dickreuter et al., 2016; Vehlow et al., 2017). However, in other studies 
involved kinases FAK and JNK were not significantly deregulated on the basal comparison of 
the therapy-naïve and radioresistant 3D cultures nor upon AIIB2 administration in both ana-
lyzed cell cultures. Consequently, in-depth comparative investigations of the β1 integrin sig-
naling, DNA repair and contributing kinases like CK1δ in the therapy-naïve and radioresistant 
3D cultures may shed more light into the PDAC radioresistome. 
Moreover, investigations of further drivers of resistance like stemness, cell death mech-
anisms, or genetic alterations and putative alterations between the therapy-naïve and radiore-
sistant 3D PDAC cell cultures might untangle the assembly of the PDAC radioresistome. Using 
whole exome sequencing, it was proven utterly helpful to characterize the differential muta-




and EGFR targeting for radiosensitization. Thereupon, efficient radiosensitization of non-re-
sponders was achieved via a multitargeting approach of mTOR or KEAP1 concomitantly with 
AIIB2 and cetuximab (Klapproth et al., 2018). In the already mentioned 2D cultured radiore-
sistant MiaPaCa-2 cells a proteomic and subsequent pathway analysis revealed an upregula-
tion of signaling pathways responsible for EMT and anti-apoptotic mechanisms compared to 
the parental cell line (Nguyen et al., 2020). In line, Zhao et al. discovered Wnt signaling to be 
upregulated together with an EMT phenotype switch in radioresistant cell lines of esophageal 
squamous cell carcinoma (Zhao et al., 2018). Consequently, whole exome sequencing or RNA 
sequencing and the characterization of EMT markers present promising tools to unravel mo-
lecular distinctions that could explain the different susceptibilities for treatments between the 
therapy-naïve and radioresistant cell lines. 
In conclusion, the radioresistant 3D PDAC cultures remained rather refractory to double 
targeting combined with irradiation, fostering the notion of an independence of β1 integrin in 
the response to radiation. This independence is accompanied by a resistance to other targeting 
strategies. However, with careful evaluation of cytotoxic side effects, a triple targeting of β1 in-
tegrins, GFRs, and other kinases combined with irradiation might present a promising ap-
proach to harm the radioresistant cell cultures. To improve targeting options substantially, the 
molecular mechanisms underlying the tremendous therapy resistance must be carefully un-
tangled by an in-depth characterization of the genetic, epigenetic, and transcriptional altera-
tions. Consequently, the risk for the survival of resistant clones upon therapeutic strategies 
might be reduced. 
Despite giving a profound insight into the present alterations in the kinome both basal 
and upon AIIB2 in the therapy-naïve and radioresistant 3D MiaPaCa-2 cell cultures, the meth-
odology had some restrictions, such as a limited number of peptides. Consequently, the spec-
trum of predicted kinases is narrowed and potentially forfeits the drivers of radioresistance in 
the here analyzed cell model. Heterogeneity within the trials is a common biological issue and 
might explain the low number of significantly altered peptide phosphorylations that conse-
quently may affect the prediction of altered kinases. To unravel immediate cellular responses, 
the time point 1 h after treatment was chosen. However, to untangle bypass signaling or ad-
aptation mechanisms, other time points would be necessary. In general, the deregulation de-
gree of the kinases upon blocking β1 integrin did not correlate with the radiosensitizing efficacy 
of the kinases. VEGFR1 (FLT1) is a prime example worth mentioning here. Vice versa, for 
Erk2, a weak downregulation in therapy-naïve MiaPaCa-2 cells but a considerable degree in 
the radioresistant counterpart was observed. However, Erk2 silencing mediated a radiosensi-
tization as strong as seen for β1 integrin in the parental cell line. In conclusion, potentially 
critically involved kinases were possibly not targeted in the RNAi screen due to a weak degree 




conditions and alterations upon targeting are demanded. Moreover, the double targeting suc-
cess in the therapy-naïve 3D MiaPaCa-2 cultures must be substantiated by experiments in the 
whole PDAC cell line panel. In line, the radio- and β1 integrin-resistome and underlying mo-
lecular mechanisms observed in the radioresistant 3D MiaPaCa-2 cultures must be investi-
gated in the additional radioresistant PDAC cell models. 
In summary, this study unraveled a crucial function of β1 integrins in the radiation re-
sponse, both upon photon and proton irradiation, in therapy-naïve and radioresistant PDAC 
cells. However, a decline in the β1 integrin-dependence in the two radioresistant counterparts 
was observed for photon irradiation. β1 integrin targeting induced a stronger downregulation 
of kinase activity in therapy-naïve MiaPaCa-2 cells than in the radioresistant counterpart, giv-
ing insight into differential molecular processes potentially underlying the radioresistance in 
PDAC cells. Furthermore, this study revealed Erk2, PKD1, and CK1δ as potential partners of 
β1 integrin signaling in response to radiation. In the therapy-naïve PDAC cells, multitargeting 
approaches including β1 integrin targeting increased the efficacy of radiation in PDAC vigor-
ously. An observation that was absent in the radioresistant counterpart. 
At this point of the work, the in-depth analyses of mechanistic events underlying the 
extremely encouraging radiosensitization induced by the inhibition of β1 integrins upon photon 
and proton irradiation are queued for future work. The observation of differential radiosensitiv-
ities upon IgG treatment, i.e. intrinsic radiosensitivity, for proton and photon irradiation in 3D 
PDAC cultures caught the attention. Hence, investigations were directed towards a better un-
derstanding of potential molecular events upon photon or proton irradiation. 
6.7 Comparative proton and photon irradiation combined with 
pharmacological inhibitors in 3D PDAC cultures 
The contents of this chapter have been published in similar form by Görte et al. (Görte et al., 
2020), Erratum/Corrigendum submitted to Cancers on May 11th in 2021. 
Given higher precision accompanied by optimized sparing of normal tissue, proton beam irra-
diation is considered more favorable for PDAC patients than photon irradiation. However, sup-
portive large clinical data sets as well as systematic preclinical insights are lacking. To address 
this point, a preclinical study was conducted in a panel of PDAC cell lines grown in 3D extra-
cellular matrix with and without molecular-targeted pretreatments. The study revealed equal or 
higher efficacy of low-LET protons over photons in terms of reducing PDAC tumoroid for-
mation. Moreover, a greater extent of phosphoproteome alterations was shown upon proton 
irradiation compared with photon irradiation. The targeting of proteins identified in the phos-




specific radiosensitization. Instead, inhibition of DNA repair proteins acting in NHEJ revealed 
a strong radiosensitizing potential independent from the radiation type. 
These observations are in line with comparative survival analysis of proton versus pho-
ton irradiation in other tumor entities such as glioma stem cells (Chiblak et al., 2016; Mitteer et 
al., 2015) or lung cancer cells (Liu et al., 2015). Slightly different results, however, were found 
in cells cultured under 2D conditions (Szymonowicz et al., 2020). The higher efficacy of protons 
over photons reported in such studies might have been caused by differences in cell and nu-
clear size and chromatin organization; both parameters have been reported in previous work 
for photon irradiation (Storch et al., 2010). Intensive discussion about the RBE as a clinically 
relevant parameter requires in vivo growth conditions to be determined. Generally, the RBE 
for protons is considered to be 1.1, but recent studies already demonstrated its variability 
(Chaudhary et al., 2014; Guan et al., 2015; Liu et al., 2015; Szymonowicz et al., 2020), which 
is also reflected in the PDAC cell line panel presented here. 
Taking into consideration the therapeutic exploitability of the hallmarks of cancer rep-
resented by altered prosurvival signal transduction and the associated opportunities for treat-
ment personalization (Hanahan & Weinberg, 2011; Jackson & Chester, 2015), a comparative 
broad-spectrum phosphoproteome analysis of the response to proton versus photon irradiation 
1 hour post-irradiation was undertaken. To identify common targets in PDAC cells, the most 
sensitive and most resistant cell lines to photon irradiation were chosen revealing only a minor 
overlap of protein phospho-site modifications. The obtained results largely defeated the aim to 
find uniquely altered proteins to exploit them as sensitizers in PDAC cell lines towards either 
photon or proton irradiation. Several reasons might be causative like the chosen early snap-
shot at 1 hour after irradiation, the limited number of proteins on the array or the limited number 
of cell models tested. Future, more systematic examinations are warranted. 
Nevertheless, three druggable targets were discovered from the array. Targeting the 
ER-α, unique for photon irradiation, and Chk1, for both photon and proton irradiation, resulted 
in moderate but significant radiosensitization irrespective of the radiation type. The ineffective-
ness of trastuzumab-mediated HER2 deactivation in PDAC cell models observed in our study 
is in line with both preclinical and clinical findings but has not been addressed in combination 
with radiotherapy so far (Assenat et al., 2015; Maron et al., 2019). As trastuzumab cytotoxicity 
has been connected to immune cells to induce antibody-dependent cell-mediated cytotoxicity 
in PDAC cells (Kimura et al., 2006), a second, non-antibody based small molecule inhibitor, 
lapatinib was applied prior to photon or proton irradiation. Potentially the higher efficacy of 
lapatinib, as compared with trastuzumab, could originate from its inhibitory spectrum against 
HER2 and EGFR. Concerning tamoxifen, this present study is the first to identify a radiosensi-
tizing potential towards both photon and proton irradiation in PDAC cells. For other cancer cell 




and attributed to its interactions with DNA repair proteins (Rong et al., 2018). With regard to 
Chk1 inhibition, Vance et al. showed a sensitization of pancreatic cancer cell lines towards 
photon irradiation (Vance et al., 2011). Likewise, Chk1 deactivation elicited radiochemosensi-
tizing effects for photons together with gemcitabine (Engelke et al., 2013). The body of litera-
ture for combined treatment with protons and biologicals is limited. Only one report outlined a 
higher degree of sensitization towards protons than to photons after Chk1 inhibition in triple 
negative breast cancer MDA-MB-231 cells (Choi et al., 2020). Conversely, the results of this 
present study, especially the ones obtained in MiaPaCa-2 cells, indicate rather a higher effi-
cacy of photons over protons. 
As alternative approach, the inhibitor spectrum was widened including candidates that 
are either validated molecular targets for other cancer types or are considered as potential 
cancer targets (Gross et al., 2015). Beyond targets identified from the phosphoproteome array, 
a screening with a panel of signal transduction and DNA repair inhibitors provided clear evi-
dence for a superiority of DNA repair inhibitors over inhibitors for receptor tyrosine kinase or 
cytoplasmic protein kinases. In contrast to others demonstrating afatinib, a pan-ErbB inhibitor, 
to radiosensitize PDAC cell lines (Huguet et al., 2016), here no effect after specific 
ErbB2/HER2 targeting was found. This, however, is in line with the findings of Kimple et al. 
(Kimple et al., 2010). PI3K inhibition, still under debate as potential cancer target (Janku et al., 
2018), did sensitize PDAC cells to photon and proton irradiation (J. H. Park et al., 2017). Alt-
hough the phosphoproteome array encompassed a part of these proteins such as DNA-PK, 
EGFR, MEK1, MDM2, p38 MAPK and VEGFR1/2, these proteins neither fulfilled our definition 
in terms of ≥ 30 % decrease or ≥ 50 % increase in phosphorylation nor did they overlap in the 
two tested cell lines. Yet, inhibition of these proteins, except for MDM2 and p38 MAPK, resulted 
in a cell line-dependent and similar sensitization to photon and proton irradiation. These find-
ings propose that the function of a protein in the radiation survival response upon photons and 
protons is not necessarily reflected by the detectable radiation-induced changes in phosphor-
ylation or activity. Future studies are warranted, which analyze time points after irradiation 
beyond our, here presented 1 hour post-irradiation snapshot. 
Intriguingly, the conducted experiments revealed the efficacy of the selected inhibitors 
to be independent from the radiation type in 3D lrECM PDAC cultures. The obtained data 
pinpoint two aspects: (i) the radiation type-unrelated strong dependence of PDAC cell survival 
on DNA repair; (ii) the great similarity in dependence on the same DNA repair machinery upon 
photon and proton irradiation. DNA double strand breaks are repaired by two main DNA repair 
pathways, i.e. homologous recombination (HR) and NHEJ (Chang et al., 2017; Vitti & Parsons, 
2019). The 3D lrECM PDAC cell culture panel showed clear a dependence on classical and 
alternative NHEJ as indicated by DNA-PKcs and PARP inhibitors in contrast to HR impairment 




repair via NHEJ when irradiated with photons (Y. H. Li et al., 2012). In Panc-1 and KP4 cells 
as well as in esophageal cancer cells, PARP inhibition resulted in sensitization towards proton 
irradiation (Kageyama et al., 2020; Wéra et al., 2019). In further studies in Ligase IV knockout 
mouse embryonic fibroblasts and DNA-PKcs-deficient glioblastoma cells, both resembling 
NHEJ deficiency, similar radiosensitization to photons or protons was exhibited (Szymonowicz 
et al., 2020). Previous work and other studies already reported radiosensitization by ATM in-
hibition in photon-irradiated 2D cultured PDAC cells (Ayars et al., 2017; Hennig et al., 2014). 
Here, the sensitizing potential of ATM inhibition was documented in a panel of 3D cultured, 
proton-irradiated PDAC cell lines. Intriguingly, inhibition of MRN complex, consisting of 
MRE11, Rad50 and NBS1 (Blackford & Jackson, 2017), failed to mediate radiosensitization in 
contrast to ATM deactivation. 
Concerning HR targeting, Colo357 cells were the only cell line strongly and marginally 
radiosensitized by Rad51 inhibition to photon and proton irradiation, respectively. Importantly, 
the here observed findings did not confirm the reported greater cellular sensitivity towards pro-
tons under HR-deficiency in the here presented 3D lrECM PDAC cell cultures (Fontana et al., 
2015; Grosse et al., 2014; Wéra et al., 2019). 
In summary, the comparative study unravels a cell line-dependent higher efficacy of 
proton over photon irradiation. Phosphoproteome analysis revealed different phosphorylation 
patterns induced by photon and proton irradiation, the latter leading to more critical changes 
1 h post-irradiation. Contrary to the proposed hypothesis, no radiation-type-specific targets in 
this data set were found that can be used for a clear radiosensitization in a cell line-dependent 
manner. Instead, it was discovered that a radiosensitization mediated by inhibition of specific 
kinases occurs to a similar extent for protons and for photons in a panel of PDAC cell lines 
cultures under more physiological 3D, matrix-based conditions. Considering translation of 
these results to the treatment of patients suffering from PDAC, further insights are required to 
better discriminate the differences in sensitivity towards proton versus photon irradiation. De-
spite the great benefit of higher precision and sparing of normal tissue, the presented data fails 







Background: A highly desmoplasmic microenvironment, the mutational landscape, and intra-
tumoral heterogeneity contribute to the therapy resistance in pancreatic ductal adenocarci-
noma (PDAC). Due to higher precision, proton beam therapy is regarded beneficial compared 
to standard photon radiotherapy, although the role of radiotherapy is still ambiguous in PDAC. 
Cellular adhesion to the extracellular matrix (ECM) via integrins is well-known to mediate radi-
ochemoresistance in various tumor entities. In PDAC, β1 integrins are associated with tumor 
progression. However, their role in radiochemoresistance is yet to be unraveled. Conse-
quently, a comparative evaluation of cell survival and therapy sensitization after inhibition of 
β1 integrins or other survival-promoting protein kinases combined with either photon or proton 
irradiation and the underlying molecular mechanisms was carried out in this work. 
Materials and Methods: The expression of β1 integrins in PDAC and the correlation with 
patient survival were assessed using publicly available patient data. The effect of β1 integrin 
inhibition by inhibitory antibodies or depletion on PDAC cell survival upon photon and proton 
irradiation was explored using the tumoroid formation assay in three therapy-naïve and one 
radioresistant PDAC cell lines grown in more physiological 3D laminin-rich ECM. Protein ex-
pression and cellular localization of β1 integrins were analyzed applying Western blot and im-
munofluorescence in the cell line panel. Basal molecular differences and those upon β1 integ-
rin inhibition were determined by a broad-spectrum kinome profiling in therapy-naïve and radi-
oresistant 3D PDAC cultures. A potential interrelation of specific kinases with β1 integrin sig-
naling in response to radiation was investigated in a single and double knockdown screen. The 
effects of photon and proton irradiation on PDAC cell survival of five 3D cultured PDAC cell 
lines were comparatively assessed using the 3D tumoroid formation assay. Molecular altera-
tions upon both radiation types were identified by a broad-spectrum phosphoproteome analy-
sis and Western blot. The exploitation of uniquely altered molecules and other signal transduc-
tion and DNA repair molecules for specific sensitization to photon and proton radiation was 




Results: β1 integrins are overexpressed in PDAC compared to the normal pancreas, and the 
expression correlates with poorer patient survival. β1 integrin expression and localization var-
ied cell line-dependently in the PDAC cell line panel. β1 integrin inhibition elicited an increase 
in radiosensitivity in all analyzed therapy-naïve and radioresistant 3D PDAC cultures, although 
less prominent in the latter. In line, the extent of kinase deregulation induced by AIIB2 was 
lower in the radioresistant 3D PDAC cultures. Double targeting of specific kinases with β1 
integrins further increased the radiosensitization in the therapy-naïve 3D PDAC cell cultures, 
whereas in the radioresistant counterpart, the effect was weak. Further, Erk2, PKD1, and CK1δ 
were revealed as potential interactors in the β1 integrin-mediated response to radiation. Proton 
irradiation showed a higher efficacy in the reduction of PDAC cell survival than photon irradia-
tion. On the molecular level, irradiation with protons induced more phosphoproteomic altera-
tions than photon radiation. Targeting of molecules uniquely altered upon irradiation failed to 
sensitize 3D PDAC cultures radiation type-specifically. However, a similar degree of radiosen-
sitization for proton and photon irradiation in 3D PDAC cultures was observed upon targeting 
signal transduction and DNA repair proteins. Targeting non-homologous end joining (NHEJ)-
specific proteins increased cellular radiosensitivity exceedingly for both radiation types in all 
3D PDAC cell cultures. 
Conclusion: This work revealed a fundamental role of β1 integrins in intrinsic and acquired 
radioresistance of PDAC. However, to substantially overcome acquired radioresistance, fur-
ther investigation is needed. Furthermore, a similar efficacy of proton and photon irradiation 
when combined with targeted therapies was demonstrated. These results suggest that multi-
targeting approaches based on targeting of β1 integrins or NHEJ-specific molecules combined 
with photon or proton irradiation may turn out particularly promising. The strong radiosensitiz-
ing potential of targeting these molecules may enable a more frequent use of radiotherapy for 





Hintergrund: Ein stark desmoplasmatisches Mikromilieu, das Mutationsprofil und die intra-
tumorale Heterogenität tragen zur Therapieresistenz des Pankreaskarzinoms bei. Aufgrund 
der höheren Präzision wird die Protonentherapie als vorteilhaft gegenüber der Standard Pho-
tonentherapie angesehen, obwohl ihre Wirksamkeit im Pankreaskarzinom noch ungewiss ist. 
Es ist bekannt, dass die zelluläre Adhäsion an die extrazelluläre Matrix (EZM) über Integrine 
die Radiochemoresistenz in verschiedenen Tumorentitäten vermittelt. Hierbei stehen β1 In-
tegrine in Zusammenhang mit dem Fortschreiten der Erkrankung. Welche Rolle die β1 In-
tegrine in der Radiochemoresistenz im Pankreaskarzinom spielen ist jedoch noch nicht be-
kannt. In dieser Arbeit wurde daher eine vergleichende Analyse des Zellüberlebens und der 
Therapieempfindlichkeit nach Hemmung von β1 Integrinen oder anderen überlebensfördern-
den Proteinkinasen in Kombination mit Photonen- oder Protonenbestrahlung sowie der zu-
grundeliegenden molekularen Mechanismen durchgeführt. 
Material und Methoden: Die Expression von β1 Integrinen im Pankreaskarzinom und die 
Korrelation mit dem Patientenüberleben wurden mittels öffentlich verfügbarer Patientendaten 
bestimmt. Die Wirkung der β1-Integrin-Hemmung durch inhibitorische Antikörper oder mittels 
knockdown auf das Überleben von Pankreaskarzinomzellen bei Bestrahlung mit Photonen und 
Protonen wurde durch den Tumoroidbildungsassay in drei therapienaiven und einer strahlen-
resistenten Pankreaskarzinomzelllinien untersucht. Diese wurden in physiologischer, 3D La-
minin-reicher EZM kultiviert. Die Proteinexpression und die zelluläre Lokalisation von β1 In-
tegrinen wurden in allen Zelllinien mittels Western Blot und Immunfluoreszenz analysiert. Ba-
sale molekulare Unterschiede und solche nach Hemmung von β1 Integrinen wurden durch 
eine Breitspektrum-Kinomanalyse in therapienaiven und strahlenresistenten 3D-Pankreaskar-
zinomkulturen bestimmt. Eine mögliche Wechselbeziehung spezifischer Kinasen mit der β1 In-
tegrin-vermittelten Strahlenantwort wurde in einem Einzel- und Doppel-knockdown Screen un-
tersucht. Die Effekte der Bestrahlung mit Photonen und Protonen auf das Überleben von Pan-
kreaskarzinomzellen wurden vergleichend anhand des Tumoroidbildungsassays in fünf 3D-




lekulare Veränderungen wurden durch eine Breitspektrum-Phosphoproteomanalyse und mit-
tels Western Blot identifiziert. Die Nutzung einzigartig veränderter Moleküle sowie anderer Sig-
naltransduktions- und DNA-Reparaturmoleküle zur spezifischen Sensibilisierung für Photo-
nen- und Protonenstrahlung wurde untersucht. Dies erfolgte durch eine gezielte Hemmung 
dieser Moleküle durch spezifische Biologika in 3D-kultivierten Pankreaskarzinomzelllinien. 
Ergebnisse: β1 Integrine sind im Pankreaskarzinom im Vergleich zum gesunden Pankreas 
überexprimiert und ihre Expression korreliert negativ mit dem Patientenüberleben. Die Expres-
sion und Lokalisierung der β1 Integrine variierte zelllinienabhängig in den Pankreaskarzinom-
zelllinien. Die Hemmung der β1 Integrine führte zu einer Erhöhung der Strahlenempfindlichkeit 
in allen analysierten therapienaiven und strahlenresistenten 3D kultivierten Pankreaskarzi-
nomzelllinien, auch wenn diese in den letzteren weniger stark ausfiel. Auch der Grad der durch 
die Hemmung induzierten Deregulierung von Kinasen in den strahlenresistenten 3D Pankre-
askarzinomzellkulturen war geringer. Der gleichzeitige knockdown spezifischer Kinasen mit β1 
Integrinen potenzierte die Strahlenempfindlichkeit in den therapienaiven 3D Pankreaskarzi-
nomzellkulturen, während diese im strahlenresistenten Pendant nur wenig beeinflusst wurde. 
Ferner wurden Erk2, PKD1 und CK1δ als potenziell beteiligte Kinasen in der durch β1 Integrine 
vermittelten Strahlenantwort entdeckt. Die Bestrahlung mit Protonen zeigte eine höhere Wirk-
samkeit bei der Verringerung des Pankreaskarzinomzellüberlebens als die Photonenbestrah-
lung. Auf molekularer Ebene induzierte die Protonenbestrahlung mehr Veränderungen im 
Phosphoproteom als die Photonenbestrahlung. Die gezielte Hemmung von einzigartig verän-
derten Molekülen sensibilisierte die 3D Pankreaskarzinomzellkulturen nicht Strahlungsart-spe-
zifisch. Jedoch konnte eine ähnliche Effizienz der beiden Strahlungstypen nach Hemmung 
gewisser Signaltransduktions- und DNA-Reparaturproteine in 3D Pankreaskarzinomzellkultu-
ren gezeigt werden. Die zelluläre Strahlenempfindlichkeit gegenüber beiden Strahlungsarten 
wurde hierbei besonders durch die Hemmung spezifischer Proteine des non-homologous end 
joining (NHEJ) in allen 3D Pankreaskarzinomzellkulturen erhöht. 
Schlussfolgerung: Diese Arbeit konnte eine wesentliche Rolle von β1 Integrinen bei der 
intrinsischen und erworbenen Strahlenresistenz im Pankreaskarzinom ermitteln. Um die Strah-
lenresistenz jedoch gänzlich zu überwinden, sind weitere Untersuchungen erforderlich. Des 
Weiteren wurde eine ähnliche Wirksamkeit von Protonen- und Photonenbestrahlung in Kom-
bination mit gezielten Therapien gezeigt. Diese Ergebnisse legen nahe, dass Multi-Targeting-
Ansätze, die auf der Hemmung von β1 Integrinen oder NHEJ-spezifischen Molekülen in Kom-
bination mit Photonen- oder Protonenbestrahlung basieren, ausgesprochen vielversprechend 
sein können. Angesichts des enormen Potentials zur Steigerung der Strahlenempfindlichkeit 
durch die Hemmung dieser Moleküle könnte eine häufigere Anwendung der Strahlentherapie 
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